Pfizer (PFE) 10-Q 9 Aug 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jul. 01, 2018	Aug. 06, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	PFIZER INC
Entity Central Index Key	78,003
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Jul. 1, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Amendment Flag	false
Trading Symbol	PFE
Entity Common Stock, Shares Outstanding		5,862,109,503

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions		3 Months Ended		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018		Jul. 02, 2017
Income Statement [Abstract]
Revenues	[1]	$ 13,466	$ 12,896	$ 26,373		$ 25,675
Costs and expenses:
Cost of sales	[1],[2]	2,916	2,660	5,479		5,128
Selling, informational and administrative expenses	[1],[2]	3,542	3,430	6,954		6,745
Research and development expenses	[1],[2]	1,797	1,787	3,540		3,502
Amortization of intangible assets	[1]	1,191	1,208	2,387		2,394
Restructuring charges and certain acquisition-related costs	[1]	44	70	87		153
Other (income)/deductions––net	[1]	(551)	(75)	(728)		(14)
Income from continuing operations before provision for taxes on income	[1],[3]	4,527	3,815	8,654		7,767
Provision for taxes on income	[1]	648	739	1,204		1,560
Income from continuing operations	[1]	3,879	3,077	7,450	[4]	6,207	[4]
Discontinued operations––net of tax	[1]	0	2	(1)		1
Net income before allocation to noncontrolling interests	[1],[5],[6]	3,879	3,078	7,449		6,208
Less: Net income attributable to noncontrolling interests	[1]	7	5	16		14
Net income attributable to Pfizer Inc.	[1]	$ 3,872	$ 3,073	$ 7,432		$ 6,194
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 0.66	$ 0.52	$ 1.26		$ 1.04
Discontinued operations––net of tax (in dollars per share)	[1]	0	0	0		0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	0.66	0.52	1.26		1.04
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	0.65	0.51	1.24		1.02
Discontinued operations––net of tax (in dollars per share)	[1]	0	0	0		0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 0.65	$ 0.51	$ 1.24		$ 1.02
Weighted-average shares––basic	[1]	5,866	5,958	5,911		5,982
Weighted-average shares––diluted	[1]	5,952	6,037	6,004	[4]	6,065	[4]
Cash dividends paid per common share (in dollars per share)	[1]	$ 0.34	$ 0.32	$ 0.68		$ 0.64
[1]	Amounts may not add due to rounding.
[2]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
[3]	Income from continuing operations before provision for taxes on income. IH’s earnings include dividend income of $76 million and $114 million in the second quarter of 2018 and 2017, respectively, and $135 million and $157 million in the first six months of 2018 and 2017, respectively, from our investment in ViiV. For additional information, see Note 4.
[4]	These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.
[5]	Amounts may not add due to rounding.
[6]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions		3 Months Ended			6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017		Jul. 01, 2018		Jul. 02, 2017
Statement of Comprehensive Income [Abstract]
Net income before allocation to noncontrolling interests	[1],[2],[3]	$ 3,879	$ 3,078		$ 7,449		$ 6,208
Foreign currency translation adjustments, net	[2]	(699)	247		59		474
Reclassification adjustments	[2]	(35)	111	[4]	(20)	[4]	112
Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax	[2]	(734)	358		39		586
Unrealized holding gains/(losses) on derivative financial instruments, net	[2]	127	(90)		13		(99)
Reclassification adjustments for (gains)/losses included in net income	[2],[4]	310	(208)		354		(449)
Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total	[2]	437	(297)		367		(548)
Unrealized holding gains/(losses) on available-for-sale securities, net	[2]	(374)	164		(214)		314
Reclassification adjustments for (gains)/losses included in net income	[2],[4]	143	(40)		(31)		97
Reclassification adjustments for unrealized gains included in Retained Earnings	[2],[5]	0	0		(462)		0
Other comprehensive income (loss), available-for-sale securities, before tax, total	[2]	(231)	124		(707)		412
Benefit plans: actuarial gains/(losses), net	[2]	(57)	61		106		62
Reclassification adjustments related to amortization	[2]	61	145		123		308
Reclassification adjustments related to settlements, net	[2]	30	(1)		67		51
Other	[2]	107	(80)		21		(35)
Defined benefit plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total	[2]	141	124		316		385
Benefit plans: prior service costs and other, net	[2]	0	(2)		0		(2)
Reclassification adjustments related to amortization	[2]	(46)	(46)		(92)		(91)
Reclassification adjustments related to curtailments, net	[2]	(7)	(4)		(13)		(11)
Other	[2]	(1)	0		1		1
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax	[2]	(53)	(52)		(104)		(104)
Other comprehensive income/(loss), before tax	[2]	(440)	258		(88)		732
Tax provision/(benefit) on other comprehensive (loss)/income	[2]	173	(163)		605		(138)
Other comprehensive income/(loss) before allocation to noncontrolling interests	[2]	(613)	421		(693)		870
Comprehensive income before allocation to noncontrolling interests	[2]	3,266	3,499		6,755		7,078
Less: Comprehensive income/(loss) attributable to noncontrolling interests	[2]	(4)	13		6		29
Comprehensive income attributable to Pfizer Inc.	[2]	$ 3,270	$ 3,486		$ 6,750		$ 7,049
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Reclassified into Other (income)/deductions—net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Cost of sales, see Note 7F. Financial Instruments: Derivative Financial Instruments and Hedging Activities.
[5]	For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards.

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Jul. 01, 2018	Dec. 31, 2017
Assets
Cash and cash equivalents	[1]	$ 2,704	$ 1,342	[2]
Short-term investments	[1]	10,727	18,650
Trade accounts receivable, less allowance for doubtful accounts: 2018—$578; 2017—$584	[1]	9,873	8,221
Inventories	[1],[3]	8,074	7,578
Current tax assets	[1]	3,582	3,050
Other current assets	[1]	2,343	2,301
Total current assets	[1]	37,303	41,141
Long-term investments	[1]	6,595	7,015
Property, plant and equipment, less accumulated depreciation: 2018—$16,844; 2017—$16,172	[1]	13,919	13,865
Identifiable intangible assets, less accumulated amortization	[1],[4]	46,584	48,741
Goodwill	[1]	55,836	55,952
Noncurrent deferred tax assets and other noncurrent tax assets	[1]	1,848	1,855
Other noncurrent assets	[1]	2,896	3,227
Total assets	[1]	164,980	171,797
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2018—$4,262; 2017—$3,546	[1]	11,583	9,953
Trade accounts payable	[1]	4,196	4,656
Dividends payable	[1]	1,980	2,029
Income taxes payable	[1]	2,481	477
Accrued compensation and related items	[1]	1,791	2,196
Other current liabilities	[1]	10,125	11,115
Total current liabilities	[1]	32,156	30,427
Long-term debt	[1]	28,935	33,538
Pension benefit obligations, net	[1]	5,006	5,926
Postretirement benefit obligations, net	[1]	1,473	1,504
Noncurrent deferred tax liabilities	[1]	5,743	3,900
Other taxes payable	[1]	15,597	18,697
Other noncurrent liabilities	[1]	5,947	6,149
Total liabilities	[1]	94,856	100,141
Commitments and Contingencies	[1]
Preferred stock	[1]	20	21
Common stock	[1]	465	464
Additional paid-in capital	[1]	84,898	84,278
Treasury stock	[1]	(95,463)	(89,425)
Retained earnings	[1]	89,860	85,291
Accumulated other comprehensive loss	[1]	(10,003)	(9,321)
Total Pfizer Inc. shareholders’ equity	[1]	69,778	71,308
Equity attributable to noncontrolling interests	[1]	346	348
Total equity	[1]	70,124	71,656
Total liabilities and equity	[1]	$ 164,980	$ 171,797
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	The change from December 31, 2017 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery, network strategy and new product launches, partially offset by a decrease due to foreign exchange.
[4]	The decrease in Identifiable intangible assets, less accumulated amortization, is primarily due to amortization, minimally offset by additions, mainly consisting of $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E).

CONDENSED CONSOLIDATED BALANCE5

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Millions		Jul. 01, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	[1]	$ 578	$ 584
Property, plant and equipment, accumulated depreciation	[1]	16,844	16,172
Current portion of long-term debt	[1]	$ 4,262	$ 3,546
[1]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017
Operating Activities
Net income before allocation to noncontrolling interests	[1],[2],[3]	$ 7,449	$ 6,208
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization	[1]	3,129	3,129
Asset write-offs and impairments	[1]	41	97
Adjustments to loss on sale of HIS net assets	[1],[4]	1	64
TCJA impact	[1],[5]	(68)	0
Deferred taxes from continuing operations	[1]	(500)	320
Share-based compensation expense	[1]	379	388
Benefit plan contributions in excess of expense	[1]	(826)	(1,079)
Other adjustments, net	[1]	(523)	(458)
Other changes in assets and liabilities, net of acquisitions and divestitures	[1]	(3,250)	(3,844)
Net cash provided by operating activities	[1]	5,830	4,824
Investing Activities
Purchases of property, plant and equipment	[1]	(810)	(806)
Purchases of short-term investments	[1]	(3,122)	(2,394)
Proceeds from redemptions/sales of short-term investments	[1]	10,497	3,517
Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less	[1]	1,231	3,424
Purchases of long-term investments	[1]	(1,070)	(1,663)
Proceeds from redemptions/sales of long-term investments	[1]	1,361	1,538
Acquisitions of businesses, net of cash acquired	[1]	0	(1,000)
Acquisitions of intangible assets	[1]	(32)	(41)
Other investing activities, net	[1]	138	455
Net cash provided by investing activities	[1]	8,193	3,030
Financing Activities
Proceeds from short-term borrowings	[1]	1,746	4,799
Principal payments on short-term borrowings	[1]	(2,921)	(5,088)
Net proceeds from short-term borrowings with original maturities of three months or less	[1]	2,092	265
Proceeds from issuance of long-term debt	[1]	0	5,273
Principal payments on long-term debt	[1]	(3,104)	(4,473)
Purchases of common stock	[1]	(6,063)	(5,000)
Cash dividends paid	[1]	(4,021)	(3,855)
Proceeds from exercise of stock options	[1]	474	411
Other financing activities, net	[1]	(831)	(228)
Net cash used in financing activities	[1]	(12,628)	(7,896)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents	[1]	(15)	37
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents	[1]	1,381	(5)
Cash and cash equivalents and restricted cash and cash equivalents, beginning	[1]	1,431	2,666
Cash and cash equivalents and restricted cash and cash equivalents, end	[1]	2,811	2,661
Non-cash transactions:
Receipt of ICU Medical common stock	[1],[6]	0	428
Promissory note from ICU Medical	[1],[6]	0	75
Equity investment in Allogene received in exchange for Pfizer's allogeneic CAR T developmental program assets	[1],[6]	92	0
Cash paid (received) during the period for:
Income taxes	[1]	1,197	1,121
Interest	[1]	724	881
Interest rate hedges	[1]	$ (71)	$ (226)
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	In the second quarter and first six months of 2018 and 2017, represents adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical on February 3, 2017. For additional information, see Note 2B.
[5]	As a result of the enactment of the TCJA in December 2017, Pfizer’s 2018 Provision for taxes on income was favorably impacted by approximately $68 million, primarily related to certain tax initiatives associated with the lower U.S. tax rate as a result of the TCJA.
[6]	For additional information, see Note 2B. Acquisition, Divestitures, Licensing Arrangements, Collaborative Arrangements and Privately Held Investment: Divestitures.

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICAL) - USD ($) $ in Millions		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017
Statement of Cash Flows [Abstract]
TCJA impact	[1],[2]	$ 68	$ 0
[1]	Amounts may not add due to rounding.
[2]	As a result of the enactment of the TCJA in December 2017, Pfizer’s 2018 Provision for taxes on income was favorably impacted by approximately $68 million, primarily related to certain tax initiatives associated with the lower U.S. tax rate as a result of the TCJA.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jul. 01, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies A. Basis of Presentation See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q. We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 27, 2018 and May 28, 2017 . The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and six months ended July 1, 2018 and July 2, 2017 . Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2017 Form 10-K. We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). For additional information, see Note 13 and Notes to Consolidated Financial Statements–– Note 18. Segment, Geographic and Other Revenue Information in Pfizer’s 2017 Financial Report. Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts. In the first quarter of 2018, as of January 1, 2018, we adopted eleven new accounting standards. See Note 1B for further information. Our significant business development activities include: • On February 3, 2017, we completed the sale of our global infusion systems net assets, HIS, to ICU Medical. The operating results of HIS are included in our condensed consolidated statement of income and EH’s operating results through February 2, 2017 and, therefore, our financial results, and EH’s operating results, for the second quarter of 2017 do not reflect any contribution from HIS global operations, while our financial results, and EH’s operating results, for the first six months of 2017 reflect approximately one month of HIS domestic operations and approximately two months of HIS international operations. Our financial results, and EH’s operating results, for 2018 do not reflect any contribution from HIS global operations. • On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca’s small molecule anti-infectives business, primarily outside the U.S. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of this business, and, in accordance with our international reporting period, our financial results, EH’s operating results, and cash flows for the second quarter and first six months of 2017 reflect approximately three months and five months, respectively, of the small molecule anti-infectives business acquired from AstraZeneca. Our financial results, EH’s operating results, and cash flows for the second quarter and first six months of 2018 reflect three months and six months , respectively, of the small molecule anti-infective business acquired from AstraZeneca. For additional information, see Note 2 and Notes to Consolidated Financial Statements–– Note 2. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment in Pfizer’s 2017 Financial Report. B. Adoption of New Accounting Standards On January 1, 2018, we adopted eleven new accounting standards. The quantitative impacts on our prior period condensed consolidated financial statements of adopting the following new standards are summarized in the tables within the section titled Impacts to our Condensed Consolidated Financial Statements , further below. Revenues ––We adopted a new accounting standard for revenue recognition and changed our revenue recognition policies accordingly. Generally, the previous revenue recognition standards permitted recognition when persuasive evidence of a contract existed, delivery had occurred, and the seller's price to the buyer was fixed or determinable. Under the new standard, revenue is recognized upon transfer of control of the product to our customer in an amount that reflects the consideration we expect to receive in exchange. We adopted the new accounting standard utilizing the modified retrospective method, and, therefore, no adjustments were made to amounts in our prior period financial statements. We recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained earnings by $584 million on a pre-tax basis ( $450 million after-tax). This amount includes $500 million (pre-tax) related to the timing of recognizing Other (income)/deductions –– net primarily for upfront and milestone payments on our collaboration arrangements ( $394 million , pre-tax) and, to a lesser extent, product rights and out-licensing arrangements, and $84 million (pre-tax) related to the timing of recognizing Revenues and Cost of sales on certain product shipments. The impact of adoption did not have a material impact to our condensed consolidated statements of income for the three and six months ended July 1, 2018 or our condensed consolidated balance sheet as of July 1, 2018 . For additional information, see Note 1C . Financial Assets and Liabilities ––The new accounting standard related to the recognition and measurement of financial assets and liabilities makes the following changes to prior guidance and requires: • certain equity investments to be measured at fair value with changes in fair value now recognized in net income. However, equity investments that do not have readily determinable fair values may be measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer; • a qualitative assessment of equity investments without readily determinable fair values to identify impairment; and • separate presentation of financial assets and financial liabilities by measurement category and form of financial asset on the balance sheet or in the accompanying notes to the financial statements. We adopted the new accounting standard utilizing the modified retrospective method, and, therefore, no adjustments were made to amounts in our prior period financial statements. We recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained earnings by $462 million on a pre-tax basis ( $419 million after-tax) related to the net impact of unrealized gains and losses primarily on available-for-sale equity securities, restricted stock and private equity securities. In the second quarter and first six months of 2018, we recorded net unrealized gains on equity securities of $226 million and $337 million , respectively, in Other (income)/deductions––net . For additional information, see Note 4 and Note 7 . Presentation of Net Periodic Pension and Postretirement Benefit Cost ––We adopted a new accounting standard that requires the net periodic pension and postretirement benefit costs other than the service costs be presented in Other (income)/deductions––net, and that the presentation be applied retrospectively. We adopted the presentation of the net periodic benefit costs other than service costs by reclassifying these costs from Cost of sales , Selling, informational and administrative expenses , Research and development expenses and Restructuring charges and certain acquisition-related costs to Other (income)/deductions––net . We elected to apply the practical expedient as it is impracticable to determine the disaggregation of the cost components for amounts capitalized within Inventories and property, plant and equipment and amortized in each of those periods. We have therefore reclassified the prior period net periodic benefit costs/(credits) disclosed in Note 10 to apply the retrospective presentation for comparative periods. As of January 1, 2018, only service costs will be included in amounts capitalized in Inventories or property, plant and equipment, while the other components of net periodic benefit costs will be included in Other (income)/deductions –– net . For additional information, see Note 4 and Note 10 . Income Tax Accounting ––The new guidance removes the prohibition against recognizing current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to a third party, unless the asset transferred is inventory. We adopted the standard utilizing the modified retrospective method, and, therefore, no adjustments were made to amounts in our prior period financial statements. We recorded the cumulative effect of adopting the standard as an adjustment to decrease the opening balance of Retained earnings by $189 million . Accounting for Hedging Activities ––The standard makes the following changes: • Permits hedge accounting for risk components in hedging relationships involving nonfinancial risk and interest rate risk; • Changes the guidance for designating fair value hedges of interest rate risk and for measuring the change in fair value of the hedged item in fair value hedges of interest rate risk; • No longer requires the separate measurement and reporting of hedge ineffectiveness, but requires the income statement presentation of the earnings effect of the hedging instrument with the earnings effect of the hedged item; • Permits us to exclude the portion of the change in fair value of a currency swap that is attributable to a cross-currency basis spread from the assessment of hedge effectiveness; and • Simplifies hedge effectiveness testing. We early adopted the new accounting standard on January 1, 2018 on a prospective basis. In the second quarter and first six months of 2018, we recorded income of $16 million and $45 million , respectively, in Other (income)/deductions –– net , whereas this item would have been classified in interest income in prior periods. For additional information, see Note 7F . Reclassification of Certain Tax Effects from AOCI ––We early adopted a new accounting standard that provides guidance on the reclassification of certain tax effects from AOCI. Under the new guidance, we elected to reclassify the stranded tax amounts related to the TCJA from AOCI to Retained earnings . We adopted the new accounting standard utilizing the modified retrospective method, and recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained earnings by $495 million , primarily due to the effect of the change in the U.S. Federal corporate tax rate. The impact on other stranded tax amounts related to the application of the TCJA was not material to our condensed consolidated financial statements. Classification of Certain Transactions in the Statement of Cash Flows ––We retrospectively adopted an accounting standard that changed the presentation of certain information in the condensed consolidated statements of cash flows, including the classification of: • debt prepayment and extinguishment costs, resulting in an increase in Operating activities –– Other adjustments, net and a decrease in Financing activities –– Other financing activities, net of $7 million for the six months ended July 1, 2018 ; and • accreted interest on the settlement of commercial paper debt instruments, resulting in a decrease in Operating activities –– Other adjustments, net , and an increase in Financing activities –– Other financing activities, net of $38 million for the six months ended July 1, 2018 . The new standard also establishes guidance on the classification of certain cash flows related to contingent consideration in a business acquisition. Cash payments made soon after a business acquisition date will be classified as Investing activities , while payments made thereafter will be classified as Financing activities . Payments made in excess of the amount of the original contingent consideration liability will be classified as Operating activities . The adoption of this guidance did not have a material impact to our condensed consolidated financial statements. Presentation of Restricted Cash in the Statement of Cash Flows ––We adopted, on a retrospective basis, the new accounting standard, which requires that restricted cash and restricted cash equivalents be included with Cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the condensed consolidated statements of cash flows. As a result, for the six months ended July 1, 2018 , $19 million is presented as an increase in Cash, cash equivalents, restricted cash and restricted cash equivalents. Definition of a Business ––We prospectively adopted the standard for determining whether business development transactions should be accounted for as acquisitions (or disposals) of assets or businesses. If substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, the transaction will not qualify for treatment as a business. To be considered a business, a set of integrated activities and assets must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs, without regard as to whether a purchaser could replace missing elements. In addition, the definition of the term “output” has been narrowed to make it consistent with the updated revenue recognition guidance. In the second quarter and first six months of 2018, there was no impact to our condensed consolidated financial statements from the adoption of this new standard. Derecognition of Nonfinancial Assets ––We prospectively adopted the standard, which applies to the full or partial sale or transfer of nonfinancial assets, including intangible assets, real estate and inventory. The standard provides that the gain or loss is determined by the difference between the consideration received and the carrying value of the asset. In the second quarter and first six months of 2018, there was no impact to our condensed consolidated financial statements from the adoption of this new standard. Accounting for Modifications of Share-Based Payment Awards ––We prospectively adopted the standard, which clarifies that certain changes in the terms or conditions of a share-based payment award be accounted for as a modification. There was no impact to our condensed consolidated financial statements from the adoption of this new standard. Impacts to our Condensed Consolidated Financial Statements ––The impacts on our prior period condensed consolidated financial statements of adopting the new standards described above are summarized in the following tables: Adoption of the standard related to pension and postretirement benefit costs impacted our prior period condensed consolidated statements of income as follows: Three Months Ended July 2, 2017 (MILLIONS OF DOLLARS) As Previously Reported Effect of Change Higher/(Lower) As Restated Cost of sales $ 2,663 $ (3 ) $ 2,660 Selling, informational and administrative expenses 3,425 5 3,430 Research and development expenses 1,780 7 1,787 Restructuring charges and certain acquisition-related costs 70 (1 ) 70 Other (income)/deductions––net (66 ) (8 ) (75 ) Income from continuing operations before provision for taxes on income 3,815 — 3,815 Six Months Ended July 2, 2017 (MILLIONS OF DOLLARS) As Previously Reported Effect of Change Higher/(Lower) As Restated Cost of sales $ 5,134 $ (6 ) $ 5,128 Selling, informational and administrative expenses 6,733 12 6,745 Research and development expenses 3,487 15 3,502 Restructuring charges and certain acquisition-related costs 228 (74 ) 153 Other (income)/deductions––net (68 ) 53 (14 ) Income from continuing operations before provision for taxes on income 7,767 — 7,767 Adoption of the standards impacted our condensed consolidated balance sheet as follows: Effect of New Accounting Standards Higher/(Lower) (MILLIONS OF DOLLARS) As Previously Reported Balance at December 31, 2017 Revenues Financial Assets and Liabilities Income Tax Accounting Reclassification of Certain Tax Effects from AOCI Balance at January 1, 2018 Trade accounts receivable $ 8,221 $ 13 $ — $ — $ — $ 8,234 Inventories 7,578 (11 ) — — — 7,567 Current tax assets 3,050 (11 ) — (3 ) — 3,036 Noncurrent deferred tax assets and other noncurrent tax assets 1,855 (17 ) — — — 1,838 Other noncurrent assets 3,227 — — (204 ) — 3,023 Other current liabilities 11,115 (123 ) — — — 10,992 Noncurrent deferred tax liabilities 3,900 106 — (18 ) — 3,988 Other noncurrent liabilities 6,149 (459 ) — — — 5,690 Retained earnings 85,291 450 419 (189 ) 495 86,466 Accumulated other comprehensive loss (9,321 ) — (419 ) — (495 ) (10,235 ) Adoption of the standards related to the classification of certain transactions in the statement of cash flows and the presentation of restricted cash in the statement of cash flows impacted our condensed consolidated statement of cash flows as follows: Six Months Ended July 2, 2017 Effect of New Accounting Standards Inflow/(Outflow) (MILLIONS OF DOLLARS) As Previously Reported Cash Flow Classification Restricted Cash As Restated Operating Activities Other adjustments, net $ (433 ) $ (26 ) $ — $ (458 ) Other changes in assets and liabilities, net of acquisitions and divestitures (3,853 ) — 9 (3,844 ) Investing Activities Proceeds from redemptions/sales of short-term investments 3,520 — (3 ) 3,517 Proceeds from redemptions/sales of long-term investments 1,539 — (2 ) 1,538 Financing Activities Principal payments on short-term borrowings (5,110 ) 22 — (5,088 ) Net proceeds from short-term borrowings with original maturities of three months or less 261 4 — 265 Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents (10 ) — 5 (5 ) Cash and cash equivalents and restricted cash and cash equivalents, beginning 2,595 — 70 2,666 Cash and cash equivalents and restricted cash and cash equivalents, ending 2,585 — 75 2,661 The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheet that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows: (MILLIONS OF DOLLARS) July 1, 2018 December 31, Cash and cash equivalents $ 2,704 $ 1,342 Restricted cash and cash equivalents in Short-term investments 42 — Restricted cash and cash equivalents in Long-term investments 66 — Restricted cash and cash equivalents in Other current assets — 14 Restricted cash and cash equivalents in Other noncurrent assets — 75 Total cash and cash equivalents and restricted cash and cash equivalents shown in the condensed consolidated balance sheets $ 2,811 $ 1,431 Amounts included in restricted cash represent those required to be set aside by a contractual agreement in connection with ongoing litigation or to secure delivery of Pfizer medicines at the agreed upon terms. The restriction will lapse upon the resolution of the litigation or the proper delivery of the medicines. C. Revenues On January 1, 2018, we adopted a new accounting standard for revenue recognition. For further information, see Note 1B . We recorded direct product and/or alliance revenues of more than $1 billion for each of nine products in 2017. These direct products sales and/or alliance product revenues represented 46% of our revenues in 2017. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices due to added competition and we generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights. Our Consumer Healthcare business includes OTC brands with a focus on dietary supplements, pain management, gastrointestinal and respiratory and personal care. According to Euromonitor International’s retail sales data, in 2017, our Consumer Healthcare business was the fifth-largest branded multi-national, OTC consumer healthcare business in the world and produced two of the ten largest selling consumer healthcare brands ( Centrum and Advil ) in the world. We sell biopharmaceutical products after patent expiration, and under patent, and, to a much lesser extent, consumer healthcare products worldwide to developed and emerging market countries. Revenue Recognition ––We record revenues from product sales when there is a transfer of control of the product from us to the customer. We determine transfer of control based on when the product is shipped or delivered and title passes to the customer. • Customers ––Our biopharmaceutical products are sold principally to wholesalers but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies, and, in the case of our vaccine products in the U.S., we primarily sell directly to the CDC, wholesalers and individual provider offices. Our consumer healthcare customers include retailers and, to a lesser extent, wholesalers and distributors. Biopharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs, including those managed through pharmacy benefit managers, and are subject to sales allowances and/or rebates payable directly to those programs. Those sales allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented or unpatented). • Our Sales Contracts ––Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in the U.S. Sales are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns occur due to loss of exclusivity, product recalls or a changing competitive environment. • Deductions from Revenues –– Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period. Specifically: • In the U.S., we sell our products to distributors and hospitals under our sales contracts. However, we also have contracts with managed care or pharmacy benefit managers and legislatively mandated contracts with the federal and state governments under which we provide rebates to them based on medicines utilized by the lives they cover. We record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior quarters. We apply the experience ratio to the respective period’s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap,” also known as the “doughnut hole,” based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates. • Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government’s total unbudgeted pharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals. • Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices to third parties) closely approximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability. • Provisions for pharmaceutical sales returns are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as loss of exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit. • We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior. Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $5.4 billion and $4.9 billion as of July 1, 2018 and December 31, 2017 , respectively. The following table provides information about the balance sheet classification of these accruals: (MILLIONS OF DOLLARS) July 1, 2018 December 31, 2017 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 1,252 $ 1,352 Other current liabilities : Accrued rebates 3,039 2,674 Other accruals 698 512 Other noncurrent liabilities 406 385 Total accrued rebates and other accruals $ 5,396 $ 4,923 Amounts recorded for revenue deductions can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. On a quarterly basis, our adjustments of estimates to reflect actual results generally have been less than 1% of revenues, and have resulted in either a net increase or a net decrease in Revenues . Product-specific rebates, however, can have a significant impact on year-over-year individual product growth trends. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from Revenues . D. Collaborative Arrangements Payments to and from our collaboration partners are presented in our condensed consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received from our collaboration partners as alliance revenues, a component of Revenues, when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded as we perform co-promotion services for the collaboration and the collaboration partners sell the products to their customers within the applicable period. The related expenses for selling and marketing these products are included in Selling, informational and administrative expenses. In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. All royalty payments to collaboration partners are included in Cost of sales . Royalty payments received from collaboration partners are included in Other (income)/deductions—net. Reimbursements to or from our collaboration partners for development costs are recorded net in Research and development expenses . Upfront payments and pre-approval milestone payments due from us to our collaboration partners in development stage collaborations are recorded as Research and development expenses . Milestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in Identifiable intangible assets—Developed technology rights . Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in Other (income)/deductions—net over the development period for the collaboration products, when our performance obligations include providing R&D services to our collaboration partners. Upfront, pre-approval and post-approval milestone payments earned by us may be recognized in Other (income)/deductions—net immediately when earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be probable of a significant reversal. On January 1, 2018, we adopted a new accounting standard on revenue recognition (see Note 1B ). As a result of the adoption, we recognized the following cumulative effect adjustments related to collaboration arrangements to Retained earnings : • $394 million (pre-tax) for collaborative arrangements where the period over which upfront, pre-approval and regulatory approval milestone payments received from our collaboration partners are recognized in Other (income)/deductions—net over a reduced period. Under the new standard, the income from upfront and pre-approval milestone payments due to us is typically recognized over the development period for the collaboration when our performance obligation, in addition to granting a license, is to provide research and development services to our collaboration partners, and major regulatory approval milestones are typically recognized immediately when earned as the related development period has ended. The income from upfront and milestone payments is typically recognized immediately as earned if our performance obligation, in addition to granting a license, is only for commercialization activities. Under the old standard, this income was recognized over the combined development and estimated commercialization (including co-promotion) period for the collaboration products. • $82 million (pre-tax) for collaborative arrangements where we manufacture products for our collaboration partners and recognize Revenues and Cost of sales for product shipments at an earlier point in time. Under the new standard, revenue is recognized when we transfer control of the products to our collaboration partners. Under the old standard, revenue was recognized when our collaboration partners sell the products and transfer title to their third party customers.

Acquisition, Divestitures, Lice

Acquisition, Divestitures, Licensing Arrangements, Collaborative Arrangements and Privately Held Investment	6 Months Ended
	Jul. 01, 2018
Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]
Acquisition, Divestitures, Licensing Arrangements, Collaborative Arrangements and Privately Held Investment	Acquisition, Divestitures, Licensing Arrangements, Collaborative Arrangements and Privately Held Investment A. Acquisition AstraZeneca’s Small Molecule Anti-Infectives Business (EH) On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca’s small molecule anti-infectives business, primarily outside the U.S., including the commercialization and development rights to the approved EU drug Zavicefta™ (ceftazidime-avibactam), the marketed agents Merrem™/Meronem™ (meropenem) and Zinforo™ (ceftaroline fosamil), and the clinical development assets ATM-AVI and CXL (ceftaroline fosamil-AVI). Under the terms of the agreement, we made an upfront payment of approximately $552 million to AstraZeneca upon the close of the transaction and an additional $3 million payment for a contractual purchase price adjustment in the second quarter of 2017. We also made a $50 million milestone payment in the second quarter of 2017, we made an additional milestone payment of $125 million in our first fiscal quarter of 2018 and we will make a deferred payment of $175 million to AstraZeneca in January 2019. In addition, AstraZeneca may be eligible to receive an additional milestone payment of $75 million if the related milestone is achieved prior to December 31, 2021, and up to $600 million if sales of Zavicefta™ exceed certain thresholds prior to January 1, 2026, as well as tiered royalties on sales of Zavicefta™ and ATM-AVI in certain markets for a period ending on the later of 10 years from first commercial sale or the loss of patent protection or loss of regulatory exclusivity. The total royalty payments are unlimited during the royalty term and the undiscounted payments are expected to be in the range of approximately $250 million to $430 million . The total fair value of consideration transferred for AstraZeneca’s small molecule anti-infectives business was approximately $1,040 million , which includes $555 million in cash, plus the fair value of contingent consideration of $485 million (which is composed of the deferred payment, the $50 million milestone payment made in the second quarter of 2017, the $125 million milestone payment made in our first fiscal quarter of 2018 and the future expected milestone and royalty payments). In connection with this acquisition, we recorded $894 million in Identifiable intangible assets , consisting of $728 million in Developed technology rights and $166 million in IPR&D . We also recorded $92 million in Other current assets related to the economic value of inventory which was retained by AstraZeneca for sale on our behalf, $73 million in Goodwill and $19 million of net deferred tax liabilities. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed. B. Divestitures Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH) On October 6, 2016, we announced that we entered into a definitive agreement under which ICU Medical agreed to acquire all of our global infusion systems net assets, HIS, for approximately $1 billion in cash and ICU Medical common stock . HIS includes IV pumps, solutions, and devices. As a result of the performance of HIS relative to ICU Medical’s expectations, on January 5, 2017, we entered into a revised agreement with ICU Medical under which ICU Medical would acquire HIS for up to approximately $900 million , composed of cash and contingent cash consideration, ICU Medical common stock and seller financing. The revised transaction closed on February 3, 2017. At closing, under the terms of the revised agreement, we received 3.2 million newly issued shares of ICU Medical common stock (as originally agreed), which we initially valued at approximately $428 million (based upon the closing price of ICU Medical common stock on the closing date less a discount for lack of marketability) and which are reported as equity securities at fair value in Long-term investments on the condensed consolidated balance sheets as of July 1, 2018 and December 31, 2017, a promissory note in the amount of $75 million , which was repaid in full as of December 31, 2017, and net cash of approximately $200 million before customary adjustments for net working capital, which is reported in Other investing activities, net on the condensed consolidated statement of cash flows for the six months ended July 2, 2017 . In addition, we are entitled to receive a contingent amount of up to an additional $225 million in cash based on ICU Medical’s achievement of certain cumulative performance targets for the combined company through December 31, 2019. After receipt of the ICU Medical shares, we own approximately 16% of ICU Medical. We have agreed to certain restrictions on transfer of our ICU Medical shares for 18 months after the closing date. We recognized pre-tax income of approximately $2 million in the second quarter of 2018 and a pre-tax loss of approximately $1 million in the first six months of 2018 , and we recognized pre-tax losses of approximately $28 million and $64 million in the second quarter and first six months of 2017 , respectively, in Other (income)/deductions––net, representing adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell. For additional information, see Note 4 and Notes to Consolidated Financial Statements–– Note 2. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment in Pfizer’s 2017 Financial Report. While we have received the full purchase price excluding the contingent amount as of the February 3, 2017 closing, the sale of the HIS net assets was not completed in certain non-U.S. jurisdictions due to temporary regulatory or operational constraints. In these jurisdictions, which represent a relatively small portion of the HIS net assets, we have continued to operate the net assets for the net economic benefit of ICU Medical, and we are indemnified by ICU Medical against risks associated with such operations during the interim period, subject to our obligations under the definitive transaction agreements. Sales of the HIS net assets have occurred in nearly all of these jurisdictions as of December 31, 2017 and we expect the sale of the HIS net assets in the remaining jurisdictions to be fully completed by the third quarter of 2018. As such, and as we have already received all of the non-contingent proceeds from the sale and ICU Medical is contractually obligated to complete the transaction, we have treated these jurisdictions as sold for accounting purposes. In connection with the sale transaction, we entered into certain transitional agreements designed to facilitate the orderly transition of the HIS net assets to ICU Medical. These agreements primarily relate to administrative services, which are generally to be provided for a period of up to 24 months after the closing date. We will also manufacture and supply certain HIS products for ICU Medical and ICU Medical will manufacture and supply certain retained Pfizer products for us after closing, generally for a term of five years. These agreements are not material to Pfizer and none confers upon us the ability to influence the operating and/or financial policies of ICU Medical subsequent to the sale. Contribution Agreement Between Pfizer and Allogene Therapeutics, Inc. (IH) In April 2018, Pfizer and Allogene announced that the two companies entered into a contribution agreement for Pfizer’s portfolio of assets related to allogeneic CAR T therapy, an investigational immune cell therapy approach to treating cancer. Under this agreement, Allogene will receive from Pfizer rights to pre-clinical and clinical CAR T assets, all of which were previously licensed to Pfizer from French cell therapy company, Cellectis, and French pharmaceutical company, Servier, beginning in 2014 and 2015, respectively. Allogene will assume responsibility for all potential financial obligations to both Cellectis and Servier. Pfizer will continue to participate financially in the development of the CAR T portfolio through a 25% ownership stake in Allogene. Separately, Pfizer continues to maintain its approximate 7% ownership stake in Cellectis that was obtained in 2014 as part of the licensing agreement in which Pfizer obtained exclusive rights to pursue the development and commercialization of certain Cellectis CAR T therapies in exchange for an upfront payment of $80 million , as well as potential future development, regulatory and commercial milestone payments and royalties. In connection with the Allogene transaction, Pfizer recognized a non-cash $50 million pre-tax gain in Other (income)/deductions––net, representing the difference between the fair value of the equity investment received and the book value of assets transferred (including an allocation of goodwill) (see Note 4 ). Sale of Phase 2b Ready AMPA Receptor Potentiator for CIAS to Biogen Inc. (WRD) In April 2018, we sold our Phase 2b ready AMPA receptor potentiator for CIAS to Biogen. We received $75 million upfront and have the opportunity to receive up to $515 million in future development and commercialization milestones, as well as tiered royalties in the low-to-mid-teen percentages. We recognized $75 million in Other (income)/deductions––net in the second quarter of 2018 (see Note 4 ). We will record the milestones and royalties to Other (income)/deductions––net when due, or earlier if we have sufficient experience to determine such amounts are not probable of significant reversal. C. Licensing Arrangement Shire International GmbH In 2016, we out-licensed PF-00547659, an investigational biologic being evaluated for the treatment of moderate-to-severe inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, to Shire for an upfront payment of $90 million , up to $460 million in development and sales-based milestone payments and potential future royalty payments on commercialized products. The $90 million upfront payment was initially deferred and recognized in Other (income)/deductions––net ratably through December 2017. In the first quarter of 2018, we recognized $75 million in Other (income)/deductions––net for a milestone payment received from Shire related to their first dosing of a patient in a Phase 3 clinical trial of the compound for the treatment of ulcerative colitis (see Note 4 ). D. Collaboration Arrangements Collaboration with Merck & Co., Inc. In 2013, we announced that we entered into a worldwide collaboration agreement, except for Japan, with Merck for the development and commercialization of ertugliflozin (PF-04971729), our oral sodium glucose cotransporter (SGLT2) inhibitor for the treatment of type 2 diabetes. Under the agreement, we collaborated with Merck on the clinical development of ertugliflozin and ertugliflozin-containing fixed-dose combinations with metformin and Januvia (sitagliptin) tablets, which were approved by the FDA in December 2017 and the European Commission in March 2018 as Steglatro, Segluromet and Steglujan, respectively. The Merck sales force will exclusively promote Steglatro and the two fixed-dose combination products and we will share revenues and certain costs with Merck on a 60% / 40% basis, with Pfizer having the 40% share. Pfizer will record its share of the collaboration revenues as product sales as we supply the ertugliflozin active pharmaceutical ingredient to Merck for use in the alliance products. In the first quarter of 2017 , we received a $90 million milestone payment from Merck upon the FDA’s acceptance for review of the NDAs for ertugliflozin and two fixed-dose combinations (ertugliflozin plus Januvia (sitagliptin) and ertugliflozin plus metformin), which, as of December 31, 2017, was deferred and primarily reported in Other noncurrent liabilities, and through December 31, 2017, was being recognized in Other (income)/deductions––net over a multi-year period. As of December 31, 2017, we were due a $60 million milestone payment from Merck, which we received in the first quarter of 2018, in conjunction with the approval of ertugliflozin by the FDA. As of December 31, 2017, the $60 million due from Merck was deferred and primarily reported in Other noncurrent liabilities . In the first quarter of 2018, in connection with the approval of ertugliflozin in the EU, we recognized a $40 million milestone payment from Merck in Other (income)/deductions––net (see Note 4 ). We are eligible for additional payments associated with the achievement of future regulatory and commercial milestones. In the first quarter of 2018, in connection with the adoption of a new accounting standard, as of January 1, 2018, the $60 million of deferred income and approximately $85 million of the $90 million of deferred income associated with the above-mentioned milestone payments were recorded to and included in the $584 million cumulative effect adjustment to Retained earnings . See Note 1B for additional information. Collaboration with Eli Lilly & Company In 2013, we entered into a collaboration agreement with Lilly to jointly develop and globally commercialize Pfizer’s tanezumab, which provides that Pfizer and Lilly will equally share product-development expenses as well as potential revenues and certain product-related costs. We received a $200 million upfront payment from Lilly in accordance with the collaboration agreement between Pfizer and Lilly, which was deferred and primarily reported in Other noncurrent liabilities, and through December 31, 2017, was being recognized in Other (income)/deductions––net over a multi-year period beginning in the second quarter of 2015. Pfizer and Lilly resumed the Phase 3 chronic pain program for tanezumab in July 2015. The FDA granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis and chronic low back pain in June 2017. Under the collaboration agreement with Lilly, we are eligible to receive additional payments from Lilly upon the achievement of specified regulatory and commercial milestones. In the first quarter of 2018, in connection with the adoption of a new accounting standard, as of January 1, 2018, approximately $107 million of deferred income associated with the above-mentioned upfront payment was recorded to and included in the $584 million cumulative effect adjustment to Retained earnings . See Note 1B for additional information. Approximately $43 million of the upfront payment continues to be deferred, of which approximately $29 million is reported in Other current liabilities and approximately $14 million is reported in Other noncurrent liabilities as of July 1, 2018 . This amount is expected to be recognized in Other (income)/deductions––net over the remaining development period for the product between 2018 and 2020. E. Privately Held Investment AM-Pharma B.V. In April 2015, we acquired a minority equity interest in AM-Pharma B.V., a privately-held Dutch biopharmaceutical company focused on the development of human recombinant Alkaline Phosphatase (recAP) for inflammatory diseases, and secured an exclusive option to acquire the remaining equity in the company. The option became exercisable after completion of a Phase 2 trial of recAP in the treatment of Acute Kidney Injury related to sepsis in the first quarter of 2018. We have declined to exercise the option and the option expired unexercised during the second quarter of 2018.

Restructuring Charges and Other

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	6 Months Ended
	Jul. 01, 2018
Restructuring and Related Activities [Abstract]
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example: • In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and • In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems. All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as groups such as information technology, shared services and corporate operations. In connection with our acquisition of Hospira, we are focusing our efforts on achieving an appropriate cost structure for the combined company. We expect to incur costs of approximately $1 billion (not including costs of $215 million associated with the return of acquired IPR&D rights as described in the Current-Period Key Activities section of Notes to Consolidated Financial Statements–– Note 3 . Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives in our 2017 Financial Report) associated with the integration of Hospira. The majority of these costs are expected to be incurred within the three -year period post-acquisition. As a result of the evaluation performed in connection with our decision in September 2016 to not pursue, at that time, splitting IH and EH into two separate publicly-traded companies, we identified new opportunities to potentially achieve greater optimization and efficiency to become more competitive in our business. Therefore, in early 2017 , we initiated new enterprise-wide cost reduction/productivity initiatives, which we expect to substantially complete by the end of 2019. These initiatives encompass all areas of our cost base and include: • Optimization of our manufacturing plant network to support IH and EH products and pipelines. During 2017-2019, we expect to incur costs of approximately $800 million related to this initiative. Through July 1, 2018 , we incurred approximately $283 million associated with this initiative. • Activities in non-manufacturing related areas, which include further centralization of our corporate and platform functions, as well as other activities where opportunities are identified. During 2017-2019, we expect to incur costs of approximately $400 million related to this initiative. Through July 1, 2018 , we incurred approximately $217 million associated with this initiative. The costs expected to be incurred during 2017-2019, of approximately $1.2 billion for the above-mentioned programs (but not including expected costs associated with the Hospira integration), include restructuring charges, implementation costs and additional depreciation––asset restructuring. Of this amount, we expect that about 20% of the total charges will be non-cash. Current-Period Key Activities For the first six months of 2018 , we incurred costs of $152 million associated with the 2017-2019 program, $81 million associated with the integration of Hospira and $29 million associated with all other acquisition-related initiatives. The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) July 1, July 2, July 1, July 2, Restructuring (credits)/charges: Employee terminations $ (21 ) $ (27 ) $ (29 ) $ (57 ) Asset impairments (6 ) — (4 ) 24 Exit costs 3 4 — 6 Restructuring credits (a) (24 ) (23 ) (33 ) (27 ) Transaction costs (b) — 6 — 18 Integration costs (c) 68 86 120 163 Restructuring charges and certain acquisition-related costs 44 70 87 153 Net periodic benefit costs recorded in Other (income)/deductions––net (d) 29 1 61 74 Additional depreciation––asset restructuring, virtually all of which is recorded in Cost of sales (e) 13 21 31 35 Implementation costs recorded in our condensed consolidated statements of income as follows (f) : Cost of sales 20 36 36 51 Selling, informational and administrative expenses 16 15 34 24 Research and development expenses 7 11 13 17 Total implementation costs 44 62 82 93 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 131 $ 153 $ 262 $ 356 (a) In the three and six months ended July 1, 2018 , restructuring credits are associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as acquisition-related costs, primarily associated with Hospira. In the three and six months ended July 2, 2017 , restructuring credits are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, partially offset by charges related to our acquisition of mainly Anacor in the second quarter of 2017, and mainly Anacor and Medivation in the first six months of 2017. In the three and six months ended July 1, 2018 , Employee terminations primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, many of which may be paid out during periods after termination. The restructuring activities for 2018 are associated with the following: • For the second quarter of 2018 , IH ( $12 million income); EH ( $2 million ); manufacturing operations ( $13 million ); and Corporate ( $26 million income). • For the first six months of 2018 , IH ( $12 million income); EH ( $12 million income); WRD/GPD ( $2 million income); manufacturing operations ( $15 million ); and Corporate ( $22 million income). The restructuring activities for 2017 are associated with the following: • For the second quarter of 2017 , IH ( $8 million income); EH ( $7 million ); WRD/GPD ( $14 million income); manufacturing operations ( $8 million income); and Corporate ( $1 million ). • For the first six months of 2017 , IH ( $1 million income); EH ( $11 million income); WRD/GPD ( $26 million income); manufacturing operations ( $9 million ); and Corporate ( $3 million ). (b) Transaction costs represent external costs for banking, legal, accounting and other similar services, virtually all of which for the second quarter and first six months of 2017 were directly related to our acquisition of Medivation. (c) Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the second quarter and first six months of 2018 , integration costs were primarily related to our acquisition of Hospira. In the second quarter and first six months of 2017 , integration costs were primarily related to our acquisitions of Hospira and Medivation, including a net gain of $12 million related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see Note 10 ). (d) In the three and six months ended July 1, 2018 , primarily represents the net pension curtailments and settlements included in Other (income)/deductions––net upon the adoption of a new accounting standard in the first quarter of 2018. In the three and six months ended July 2, 2017 , primarily represents the net pension curtailments and settlements, partially offset by net periodic benefit credits, excluding service costs, related to our acquisition of Hospira, both of which were reclassified to Other (income)/deductions––net as a result of the retrospective adoption of a new accounting standard in the first quarter of 2018. These credits included a net settlement gain, partially offset by accelerated amortization of actuarial losses and prior service costs upon the settlement of the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. For additional information, see Note 1B and Note 10 . (e) Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (f) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives. The following table provides the components of and changes in our restructuring accruals: (MILLIONS OF DOLLARS) Employee Termination Costs Asset Impairment Charges Exit Costs Accrual Balance, December 31, 2017 (a) $ 1,039 $ — $ 66 $ 1,105 Credits (29 ) (4 ) — (33 ) Utilization and other (b) (171 ) 4 (28 ) (195 ) Balance, July 1, 2018 (c) $ 839 $ — $ 38 $ 877 (a) Included in Other current liabilities ( $643 million ) and Other noncurrent liabilities ( $462 million ). (b) Includes adjustments for foreign currency translation. (c) Included in Other current liabilities ( $460 million ) and Other noncurrent liabilities ( $418 million ).

Other (Income)_Deductions - Net

Other (Income)/Deductions - Net	6 Months Ended
	Jul. 01, 2018
Other Income and Expenses [Abstract]
Other (Income)/Deductions - Net	Other (Income)/Deductions—Net The following table provides components of Other (income)/deductions––net : Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) July 1, July 2, July 1, July 2, Interest income (a) $ (80 ) $ (94 ) $ (157 ) $ (175 ) Interest expense (a) 326 312 635 621 Net interest expense 245 218 478 446 Royalty-related income (121 ) (105 ) (217 ) (191 ) Net gains on asset disposals (b) (17 ) (34 ) (36 ) (125 ) Income from collaborations, out-licensing arrangements and sales of compound/product rights (c) (174 ) (37 ) (316 ) (85 ) Net unrealized gains on equity securities (d) (226 ) — (337 ) — Net periodic benefit costs/(credits) other than service costs (e) (84 ) (8 ) (166 ) 53 Certain legal matters, net (f) (88 ) 3 (107 ) 11 Certain asset impairments (g) 31 — 31 13 Adjustments to loss on sale of HIS net assets (h) (2 ) 28 1 64 Business and legal entity alignment costs (i) 1 17 4 38 Other, net (j) (115 ) (155 ) (64 ) (239 ) Other (income)/deductions––net $ (551 ) $ (75 ) $ (728 ) $ (14 ) (a) Interest income decreased in the second quarter and first six months of 2018 , primarily driven by a lower investment balance. Interest expense increased in the second quarter and first six months of 2018 , primarily as a result of higher short-term interest rates, offset, in part, by refinancing activity that occurred in the fourth quarter of 2017. (b) In the second quarter of 2018 , primarily includes gains on fixed assets and other asset disposals of $15 million . In the first six months of 2018 , includes gains on fixed assets and other asset disposals of $22 million and net gains on sales of investments in equity and debt securities of approximately $14 million . In the second quarter of 2017 , primarily includes gains on sales and redemptions of investments in equity and debt securities (approximately $60 million ), partially offset by a net loss related to the sale of our 40% ownership investment in Teuto, including the extinguishment of a put option for the then remaining 60% ownership interest (approximately $30 million ). In the first six months of 2017 , primarily includes gains on sales and redemptions of investments in equity and debt securities (approximately $102 million ) and a gain on sale of property (approximately $50 million ), partially offset by the net loss related to the sale of our investment in Teuto discussed above. (c) Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the second quarter of 2018 , primarily includes, among other things, approximately $88 million in milestone income from multiple licensees and an upfront payment to us of $75 million for the sale of an AMPA receptor potentiator for CIAS to Biogen. In the first six months of 2018 , primarily includes, among other things, all of the factors discussed above for the second quarter of 2018 , as well as a $75 million milestone payment received from Shire related to their first dosing of a patient in a Phase 3 clinical trial of a compound out-licensed by Pfizer to Shire for the treatment of ulcerative colitis, and a $40 million milestone payment from Merck in conjunction with the approval of ertugliflozin in the EU. For additional information, see Note 2B, Note 2C and Note 2D . (d) Represents the unrealized net gains on equity securities reflecting the adoption of a new accounting standard in the first quarter of 2018. Approximately $142 million of these unrealized gains in the second quarter of 2018 and approximately $203 million of these unrealized gains in the first six months of 2018 relate to 3.2 million shares of ICU Medical stock that were received as part of the consideration for the sale of HIS net assets to ICU Medical. Prior to the adoption of the new standard, net unrealized gains and losses on virtually all equity securities with readily determinable fair values were reported in Accumulated other comprehensive income. For additional information, see Note 1B and Note 7B . (e) Represents the net periodic benefit costs/(credits), excluding service costs, as a result of the adoption of a new accounting standard in the first quarter of 2018. Effective January 1, 2018, the U.S. Pfizer Consolidated Pension Plan was frozen to future benefit accruals and for the second quarter and first six months of 2018 , resulted in the recognition of lower net periodic benefit costs due to the extension of the amortization period for the actuarial losses and the elimination of service costs. There was also a greater than expected gain on plan assets due to a higher plan asset base compared to the second quarter and first six months of 2017. For additional information, see Note 1B and Note 10 . (f) In the second quarter and first six months of 2018 , primarily represents the reversal of a legal accrual where a loss was no longer deemed probable. (g) In the second quarter and first six months of 2018 , includes an intangible asset impairment charge related to a finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the U.S. market only. The impairment charge for the second quarter and first six months of 2018 is associated with IH and reflects , among other things, updated commercial forecasts. (h) In the second quarter and first six months of 2018 and 2017 , represents adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical on February 3, 2017. For additional information, see Note 2B . (i) In the second quarter and first six months of 2018 and 2017 , represents expenses for changes to our infrastructure to align our commercial operations of our current segments, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. (j) In the second quarter and first six months of 2018 , includes, among other things, dividend income of $76 million and $135 million , respectively, from our investment in ViiV, and charges of $23 million and $135 million , respectively, reflecting the change in the fair value of contingent consideration. The second quarter and first six months of 2018 also include a non-cash $50 million pre-tax gain on the contribution of Pfizer’s allogeneic CAR T therapy development program assets obtained from Cellectis and Servier in connection with our contribution agreement entered into with Allogene in which Pfizer obtained a 25% ownership stake in Allogene (see Note 2B ), and a non-cash $17 million pre-tax gain on the cash settlement of a liability that we incurred in April 2018 upon the EU approval of Mylotarg (see Note 7E ). In the second quarter and first six months of 2017 , primarily includes, among other things, dividend income of $114 million and $157 million , respectively, from our investment in ViiV. The following table provides additional information about the intangible asset that was impaired during 2018 in Other (income)/deductions: Fair Value (a) Three and Six Months Ended July 1, 2018 (MILLIONS OF DOLLARS) Amount Level 1 Level 2 Level 3 Impairment Intangible assets––Developed technology right, finite-lived (b) $ 35 $ — $ — $ 35 $ 31 (a) The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. (b) Reflects intangible assets written down to fair value in the second quarter and first six months of 2018 . Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax Matters

Tax Matters	6 Months Ended
	Jul. 01, 2018
Income Tax Disclosure [Abstract]
Tax Matters	Tax Matters A. Taxes on Income from Continuing Operations In the fourth quarter of 2017, we recorded an estimate of certain tax effects of the TCJA, including the impact on deferred tax assets and liabilities from the reduction in the U.S. Federal corporate tax rate from 35% to 21% , the impact on valuation allowances and other state income tax considerations, the $15.2 billion repatriation tax liability on accumulated post-1986 foreign earnings for which we plan to elect payment over eight years through 2026 (with the first of eight installments due in April 2019) that is reported primarily in Other taxes payable , and deferred taxes on basis differences expected to give rise to future taxes on global intangible low-taxed income. In addition, we had provided deferred tax liabilities in the past on foreign earnings that were not indefinitely reinvested. As a result of the TCJA, we reversed an estimate of the deferred taxes that are no longer expected to be needed due to the change to the territorial tax system. The estimated amounts recorded may change in the future due to uncertain tax positions. With respect to the aforementioned repatriation tax liability related to the TCJA repatriation tax, our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards. The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income , states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We have elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years. However, given the complexity of these provisions, we have not finalized our analysis. We were able to make a reasonable estimate of the deferred taxes on the temporary differences expected to reverse in the future and provided a provisional deferred tax liability of approximately $1 billion as of December 31, 2017. The provisional amount is based on the evaluation of certain temporary differences inside each of our foreign subsidiaries that are expected to reverse as global intangible low-taxed income. However, as we continue to evaluate the TCJA’s global intangible low-taxed income provisions during the measurement period, we may revise the methodology used for determining the deferred tax liability associated with such income. We believe that we have made reasonable estimates with respect to each of the above items, however, all of the amounts recorded are provisional as we have not completed our analysis of the complex and far reaching effects of the TCJA. Further, we continue to consider our assertions on any remaining outside basis differences in our foreign subsidiaries as of July 1, 2018 and have not completed our analysis. Under guidance issued by the staff of the SEC, we expect to finalize our accounting related to the tax effects of the TCJA on deferred taxes, valuation allowances, state tax considerations, the repatriation tax liability, global intangible low-taxed income, and any remaining outside basis differences in our foreign subsidiaries during 2018 as we complete our analysis, computations and assertions. It is possible that others, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. We will revise these estimates during the second half of 2018 as we gather additional information to complete our tax returns and as any interpretation or clarification of the TCJA occurs through legislation, U.S. Treasury actions or other means. Our effective tax rate for continuing operations was 14.3% for the second quarter of 2018 , compared to 19.4% for the second quarter of 2017 and was 13.9% for the first six months of 2018 , compared to 20.1% for the first six months of 2017 . The lower effective tax rate for the second quarter and first six months of 2018 in comparison with the same periods in 2017 was primarily due to: • the December 2017 enactment of the TCJA; • the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business; as well as • an increase in benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various foreign authorities, and the expiration of certain statutes of limitations. B. Deferred Taxes We have not completed our analysis of the TCJA on our prior assertion of indefinitely reinvested earnings. Accordingly, we continue to evaluate our assertion with respect to our accumulated foreign earnings subject to the deemed repatriation tax and we also continue to evaluate the amount of earnings that are indefinitely reinvested. Additionally, we continue to evaluate our assertions on any remaining outside basis differences in our foreign subsidiaries as of July 1, 2018 as we have not finalized our analysis of the effects of all of the new provisions in the TCJA. As of July 1, 2018 , it is not practicable to estimate the additional deferred tax liability that would be recorded if the earnings subject to the deemed repatriation tax and any remaining outside basis differences as of July 1, 2018 are not indefinitely reinvested. In accordance with the authoritative guidance issued by the SEC Staff Accounting Bulletin 118, we expect to complete our analysis within the measurement period. C. Tax Contingencies We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS: • With respect to Pfizer, the IRS has issued a Revenue Agent’s Report (RAR) for tax years 2009-2010. We are not in agreement with the RAR and are currently appealing certain disputed issues. As of the date of the filing of this Quarterly Report on Form 10-Q, tax years 2011-2015 are currently under audit. Tax years 2016-2018 are open but not under audit. All other tax years are closed. • With respect to Hospira, the federal income tax audit of tax year 2014 through short-year 2015 was effectively settled in the second quarter of 2018. All other tax years are closed. • With respect to Anacor and Medivation, the open tax years are not considered material to Pfizer. In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2013-2018), Japan (2015-2018), Europe (2011-2018, primarily reflecting Ireland, the United Kingdom, France, Italy, Spain and Germany), Latin America (1998-2018, primarily reflecting Brazil) and Puerto Rico (2011-2018). D. Tax Provision/(Benefit) on Other Comprehensive Income/(loss) The following table provides the components of Tax provision/(benefit) on other comprehensive income/(loss): Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) July 1, July 2, July 1, July 2, Foreign currency translation adjustments, net (a) $ 101 $ (109 ) $ 67 $ (130 ) Unrealized holding gains/(losses) on derivative financial instruments, net 8 (1 ) 4 2 Reclassification adjustments for (gains)/losses included in net income 72 (88 ) 65 (140 ) Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b) — — 1 — 79 (89 ) 70 (138 ) Unrealized holding gains/(losses) on available-for-sale securities, net (48 ) 18 (28 ) 55 Reclassification adjustments for (gains)/losses included in net income 20 (7 ) (2 ) 4 Reclassification adjustments for tax on unrealized gains from AOCI to Retained earnings (c) — — (45 ) — (29 ) 11 (76 ) 59 Benefit plans: actuarial gains/(losses), net (13 ) 22 25 22 Reclassification adjustments related to amortization 14 43 28 92 Reclassification adjustments related to settlements, net 7 (4 ) 15 8 Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b) — — 637 — Other 27 (17 ) 6 (13 ) 34 43 712 110 Benefit plans: prior service costs and other, net — — — — Reclassification adjustments related to amortization (11 ) (17 ) (22 ) (33 ) Reclassification adjustments related to curtailments, net 4 (1 ) (3 ) (4 ) Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b) — — (144 ) — Other (6 ) — — — (13 ) (19 ) (168 ) (38 ) Tax provision/(benefit) on other comprehensive income/(loss) $ 173 $ (163 ) $ 605 $ (138 ) (a) Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely. (b) For additional information on the adoption of a new accounting standard related to reclassification of certain tax effects from AOCI, see Note 1B. (c) For additional information on the adoption of a new accounting standard related to financial assets and liabilities, see Note 1B .

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	6 Months Ended
	Jul. 01, 2018
Equity [Abstract]
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests The following table provides the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gains/(Losses) Benefit Plans (MILLIONS OF DOLLARS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Actuarial Gains/(Losses) Prior Service (Costs)/Credits and Other Accumulated Other Comprehensive Income/(Loss) Balance, December 31, 2017 $ (5,180 ) $ (30 ) $ 401 $ (5,262 ) $ 750 $ (9,321 ) Other comprehensive income/(loss) due to the adoption of new accounting standards (a) (2 ) (1 ) (416 ) (637 ) 144 (913 ) Other comprehensive income/(loss) (b) (15 ) 298 (215 ) 241 (80 ) 231 Balance, July 1, 2018 $ (5,198 ) $ 267 $ (230 ) $ (5,657 ) $ 814 $ (10,003 ) (a) Amounts represent the cumulative effect adjustments as of January 1, 2018 from the adoption of new accounting standards related to (i) financial assets and liabilities and (ii) the reclassification of certain tax effects from AOCI. For additional information, see Note 1B. (b) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $11 million loss for the first six months of 2018 . As of July 1, 2018 , with respect to derivative financial instruments, the amount of unrealized pre-tax net gains on derivative financial instruments estimated to be reclassified into income within the next 12 months is approximately $213 million , which is expected to be offset primarily by net losses resulting from reclassification adjustments related to net losses related to available-for-sale debt securities and foreign currency exchange-denominated forecasted intercompany inventory sales.

Financial Instruments

Financial Instruments	6 Months Ended
	Jul. 01, 2018
Financial Instruments [Abstract]
Financial Instruments	Financial Instruments A. Fair Value Measurements Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis On January 1, 2018, we adopted a new accounting and disclosure standard related to accounting for the recognition of financial assets and liabilities. For additional information see Note 1B . The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in Notes to Consolidated Financial Statements–– Note 1E. Basis of Presentation and Significant Accounting Policies: Fair Value in Pfizer’s 2017 Financial Report: July 1, 2018 December 31, 2017 (MILLIONS OF DOLLARS) Total Level 1 Level 2 Total Level 1 Level 2 Financial assets measured at fair value on a recurring basis: Short-term investments Classified as equity securities: Money market funds $ 1,302 $ — $ 1,302 $ 2,115 $ — $ 2,115 Equity (a) 30 19 12 35 16 19 1,332 19 1,314 2,150 16 2,134 Classified as available-for-sale debt securities: Government and agency—non-U.S. 5,527 — 5,527 12,242 — 12,242 Corporate 2,659 — 2,659 2,766 — 2,766 Government—U.S. 8 — 8 252 — 252 Agency asset-backed—U.S. 19 — 19 23 — 23 Other asset-backed 7 — 7 79 — 79 8,220 — 8,220 15,362 — 15,362 Total short-term investments 9,553 19 9,534 17,512 16 17,496 Other current assets Derivative assets: Interest rate contracts 98 — 98 104 — 104 Foreign exchange contracts 353 — 353 234 — 234 Total other current assets 451 — 451 337 — 337 Long-term investments Classified as equity securities: Equity (a) 1,737 1,704 33 1,440 1,398 42 Classified as trading securities: Debt 50 50 — 73 73 — 1,787 1,754 33 1,514 1,472 42 Classified as available-for-sale debt securities: Government and agency—non-U.S. 141 — 141 387 — 387 Corporate 3,579 — 3,579 4,172 36 4,136 Government—U.S. 425 — 425 495 — 495 Other asset-backed 14 — 14 35 — 35 4,160 — 4,160 5,090 36 5,054 Total long-term investments 5,947 1,754 4,193 6,603 1,507 5,096 Other noncurrent assets Derivative assets: Interest rate contracts 290 — 290 477 — 477 Foreign exchange contracts 200 — 200 7 — 7 Total other noncurrent assets 489 — 489 484 — 484 Total assets $ 16,440 $ 1,773 $ 14,668 $ 24,937 $ 1,523 $ 23,414 Financial liabilities measured at fair value on a recurring basis: Other current liabilities Derivative liabilities: Interest rate contracts $ 11 $ — $ 11 $ 1 $ — $ 1 Foreign exchange contracts 115 — 115 201 — 201 Total other current liabilities 126 — 126 201 — 201 Other noncurrent liabilities Derivative liabilities: Interest rate contracts 499 — 499 177 — 177 Foreign exchange contracts 413 — 413 313 — 313 Total other noncurrent liabilities 912 — 912 490 — 490 Total liabilities $ 1,038 $ — $ 1,038 $ 691 $ — $ 691 (a) As of July 1, 2018 , short-term equity securities of $11 million and long-term equity securities of $32 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. As of December 31, 2017 , short-term equity securities of $19 million and long-term equity securities of $42 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values: July 1, 2018 December 31, 2017 Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value (MILLIONS OF DOLLARS) Total Level 2 Total Level 2 Financial Liabilities Long-term debt, excluding the current portion $ 28,935 $ 30,011 $ 30,011 $ 33,538 $ 37,253 $ 37,253 The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities at cost, and short-term borrowings not measured at fair value on a recurring basis were not significant as of July 1, 2018 or December 31, 2017 . The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs. The fair value measurements of our private equity securities carried at cost, which represent investments in the life sciences sector, are based on Level 3 inputs. In addition, as of July 1, 2018 and December 31, 2017 , we had long-term receivables whose fair value is based on Level 3 inputs. As of July 1, 2018 and December 31, 2017 , the differences between the estimated fair values and carrying values of these receivables were not significant. Total Short-Term and Long-Term Investments The following table represents our investments by classification type: (MILLIONS OF DOLLARS) July 1, 2018 December 31, 2017 Short-term investments Equity securities $ 1,332 $ 2,150 Available-for-sale debt securities 8,220 15,362 Held-to-maturity debt securities 1,174 1,138 Total Short-term investments $ 10,727 $ 18,650 Long-term investments Equity securities $ 1,787 $ 1,514 Available-for-sale debt securities 4,160 5,090 Held-to-maturity debt securities 70 4 Private equity investments carried at equity-method or cost 578 408 Total Long-term investments $ 6,595 $ 7,015 Held-to-maturity cash equivalents $ 808 $ 719 Fair Value Methodology The following inputs and valuation techniques were used to estimate the fair value of our financial assets and liabilities: • Trading debt securities—quoted market prices. • Available-for-sale debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate yield curves. Loan-backed, mortgage-backed and receivable-backed debt securities are valued by third-party models that use significant inputs derived from observable market data like prepayment rates, default rates, and recovery rates. • Equity securities—quoted market prices. • Derivative assets and liabilities (financial instruments)—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data. Where applicable, these models discount future cash flow amounts using market-based observable inputs, including interest rate yield curves, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant. • Money market funds—observable net asset value prices. We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other third-party pricing models, monitoring key observable inputs (like LIBOR interest rates) and selectively performing test-comparisons of values with actual sales of financial instruments. B. Investments At July 1, 2018, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt and equity securities at July 1, 2018 and December 31, 2017 is as follows, including, as of July 1, 2018, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to maturity debt securities: July 1, 2018 December 31, 2017 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 to 5 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 5,797 $ 5 $ (133 ) $ 5,669 $ 5,527 $ 141 $ — $ 5,669 $ 12,616 $ 61 $ (48 ) $ 12,629 Corporate (a) 6,358 2 (122 ) 6,238 2,659 2,557 1,022 6,238 6,955 15 (33 ) 6,938 Government––U.S. 458 — (25 ) 433 8 415 10 433 765 — (19 ) 747 Agency asset-backed––U.S. 19 — — 19 19 — — 19 24 — (1 ) 24 Other asset-backed (b) 22 — — 22 7 13 2 22 114 — — 114 Held-to-maturity debt securities Time deposits and other 1,482 — — 1,482 1,412 66 4 1,482 1,091 — — 1,091 Government and agency––non-U.S. 570 — — 570 570 — — 570 770 — — 770 Total debt securities $ 14,705 $ 7 $ (280 ) $ 14,432 $ 10,202 $ 3,192 $ 1,038 $ 14,432 $ 22,337 $ 77 $ (100 ) $ 22,313 Available-for-sale equity securities (c) Money market funds $ 2,115 $ — $ — $ 2,115 Equity 728 586 (124 ) 1,190 Total available-for-sale equity securities $ 2,843 $ 586 $ (124 ) $ 3,304 (a) Issued by a diverse group of corporations. (b) Includes loan-backed, mortgage-backed and receivable-backed securities, all of which are in senior positions in the capital structure of the security. Loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages. Receivable-backed securities are collateralized by credit cards receivables. (c) Upon the 2018 adoption of a new accounting standard related to financial assets and liabilities, available-for-sale equity securities were classified as equity securities. For additional information see Note 1B . The following table presents the net unrealized gains and losses for the period that relates to equity securities still held at the reporting date, calculated as follows: (MILLIONS OF DOLLARS) Three Months Ended July 1, 2018 Six Months Ended July 1, 2018 Net gains recognized during the period on equity securities (a) $ 232 $ 330 Less: Net gains recognized during the period on equity securities sold during the period (19 ) (31 ) Net unrealized gains during the reporting period on equity securities still held at the reporting date $ 213 $ 299 (a) The second quarter of 2018 includes $226 million of unrealized net gains reflecting the adoption of a new accounting standard in the first quarter of 2018 and $7 million of unrealized gains on other equity securities. The first six months of 2018 includes $337 million of unrealized net gains reflecting the adoption of a new accounting standard in the first quarter of 2018 and $7 million of unrealized losses on other equity securities. For additional information, see Note 1B and Note 4 . C. Short-Term Borrowings Short-term borrowings include: (MILLIONS OF DOLLARS) July 1, December 31, Commercial paper $ 6,800 $ 6,100 Current portion of long-term debt, principal amount 4,267 3,532 Other short-term borrowings, principal amount (a) 538 320 Total short-term borrowings, principal amount 11,605 9,951 Net fair value adjustments related to hedging and purchase accounting (4 ) 14 Net unamortized discounts, premiums and debt issuance costs (18 ) (12 ) Total Short-term borrowings, including current portion of long-term debt , carried at historical proceeds, as adjusted $ 11,583 $ 9,953 (a) Other short-term borrowings primarily include cash collateral. For additional information, see Note 7F . D. Long-Term Debt The following table provides the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt: (MILLIONS OF DOLLARS) July 1, December 31, Total long-term debt, principal amount $ 28,701 $ 32,783 Net fair value adjustments related to hedging and purchase accounting 338 872 Net unamortized discounts, premiums and debt issuance costs (112 ) (125 ) Other long-term debt 8 8 Total long-term debt, carried at historical proceeds, as adjusted $ 28,935 $ 33,538 Current portion of long-term debt, carried at historical proceeds $ 4,262 $ 3,546 E. Other Noncurrent Liabilities Mylotarg (gemtuzumab ozogamicin) In April 2018, the EU approved Mylotarg for the treatment of acute myeloid leukemia. In connection with the EU approval, we incurred an obligation to make guaranteed fixed annual payments over a ten -year period aggregating $301 million related to a research and development arrangement. We recorded the estimated net present value of $240 million as a liability and an intangible asset in Developed technology rights as of the approval date. In June 2018, we entered into a transaction with the obligee to buyout the remaining liability for the fixed annual payments for a lump sum payment of $224 million . As a result of the buyout transaction, the liability was extinguished and we recognized a non-cash $17 million pre-tax gain in Other (income)/deductions––net in the second quarter of 2018 (see Note 4) . Bosulif (bosutinib) In December 2017, the U.S. FDA approved Bosulif for the treatment of patients with newly-diagnosed chronic-phase Ph+ CML. In connection with the U.S. approval, we incurred an obligation to make guaranteed fixed annual payments over a ten -year period aggregating $416 million related to a research and development arrangement. We recorded the estimated net present value of $364 million as of the approval date as an intangible asset in Developed technology rights . The present value of the remaining future payments as of July 1, 2018 is $285 million , of which $30 million is recorded in Other current liabilities and $255 million is recorded in Other noncurrent liabilities . Besponsa (inotuzumab ozogamicin) In August 2017, the U.S. FDA approved Besponsa and in June 2017, the EU approved Besponsa as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. In connection with the U.S. approval, we incurred an obligation to make guaranteed fixed annual payments over a nine -year period aggregating $296 million related to a research and development arrangement. We recorded the estimated net present value of $248 million as of the approval date as an intangible asset in Developed technology rights . The present value of the remaining future payments as of July 1, 2018 is $239 million , of which $7 million is recorded in Other current liabilities and $232 million is recorded in Other noncurrent liabilities . In connection with the EU approval, we incurred an obligation to make guaranteed fixed annual payments over a nine -year period aggregating $148 million related to a research and development arrangement. We recorded the estimated net present value of $123 million as of the approval date as an intangible asset in Developed technology rights . The present value of the remaining future payments as of July 1, 2018 is $120 million , of which $3 million is recorded in Other current liabilities and $117 million is recorded in Other noncurrent liabilities . The differences between the estimated fair values in the Level 2 fair value hierarchy and carrying values of these obligations were not significant as of July 1, 2018 . F. Derivative Financial Instruments and Hedging Activities We adopted a new accounting standard in the first quarter of 2018, as of January 2018. For additional information, see Note 1B. Foreign Exchange Risk A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We manage our foreign exchange risk, in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. We also manage our foreign exchange risk, depending on market conditions, through fair value, cash flow, and net investment hedging programs through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income against the impact of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions. All derivative financial instruments used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the consolidated balance sheet. The derivative financial instruments primarily hedge or offset exposures in the euro, Japanese yen, Swedish krona, and U.K. pound . Changes in fair value are reported in earnings or in Other comprehensive income/(loss) , depending on the nature and purpose of the financial instrument (hedge or offset relationship) and the effectiveness of the hedge relationships, as follows: • Generally, we recognize the gains and losses on foreign exchange contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged risk. Upon the adoption of the new standard in 2018, for certain foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize that excluded amount through an amortization approach. We also recognize the offsetting foreign exchange impact attributable to the hedged item in earnings. • Generally, we record in Other comprehensive income/(loss) gains or losses on foreign exchange contracts that are designated as cash flow hedges and reclassify those amounts, as appropriate, into earnings in the same period or periods during which the hedged transaction affects earnings. Upon the adoption of the new standard in 2018, for certain foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize that excluded amount through an amortization approach. • Historically, as part of our net investment hedging program, we recognize the gain and loss impact on foreign exchange contracts designated as hedges of our net investments in earnings in three ways: over time –– for the periodic net swap payments; immediately –– to the extent of any change in the difference between the foreign exchange spot rate and forward rate; and upon sale or substantial liquidation of our net investments –– to the extent of change in the foreign exchange spot rates. Upon the adoption of the new standard in 2018, for foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize that excluded amount through an amortization approach. We record in Other comprehensive income/(loss) the foreign exchange gains and losses related to foreign exchange-denominated debt designated as a hedge of our net investments in foreign subsidiaries and reclassify those amounts into earnings upon the sale or substantial liquidation of our net investments. • For certain foreign exchange contracts not designated as hedging instruments, we recognize the gains and losses on foreign currency exchange contracts that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement. As a part of our cash flow hedging program, we designate foreign exchange contracts to hedge a portion of our forecasted euro, Japanese yen, Canadian dollar, U.K. pound, Australian dollar, and Chinese renminbi -denominated intercompany inventory sales expected to occur no more than two years from the date of each hedge. For the second quarter and first six months ended July 2, 2017 , any ineffectiveness is recognized immediately into earnings. There is no significant ineffectiveness for these periods. Interest Rate Risk Our interest-bearing investments and borrowings are subject to interest rate risk. With respect to our investments, we strive to maintain a predominantly floating-rate basis position, but our strategy may change based on prevailing market conditions. We currently borrow primarily on a long-term, fixed rate basis. Historically, we strove to borrow primarily on a floating-rate basis; but in recent years we borrowed on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps. We entered into derivative financial instruments to hedge or offset the fixed interest rates on the hedged item, matching the amount and timing of the hedged item. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt. All derivative contracts used to manage interest rate risk are measured at fair value and reported as assets or liabilities on the consolidated balance sheet. Changes in fair value are reported in earnings, as follows: • We recognize the gains and losses on interest rate contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged risk. We also recognize the offsetting earnings impact of fixed-rate debt attributable to the hedged risk in earnings. For the second quarter and first six months ended July 2, 2017 , any ineffectiveness is recognized immediately into earnings. There is no significant ineffectiveness for these periods. The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) July 1, 2018 December 31, 2017 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 19,254 $ 472 $ 458 $ 18,723 $ 179 $ 459 Interest rate contracts 11,300 387 510 12,430 581 178 859 968 760 637 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 12,134 81 70 $ 14,300 62 54 Total $ 940 $ 1,038 $ 822 $ 691 (a) As of July 1, 2018 , the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion . The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Amount of (a), (b) Amount of Gains/(Losses) (a), (c) Amount of Gains/(Losses) (a), (c) (MILLIONS OF DOLLARS) July 1, July 2, July 1, July 2, July 1, July 2, Three Months Ended Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (d) $ — $ (4 ) $ 107 $ (90 ) $ (330 ) $ 208 Amount excluded from effectiveness testing recognized in earnings based on an amortization approach — — 20 — 20 — Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts (121 ) 100 — — — — Hedged item gain/(loss) 121 (100 ) — — — — Foreign exchange contracts 12 (11 ) — — — — Hedged item gain/(loss) (12 ) 11 — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — — 153 — — — The portion of gains/(losses) on foreign exchange contracts excluded from the assessment of hedge effectiveness — — 25 — 21 — Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings (e) — — 85 — — — Foreign currency long-term debt (e) — — 186 (295 ) — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts 61 (5 ) — — — — All other net — — 1 — 1 — $ 62 $ (9 ) $ 577 $ (384 ) $ (289 ) $ 208 Amount of (a), (b) Amount of Gains/(Losses) (a), (c) Amount of Gains/(Losses) (a), (c) (MILLIONS OF DOLLARS) July 1, July 2, July 1, July 2, July 1, July 2, Six Months Ended Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (d) $ — $ (6 ) $ (36 ) $ (99 ) $ (402 ) $ 449 Amount excluded from effectiveness testing recognized in earnings based on an amortization approach — — 48 — 48 — Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts (520 ) 8 — — — — Hedged item gain/(loss) 520 (8 ) — — — — Foreign exchange contracts 4 (8 ) — — — — Hedged item gain/(loss) (4 ) 8 — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — — 148 — — — The portion of gains/(losses) on foreign exchange contracts excluded from the assessment of hedge effectiveness — — 27 — 26 — Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings (e) — — 43 — — — Foreign currency long-term debt (e) — — 94 (352 ) — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts 6 (145 ) — — — — All other net — — 1 — 1 — $ 6 $ (151 ) $ 325 $ (450 ) $ (328 ) $ 450 (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income . COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income . (b) For the second quarter and first six months ended July 2, 2017 , there was no significant ineffectiveness. (c) For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in Other comprehensive income/(loss)––Unrealized holding gains/(losses) on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income/(loss)––Foreign currency translation adjustments, net. (d) Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $55 million within the next 12 months into Cost of sales. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.8 billion U.K. pound debt maturing in 2043. (e) Short-term borrowings include foreign currency short-term borrowings with carrying values of $1.5 billion as of July 1, 2018 , which are used as hedging instruments in net investment hedges. Long-term debt includes foreign currency long-term borrowings with carrying values of $3.2 billion as of July 1, 2018 , which are used as hedging instruments in net investment hedges. The following table provides the total amount of each income and expense line in which the results of fair value or cash flow hedges are recorded: Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) July 1, 2018 July 1, 2018 Cost of sales $ 2,916 $ 5,479 Other (income)/deductions—net (551 ) (728 ) The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges: Carrying Amount of Hedged Assets/Liabilities Cumulative Amount of Fair Value Hedging Adjustment Gains/(Losses) Included in the Carrying Amount of the Hedged Assets/Liabilities (MILLIONS OF DOLLARS) July 1, 2018 July 1, 2018 Short-term investments $ 155 $ (1 ) Long-term investments 45 (1 ) Short-term borrowings, including current portion of long-term debt 1,487 11 Long-term debt 9,753 210 Certain of our derivative instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce both counterparties’ exposure to risk of defaulting on amounts owed by the other party. As of July 1, 2018 , the aggregate fair value of these derivative instruments that are in a net liability position was $413 million , for which we have posted collateral of $483 million in the normal course of business. If there had been a downgrade to below an A rating by S&P or the equivalent rating by Moody’s, we would not have been required to post any additional collateral to our counterparties. As of July 1, 2018 , we received cash collateral of $473 million from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, the obligations are reported in Short-term borrowings, including current portion of long-term debt. G. Credit Risk On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty, except for certain significant customers. For additional information as to significant customers, see Notes to Consolidated Financial Statements–– Note 18C. Segment, Geographic and Other Revenue Information: Other Revenue Information in Pfizer’s 2017 Financial Report. As of July 1, 2018 , we had amounts due from a well-diversified, high quality group of bank ( $2.1 billion ) and technology ( $751 million ) companies around the world. For details about our investments, see Note 7B above . In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the ability to request to receive cash collateral, depending on levels of exposure, our credit rating and the credit rating of the counterparty, see Note 7F above.

Inventories

Inventories	6 Months Ended
	Jul. 01, 2018
Inventory Disclosure [Abstract]
Inventories	Inventories The following table provides the components of Inventories : (MILLIONS OF DOLLARS) July 1, December 31, Finished goods $ 2,756 $ 2,883 Work-in-process 4,542 3,908 Raw materials and supplies 776 788 Inventories (a) $ 8,074 $ 7,578 Noncurrent inventories not included above (b) $ 615 $ 683 (a) The change from December 31, 2017 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery, network strategy and new product launches, partially offset by a decrease due to foreign exchange. (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Identifiable Intangible Assets

Identifiable Intangible Assets and Goodwill	6 Months Ended
	Jul. 01, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Identifiable Intangible Assets and Goodwill	Identifiable Intangible Assets and Goodwill A. Identifiable Intangible Assets Balance Sheet Information The following table provides the components of Identifiable intangible assets : July 1, 2018 December 31, 2017 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights $ 89,582 $ (56,829 ) $ 32,753 $ 89,550 $ (54,785 ) $ 34,765 Brands 2,126 (1,203 ) 923 2,134 (1,152 ) 982 Licensing agreements and other 1,957 (1,139 ) 818 1,911 (1,096 ) 815 93,665 (59,171 ) 34,494 93,595 (57,033 ) 36,562 Indefinite-lived intangible assets Brands and other 6,927 6,927 6,929 6,929 IPR&D 5,163 5,163 5,249 5,249 12,090 12,090 12,179 12,179 Identifiable intangible assets (a) $ 105,755 $ (59,171 ) $ 46,584 $ 105,774 $ (57,033 ) $ 48,741 (a) The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization, minimally offset by additions, mainly consisting of $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E ). Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: July 1, 2018 IH EH WRD Developed technology rights 68 % 32 % — % Brands, finite-lived 75 % 25 % — % Brands, indefinite-lived 71 % 29 % — % IPR&D 82 % 11 % 7 % Amortization Total amortization expense for finite-lived intangible assets was $1.2 billion for each of the 2018 and 2017 second quarters, and $2.4 billion for the first six months of 2018 and 2017 . B. Goodwill The following table provides the components of and changes in the carrying amount of Goodwill : (MILLIONS OF DOLLARS) IH EH Total Balance, December 31, 2017 $ 31,141 $ 24,811 $ 55,952 Other (a) (65 ) (51 ) (117 ) Balance, July 1, 2018 $ 31,076 $ 24,760 $ 55,836 (a) Primarily reflects the impact of foreign exchange, as well as the contribution of the allogeneic CAR T developmental program assets and operations to Allogene that constituted a business for accounting purposes (see Note 2B ).

Pension and Postretirement Bene

Pension and Postretirement Benefit Plans	6 Months Ended
	Jul. 01, 2018
Retirement Benefits [Abstract]
Pension and Postretirement Benefit Plans	Pension and Postretirement Benefit Plans The following table provides the components of net periodic benefit cost/(credit): Three Months Ended Pension Plans U.S. Qualified (a) U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 Net periodic benefit cost/(credit) (b) : Service cost (c) $ — $ 67 $ — $ 6 $ 34 $ 42 $ 10 $ 11 Interest cost 150 159 14 13 55 50 18 23 Expected return on plan assets (261 ) (252 ) — — (93 ) (85 ) (9 ) (9 ) Amortization of: Actuarial losses (c) 30 97 3 12 26 28 2 8 Prior service costs/(credits) — 1 — — (1 ) (1 ) (45 ) (46 ) Curtailments 7 4 — — — — (7 ) (5 ) Settlements 25 (7 ) 5 4 — 2 — — $ (49 ) $ 69 $ 21 $ 35 $ 21 $ 37 $ (32 ) $ (19 ) Six Months Ended Pension Plans U.S. Qualified (a) U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 Net periodic benefit cost/(credit) (b) : Service cost (c) $ — $ 135 $ — $ 12 $ 71 $ 83 $ 20 $ 21 Interest cost 301 321 26 28 109 100 36 45 Expected return on plan assets (524 ) (511 ) — — (185 ) (169 ) (18 ) (18 ) Amortization of: Actuarial losses (c) 60 212 7 25 52 56 4 15 Prior service costs/(credits) 1 3 — — (2 ) (2 ) (90 ) (92 ) Curtailments 9 9 — — — — (14 ) (12 ) Settlements 45 24 21 24 — 3 — — $ (107 ) $ 193 $ 55 $ 88 $ 44 $ 71 $ (63 ) $ (40 ) (a) In the second quarter of 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the $156 million net pension benefit obligation and recorded a pre-tax settlement gain of $41 million , partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately $30 million in Other (income)/deductions––net (see Note 3 ). (b) We adopted a new accounting standard on January 1, 2018 that requires the net periodic pension and postretirement benefit costs other than service costs be presented in Other (income)/deductions––net on the condensed consolidated statements of income. For additional information, see Note 1B and Note 4 . (c) Effective January 1, 2018, we froze two significant defined benefit pension plans to future benefit accruals in the U.S. and U.K. and as a result, service costs for those plans are eliminated. In addition, due to the plan freeze, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans was extended to the expected life expectancy of the plan participants, whereas the average amortization period in prior years utilized the expected future service period of plan participants. The following table provides the amounts we contributed, and the amounts we expect to contribute during 2018, to our pension and postretirement plans from our general assets for the periods indicated: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Contributions from our general assets for the six months ended July 1, 2018 $ 500 $ 99 $ 84 $ 71 Expected contributions from our general assets during 2018 (a) 500 140 235 155 (a) Contributions expected to be made for 2018 are inclusive of amounts contributed during the six months ended July 1, 2018 , including the $500 million voluntary contribution that was made in February 2018 for the U.S. qualified plans, which was considered pre-funding for future anticipated mandatory contributions and is also expected to reduce Pension Benefit Guaranty Corporation variable rate premiums. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.

Earnings Per Common Share Attri

Earnings Per Common Share Attributable to Common Shareholders	6 Months Ended
	Jul. 01, 2018
Earnings Per Share [Abstract]
Earnings Per Common Share Attributable to Common Shareholders	Earnings Per Common Share Attributable to Common Shareholders The following table provides the detailed calculation of EPS : Three Months Ended Six Months Ended (IN MILLIONS) July 1, July 2, July 1, July 2, EPS Numerator––Basic Income from continuing operations $ 3,879 $ 3,077 $ 7,450 $ 6,207 Less: Net income attributable to noncontrolling interests 7 5 16 14 Income from continuing operations attributable to Pfizer Inc. 3,872 3,071 7,434 6,193 Less: Preferred stock dividends––net of tax — — 1 — Income from continuing operations attributable to Pfizer Inc. common shareholders 3,871 3,071 7,433 6,192 Discontinued operations––net of tax — 2 (1 ) 1 Net income attributable to Pfizer Inc. common shareholders $ 3,871 $ 3,073 $ 7,432 $ 6,194 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions $ 3,872 $ 3,071 $ 7,434 $ 6,193 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions — 2 (1 ) 1 Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 3,872 $ 3,073 $ 7,432 $ 6,194 EPS Denominator Weighted-average number of common shares outstanding––Basic 5,866 5,958 5,911 5,982 Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements 86 80 93 83 Weighted-average number of common shares outstanding––Diluted 5,952 6,037 6,004 6,065 Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (a) 3 47 2 47 (a) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Contingencies and Certain Commi

Contingencies and Certain Commitments	6 Months Ended
	Jul. 01, 2018
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Certain Commitments	Contingencies and Certain Commitments We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. For a discussion of our tax contingencies, see Note 5C. For a discussion of our legal contingencies, see below. A. Legal Proceedings Our legal contingencies include, but are not limited to, the following: • Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets. • Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters. • Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter. • Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions. Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges. We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid. We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Amounts recorded for legal and environmental contingencies result from a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote. A1. Legal Proceedings––Patent Litigation Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, patent rights to certain of our products are being challenged in various other jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights. We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the United States. In June 2018, the Patent Trial and Appeal Board ruled on one patent, holding that one claim was valid and that all other claims were invalid. The party challenging that patent has appealed the decision. Challenges to other patents remain pending before the U.S. Patent and Trademark Office. The invalidation of these patents could potentially allow a competitor pneumococcal vaccine into the marketplace. We are also subject to patent litigation pursuant to which one or more third parties seeks damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party. Actions In Which We Are The Plaintiff Bosulif (bosutinib) In December 2016, Wyeth LLC, Wyeth Pharmaceuticals Inc., and PF Prism C.V. (collectively, Wyeth) brought a patent-infringement action against Alembic Pharmaceuticals, Ltd, Alembic Pharmaceuticals, Inc. (collectively, Alembic), Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries Limited (collectively, Sun), in the U.S. District Court for the District of Delaware in connection with abbreviated new drug applications respectively filed with the FDA by Alembic and Sun, each seeking approval to market generic versions of bosutinib. Alembic is challenging patents, which expire in 2026, covering polymorphic forms of bosutinib and methods of treating chronic myelogenous leukemia. Sun is challenging the patent covering polymorphic forms of bosutinib that expires in 2026. In March 2017, Wyeth brought a patent-infringement action against MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. (collectively, MSN), in the U.S. District Court for the District of Delaware in connection with an abbreviated new drug application filed with the FDA by MSN, seeking approval to market a generic version of bosutinib, and challenging a patent expiring in 2026 covering polymorphic forms of bosutinib. In September 2017, the case against MSN was dismissed. Also, in September 2017, Wyeth brought an additional patent-infringement action against Sun in the U.S. District Court for the District of Delaware asserting the infringement and validity of two other patents challenged by Sun, which expire in 2025 and 2026 respectively, covering compositions of bosutinib and methods of treating chronic myelogenous leukemia. EpiPen In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz’s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name. Precedex Premix In June 2014, Ben Venue Laboratories, Inc. (Ben Venue) notified our subsidiary, Hospira, that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that a patent relating to the use of Precedex in an intensive care unit setting, which expires in March 2019, was invalid or not infringed. In August 2014, Hospira and Orion Corporation (co-owner of the patent that is the subject of the lawsuit) filed suit against Ben Venue, Hikma Pharmaceuticals PLC (Hikma), and West-Ward Pharmaceutical Corp. in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patent. In October 2014, Eurohealth International Sarl was substituted for Ben Venue and Hikma. In June 2016, this case was settled on terms not material to Pfizer. In June 2015, Amneal Pharmaceuticals LLC (Amneal) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In August 2015, Hospira filed suit against Amneal in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit. In January 2018, the District Court ruled that one of the four patents was valid and infringed, and that the other three patents were invalid. In February and March 2018, respectively, each of Amneal and Hospira appealed the District Court decision to the U.S. Court of Appeals for the Federal Circuit. In December 2015, Fresenius Kabi USA LLC (Fresenius) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In January 2016, Hospira filed suit against Fresenius in the U.S. District Court for the Northern District of Illinois asserting the validity and infringement of the patents that are the subject of the lawsuit. In August 2016, Par Sterile Products, LLC (Par) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In September 2016, Hospira filed suit against Par in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit. In December 2016, the case was stayed pending the outcome of Hospira’s suit against Amneal (including all appeals). In December 2017, Gland Pharma Limited (Gland) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that six patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In February 2018, Hospira filed suit against Gland in the U.S. District Court for the District of Delaware asserting the validity and infringement of four patents that are the subject of the lawsuit. In December 2017, Jiangsu Hengrui Medicine Co., Ltd. (Hengrui) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that six patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In February 2018, Hospira filed suit against Hengrui in the U.S. District Court for the District of Delaware asserting the validity and infringement of four patents that are the subject of the lawsuit. In February 2018, Baxter Healthcare Corporation (Baxter) filed a declaratory judgment action against Hospira in the U.S. District Court for the District of Delaware seeking a declaration of non-infringement of four patents relating to the Precedex premix formulations and their use. One of the patents included in the action expires in 2019 and the other three patents expire in 2032. In March 2018, Hospira filed a counterclaim for infringement of the patent expiring in 2019. Xeljanz (tofacitinib) In February 2017, we brought a patent-infringement action against MicroLabs USA Inc. and MicroLabs Ltd. (collectively, MicroLabs) in the U.S. District Court for the District of Delaware asserting the infringement and validity of three patents challenged by MicroLabs in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. Of the three patents that are the subject of the lawsuit, one covers the active ingredient and expires in December 2025, the second covers an enantiomer of tofacitinib and expires in 2022, and the third covers a polymorphic form of tofacitinib and expires in 2023. Three other patents for Xeljanz expiring in December 2020 have not been challenged by MicroLabs. Separately, also in February 2017, we brought a patent-infringement action against Sun Pharmaceutical Industries Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering a polymorphic form of tofacitinib, expiring in 2023, that was challenged by Sun Pharmaceutical Industries Ltd. in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. In November 2017, we brought an additional patent-infringement action against Sun Pharmaceuticals Industries Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of another patent challenged by Sun Pharmaceuticals Industries Ltd, which covers the active ingredient and expires in December 2025. In March 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) in the U.S. District Court for the District of Delaware asserting the infringement and validity of the same three patents that are the subject of the action against MicroLabs, which Zydus challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. Also in March 2017, we brought separate actions in the U.S. District Court for the District of Delaware against Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC (collectively, Prinston) and against Breckenridge Pharmaceutical Inc., Pensa Pharma S.A. and Laboratorios Del Dr. Esteve, S.A. (collectively, Breckenridge) on the two patents expiring in 2022 and 2023, respectively, that were challenged by Prinston and Breckenridge in their respective abbreviated new drug applications seeking approval to market generic versions of tofacitinib 5 mg tablets. In October 2017, we brought an additional patent-infringement action against Breckenridge in the U.S. District Court for the District of Delaware asserting the infringement and validity of four additional patents challenged by Breckenridge, three of which expire in December 2020 and one of which expires in December 2025. In March 2018, we brought another patent infringement action against Prinston in the U.S. District Court for the District of Delaware asserting the infringement and validity of an additional patent, which had been subsequently challenged by Prinston and which expires in December 2025. In May 2018, we settled all of our claims against Breckenridge on terms not material to Pfizer. Xtandi (enzalutamide) In December 2016, Medivation and Medivation Prostate Therapeutics, Inc. (collectively, the Medivation Group); Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc. (collectively, Astellas); and The Regents of the University of California filed patent-infringement suits in the U.S. District Court for the District of Delaware against Actavis Laboratories FL, Inc. and Actavis LLC (collectively, Actavis); Zydus; and Apotex Inc. and Apotex Corp. (collectively, Apotex) in connection with those companies’ respective abbreviated new drug applications filed with the FDA for approval to market generic versions of enzalutamide. The generic manufacturers are challenging patents, which expire as early as 2026, covering enzalutamide and treatments for prostate cancer. In May 2017, the Medivation Group filed a patent-infringement suit against Roxane Laboratories Inc. (Roxane) in the same court in connection with Roxane’s abbreviated new drug application with the FDA for approval to market a generic version of enzalutamide. In June and July 2018, we settled all of our claims against Actavis and Apotex, respectively, on terms not material to Pfizer. Inlyta (axitinib) In April 2018, Apotex Inc. notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Apotex Inc. asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In May 2018, we filed suit against Apotex Inc. in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta. Matters Involving Our Collaboration/Licensing Partners Toviaz (fesoterodine)––Inter-Partes Reviews In January 2016, Mylan Pharmaceuticals and Mylan Laboratories (collectively, Mylan) filed petitions with the U.S. Patent and Trademark Office requesting inter partes reviews of five of the patents covering fesoterodine, the active ingredient in Toviaz: three composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. The patents are owned by UCB, and we have an exclusive, worldwide license to market Toviaz from UCB. In July 2016, the Patent Trial and Appeal Board agreed to institute inter partes reviews of all five patents. Amerigen Pharmaceuticals Limited (Amerigen), Alembic Pharmaceuticals Limited and Torrent Pharmaceuticals Limited have joined the inter partes reviews. In July 2017, the U.S. Patent and Trademark Office issued decisions upholding all five patents. In September 2017, Mylan and Amerigen appealed the U.S. Patent and Trademark Office decisions to the U.S. Court of Appeals for the Federal Circuit . In January 2018, Mylan withdrew its appeal. Eliquis In February, March, and April 2017, twenty-five generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed abbreviated new drug applications seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the three patents listed in the Orange Book for Eliquis. The patents currently are set to expire in 2019, 2026, and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. In April 2017, BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies’ proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all three patents. We and BMS have settled with certain of the generic companies on terms not material to Pfizer, and we and BMS may settle with other generic companies in the future. Actions In Which We Are The Defendant Inflectra (infliximab-dyyb) In March 2015, Janssen and New York University, together, brought a patent-infringement action in the U.S. District Court for the District of Massachusetts against Hospira, Celltrion Healthcare Co. Ltd. and Celltrion Inc. alleging that infliximab-dyyb, to be marketed by Hospira in the U.S. under the brand name Inflectra, would infringe six patents relating to infliximab, its manufacture and use. Claims with respect to four of the patents were dismissed by the plaintiffs, leaving two patents at issue: the infliximab antibody patent and a patent relating to cell culture media. In January 2018, the antibody patent was declared invalid by the Court of Appeals for the Federal Circuit. In July 2018, the U.S. District Court for the District of Massachusetts granted defendants’ motion for summary judgment and ruled that the patent relating to cell culture media was not infringed. Bavencio (avelumab) In July 2017, BMS, E.R. Squibb & Sons LLC, Ono Pharmaceutical Co. Ltd., and Tasuku Honjo brought a patent-infringement action in the U.S. District Court for the District of Delaware against Pfizer, Merck KGaA, and EMD Serono, Inc., alleging that Bavencio (avelumab) infringes one patent relating to methods for treating tumors with anti-PD-L1 antibodies, which expires in 2023. A2. Legal Proceedings––Product Litigation Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. Asbestos Between 1967 and 1982, Warner-Lambert owned American Optical Corporation, which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. As of July 1, 2018 , approximately 56,760 claims naming American Optical and numerous other defendants were pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly-owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims. Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries. There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries. Effexor Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants’ allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. In October 2014, the District Court dismissed the direct purchaser plaintiffs’ claims based on the litigation settlement agreement but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded the claims to the District Court. Lipitor • Antitrust Actions Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants’ allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation ( In re Lipitor Antitrust Litigation MDL-2332 ) in the U.S. District Court for the District of New Jersey. In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court’s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded the claims to the District Court. Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. • Personal Injury Actions A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes purportedly as a result of the ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation ( In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502 ) in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the Multi-District Litigation were remanded to certain state courts. In January 2017, the District Court granted our motion for summary judgment, dismissing substantially all of the remaining cases pending in the Multi-District Litigation. In January 2017, the plaintiffs appealed the District Court’s decision to the U.S. Court of Appeals for the Fourth Circuit. In June 2018, the U.S. Court of Appeals for the Fourth Circuit affirmed the District Court’s decision. Viagra A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed melanoma and/or the exacerbation of melanoma purportedly as a result of the ingestion of Viagra. Plaintiffs seek compensatory and punitive damages. In April 2016, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation ( In Re: Viagra (Sildenafil Citrate) Products Liability Litigation, MDL-2691 ) in the U.S. District Court for the Northern District of California. In December 2016, federal actions filed against Lilly and filed against both us and Lilly, were transferred for coordinated pre-trial proceedings to the Multi-District Litigation ( In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation, MDL-2691 ). Intravenous Solutions Beginning in November 2016, purported class actions were filed in the U.S. District Court for the Northern District of Illinois against Hospira, Hospira Worldwide, Inc. and certain other defendants relating to intravenous saline solution. Plaintiffs seek to repres

Segment, Geographic and Other R

Segment, Geographic and Other Revenue Information	6 Months Ended
	Jul. 01, 2018
Segment Reporting [Abstract]
Segment, Geographic and Other Revenue Information	Segment, Geographic and Other Revenue Information A. Segment Information We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH and EH segments are each led by a single manager. Each operating segment has responsibility for its commercial activities and for certain IPR&D projects for new investigational products and additional indications for in-line products that generally have achieved proof-of-concept. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the two operating segments, among other factors, for performance evaluation and resource allocation. We regularly review our segments and the approach used by management for performance evaluation and resource allocation. As described in Note 1A , the February 3, 2017 sale of HIS impacted our results of operations in 2017. Operating Segments Some additional information about our business segments as of July 1, 2018 follows: IH focuses on developing and commercializing novel, value-creating medicines and vaccines that significantly improve patients’ lives, as well as products for consumer healthcare. EH includes legacy brands that have lost or will soon lose market exclusivity in both developed and emerging markets, branded and generic sterile injectable products, biosimilars, and select branded products including anti-infectives. EH also includes an R&D organization, as well as our contract manufacturing business. Through February 2, 2017, EH also included HIS. Leading brands include: - Prevnar 13/Prevenar 13 - Xeljanz - Eliquis - Lyrica (U.S., Japan and certain other markets) Enbrel (outside the U.S. and Canada) Ibrance - Xtandi - Several OTC consumer healthcare products (e.g., Advil and Centrum ) Leading brands include: - Lipitor - Premarin family - Norvasc - Lyrica (Europe, Russia, Turkey, Israel and Central Asia countries) - Celebrex - Viagra* - Inflectra/Remsima - Several sterile injectable products * Viagra lost exclusivity in the U.S. in December 2017. Beginning in 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, are reported in EH (which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, beginning in 2018, total Viagra worldwide revenues are reported in EH. The following organizational change impacted our operating segments in 2018: • Effective in the first quarter of 2018, certain costs for Pfizer’s StratCO group, which were previously reported in the operating results of our operating segments and Corporate, are reported in Other Unallocated. StratCO costs primarily include headcount costs, vendor costs and data costs largely in support of Pfizer’s commercial operations. The majority of the StratCO costs reflect additional amounts that our operating segments may have generally incurred had each segment operated as a standalone company during the periods presented. The reporting change was made to streamline accountability and speed decision making. In the second quarter of 2017, we reclassified approximately $120 million of costs from IH, approximately $45 million of costs from EH and approximately $12 million of costs from Corporate to Other unallocated costs to conform to the current period presentation. In the first six months of 2017, we reclassified approximately $218 million of costs from IH, approximately $78 million of costs from EH and approximately $21 million of costs from Corporate to Other unallocated costs to conform to the current period presentation. Other Costs and Business Activities Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following: • WRD, which is generally responsible for research projects for our IH business until proof-of-concept is achieved and then for transitioning those projects to the IH segment via the GPD organization for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. The WRD organization also has responsibility for certain science-based and other platform-services organizations, which provide technical expertise and other services to the various R&D projects, including EH R&D projects. WRD is also responsible for facilitating all regulatory submissions and interactions with regulatory agencies, including all safety-event activities. • GPD, which is generally responsible for the clinical development of assets that are in clinical trials for our WRD and Innovative portfolios. GPD also provides technical support and other services to Pfizer R&D projects. • Corporate, representing platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement), the provision of medical information to healthcare providers, patients and other parties, transparency and disclosure activities, clinical trial results publication, grants for healthcare quality improvement and medical education, and partnerships with global public health and medical associations, as well as certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments. Effective in the first quarter of 2018, certain costs for StratCO, which were previously reported in the operating results of our operating segments and Corporate, are reported in Other Unallocated. For additional information, see note below on Other unallocated costs. • Other unallocated costs, representing overhead expenses associated with our manufacturing and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs (which include manufacturing variances associated with production). In connection with the StratCO reporting change, in the second quarter of 2017, we reclassified approximately $120 million of costs from IH, approximately $45 million of costs from EH and approximately $12 million of costs from Corporate to Other unallocated costs to conform to the current period presentation. In the first six months of 2017, we reclassified approximately $218 million of costs from IH, approximately $78 million of costs from EH and approximately $21 million of costs from Corporate to Other unallocated costs to conform to the current period presentation. • Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities. Segment Assets We manage our assets on a total company basis, not by operating segment, as many of our operating assets are shared (such as our plant network assets) or commingled (such as accounts receivable, as many of our customers are served by both operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately $165 billion as of July 1, 2018 and $172 billion as of December 31, 2017 . Selected Income Statement Information The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) July 1, July 2, July 1, July 2, Reportable Segments: IH (b) $ 8,273 $ 7,671 $ 5,100 $ 4,786 EH (b) 5,193 5,226 2,818 2,832 Total reportable segments 13,466 12,896 7,918 7,619 Other business activities (c), (d) — — (669 ) (758 ) Reconciling Items: Corporate (b), (d) — — (1,144 ) (1,209 ) Purchase accounting adjustments (d) — — (1,134 ) (1,201 ) Acquisition-related costs (d) — — (62 ) (68 ) Certain significant items (e) — — (20 ) (191 ) Other unallocated (b), (d) — — (362 ) (377 ) $ 13,466 $ 12,896 $ 4,527 $ 3,815 Six Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) July 1, July 2, July 1, July 2, Reportable Segments: IH (b) $ 16,102 $ 15,086 $ 10,031 $ 9,534 EH (b) 10,271 10,590 5,606 5,871 Total reportable segments 26,373 25,675 15,636 15,405 Other business activities (c), (d) — — (1,394 ) (1,445 ) Reconciling Items: Corporate (b), (d) — — (2,296 ) (2,545 ) Purchase accounting adjustments (d) — — (2,355 ) (2,373 ) Acquisition-related costs (d) — — (110 ) (192 ) Certain significant items (e) — — (221 ) (348 ) Other unallocated (b), (d) — — (607 ) (736 ) $ 26,373 $ 25,675 $ 8,654 $ 7,767 (a) Income from continuing operations before provision for taxes on income. IH’s earnings include d ividend income of $76 million and $114 million in the second quarter of 2018 and 2017 , respectively, and $135 million and $157 million in the first six months of 2018 and 2017 , respectively, from our investment in ViiV. For additional information, see Note 4. (b) In connection with the StratCO reporting change, in the second quarter of 2017 we reclassified approximately $120 million of costs from IH, approximately $45 million of costs from EH and approximately $12 million of costs from Corporate to Other unallocated costs to conform to the current period presentation. In the first six months of 2017, we reclassified approximately $218 million of costs from IH, approximately $78 million of costs from EH and approximately $21 million of costs from Corporate to Other unallocated costs to conform to the current period presentation. (c) Other business activities includes the costs managed by our WRD and GPD organizations. (d) For a description, see the “Other Costs and Business Activities” section above. (e) Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the second quarter of 2018 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $42 million , (ii) a net credit for certain legal matters of $88 million , (iii) adjustments of $2 million income to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairments of $31 million , (v) charges for business and legal entity alignment of $1 million and (vi) other charges of $37 million . For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the second quarter of 2017 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $49 million , (ii) an incremental charge to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $28 million , (iii) charges for business and legal entity alignment of $17 million and (iv) other charges of $97 million . For additional information, see Note 2B , Note 3 and Note 4 . For Earnings in the first six months of 2018 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $93 million , (ii) net credits for certain legal matters of $107 million , (iii) adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $1 million , (iv) certain asset impairments of $31 million , (v) charges for business and legal entity alignment of $4 million and (vi) other charges of $199 million , which primarily includes $119 million , in the aggregate, for a special one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA on us. For additional information, see Note 2B , Note 3 and Note 4 . For Earnings in the first six months of 2017 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $79 million , (ii) charges for certain legal matters of $8 million , (iii) adjustments to amounts previously recorded to the write-down the HIS net assets to fair value less costs to sell of $64 million , (iv) charges for business and legal entity alignment of $38 million and (v) other charges of $158 million . For additional information, see Note 2B , Note 3 and Note 4 . Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments. The operating segment information does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented. B. Geographic Information As described in Note 1A , the February 3, 2017 sale of HIS impacted our results of operations in 2017. The following table provides revenues by geographic area: Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) July 1, July 2, % Change July 1, July 2, % Change U.S. $ 6,225 $ 6,345 (2 ) $ 12,500 $ 12,982 (4 ) Developed Europe (a) 2,334 2,124 10 4,426 4,145 7 Developed Rest of World (b) 1,694 1,611 5 3,155 3,165 — Emerging Markets (c) 3,214 2,815 14 6,292 5,382 17 Revenues $ 13,466 $ 12,896 4 $ 26,373 $ 25,675 3 (a) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.9 billion and $1.7 billion in the second quarter of 2018 and 2017 , respectively, and $3.6 billion and $3.3 billion in the first six months of 2018 and 2017 , respectively. (b) Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand. (c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey. C. Other Revenue Information Significant Product Revenues As described in Note 1A , the February 3, 2017 sale of HIS impacted our results of operations in 2017. The following table provides detailed revenue information: (MILLIONS OF DOLLARS) Three Months Ended Six Months Ended PRODUCT PRIMARY INDICATIONS OR CLASS July 1, July 2, July 1, July 2, TOTAL REVENUES $ 13,466 $ 12,896 $ 26,373 $ 25,675 PFIZER INNOVATIVE HEALTH (IH) (a) $ 8,273 $ 7,671 $ 16,102 $ 15,086 Internal Medicine $ 2,530 $ 2,412 $ 4,876 $ 4,789 Lyrica IH (b) Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury 1,134 1,101 2,266 2,231 Eliquis alliance revenues and direct sales Atrial fibrillation, deep vein thrombosis, pulmonary embolism 889 605 1,654 1,169 Chantix/Champix An aid to smoking cessation treatment in adults 18 years of age or older 277 248 528 487 BMP2 Development of bone and cartilage 80 57 153 119 Toviaz Overactive bladder 70 62 130 125 Viagra IH (c) Erectile dysfunction — 255 — 505 All other Internal Medicine Various 79 84 145 153 Vaccines $ 1,400 $ 1,270 $ 2,863 $ 2,735 Prevnar 13/Prevenar 13 Vaccines for prevention of pneumococcal disease 1,250 1,154 2,631 2,547 FSME/IMMUN-TicoVac Tick-borne encephalitis vaccine 73 50 105 76 All other Vaccines Various 77 66 127 112 Oncology $ 1,822 $ 1,589 $ 3,519 $ 2,935 Ibrance Advanced breast cancer 1,027 853 1,960 1,532 Sutent Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor 275 279 537 529 Xtandi alliance revenues Castration-resistant prostate cancer 171 141 330 272 Xalkori ALK-positive and ROS1-positive advanced NSCLC 137 155 290 296 Inlyta Advanced RCC 81 88 155 172 Bosulif Philadelphia chromosome–positive chronic myelogenous leukemia 77 59 138 106 All other Oncology Various 53 14 109 28 Inflammation & Immunology (I&I) $ 1,064 $ 992 $ 1,933 $ 1,863 Enbrel (Outside the U.S. and Canada) Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis 551 617 1,057 1,205 Xeljanz Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis 463 336 788 587 Eucrisa Mild-to-moderate atopic dermatitis (eczema) 39 9 65 17 All other I&I Various 11 31 22 54 Rare Disease $ 571 $ 562 $ 1,120 $ 1,069 BeneFIX Hemophilia 141 153 288 302 Genotropin Replacement of human growth hormone 140 135 272 238 Refacto AF/Xyntha Hemophilia 141 139 271 269 Somavert Acromegaly 68 61 131 117 All other Rare Disease Various 81 74 157 141 Consumer Healthcare $ 886 $ 846 $ 1,791 $ 1,694 PFIZER ESSENTIAL HEALTH (EH) (d) $ 5,193 $ 5,226 $ 10,271 $ 10,590 Legacy Established Products (LEP) (e) $ 2,695 $ 2,707 $ 5,331 $ 5,313 Lipitor Reduction of LDL cholesterol 521 445 1,032 849 Norvasc Hypertension 271 231 526 458 Premarin family Symptoms of menopause 210 245 401 473 Zithromax Bacterial infections 72 62 162 140 Xalatan/Xalacom Glaucoma and ocular hypertension 85 81 157 158 Zoloft Depression and certain anxiety disorders 77 69 151 137 Effexor Depression and certain anxiety disorders 79 73 150 139 EpiPen Epinephrine injection used in treatment of life-threatening allergic reactions 95 90 148 171 Xanax Anxiety disorders 56 52 111 107 Sildenafil Citrate Erectile dysfunction 8 — 71 — All other LEP Various 1,220 1,360 2,424 2,681 (MILLIONS OF DOLLARS) Three Months Ended Six Months Ended PRODUCT PRIMARY INDICATIONS OR CLASS July 1, July 2, July 1, July 2, Sterile Injectable Pharmaceuticals (SIP) (f) $ 1,329 $ 1,444 $ 2,688 $ 2,996 Sulperazon Treatment of infections 150 110 319 232 Medrol Steroid anti-inflammatory 104 123 223 243 Fragmin Slows blood clotting 74 71 145 142 Tygacil Tetracycline class antibiotic 63 57 126 131 Zosyn/Tazocin Antibiotic 58 40 119 78 Precedex Sedation agent in surgery or intensive care 64 67 119 132 All other SIP Various 815 975 1,638 2,038 Peri-LOE Products (g) $ 773 $ 782 $ 1,509 $ 1,604 Viagra EH (c) Erectile dysfunction 185 93 372 183 Celebrex Arthritis pain and inflammation, acute pain 161 178 306 353 Vfend Fungal infections 110 101 207 208 Lyrica EH (b) Epilepsy, neuropathic pain and generalized anxiety disorder 88 154 170 294 Zyvox Bacterial infections 66 75 134 152 Revatio Pulmonary arterial hypertension 54 67 109 131 Pristiq Depression 51 46 104 161 All other Peri-LOE Products Various 59 68 107 121 Biosimilars (h) Various $ 188 $ 121 $ 361 $ 226 Inflectra/Remsima Inflammatory diseases 158 94 303 172 All other Biosimilars Various 29 27 58 54 Pfizer CentreOne (i) $ 209 $ 171 $ 381 $ 353 Hospira Infusion Systems (HIS) (j) Various $ — $ — $ — $ 97 Total Lyrica (b) Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury $ 1,223 $ 1,254 $ 2,436 $ 2,526 Total Viagra (c) Erectile dysfunction $ 185 $ 349 $ 372 $ 687 Total Alliance revenues Various $ 987 $ 715 $ 1,842 $ 1,370 (a) The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare. (b) Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH. (c) Viagra lost exclusivity in the U.S. in December 2017. Beginning in 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, are reported in EH (which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, beginning in 2018, total Viagra revenues are reported in EH. Total Viagra revenues in 2017 represent the aggregate of worldwide revenues from Viagra IH and Viagra EH. (d) The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017). (e) Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne. (f) Sterile Injectable Pharmaceuticals includes branded and generic injectables (excluding Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne. (g) Peri-LOE Products includes products that have recently lost or are anticipated to soon lose patent protection. These products primarily include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra; and beginning in 2018, Viagra revenues for all countries (and Viagra revenues for all countries other than the U.S. and Canada in 2017, see note (c) above). (h) Biosimilars includes Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets. (i) Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne. (j) HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.

Basis of Presentation and Sig21

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jul. 01, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q. We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 27, 2018 and May 28, 2017 . The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and six months ended July 1, 2018 and July 2, 2017 . Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2017 Form 10-K.
Adoption of New Accounting Standards	Adoption of New Accounting Standards On January 1, 2018, we adopted eleven new accounting standards. The quantitative impacts on our prior period condensed consolidated financial statements of adopting the following new standards are summarized in the tables within the section titled Impacts to our Condensed Consolidated Financial Statements , further below. Revenues ––We adopted a new accounting standard for revenue recognition and changed our revenue recognition policies accordingly. Generally, the previous revenue recognition standards permitted recognition when persuasive evidence of a contract existed, delivery had occurred, and the seller's price to the buyer was fixed or determinable. Under the new standard, revenue is recognized upon transfer of control of the product to our customer in an amount that reflects the consideration we expect to receive in exchange. We adopted the new accounting standard utilizing the modified retrospective method, and, therefore, no adjustments were made to amounts in our prior period financial statements. We recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained earnings by $584 million on a pre-tax basis ( $450 million after-tax). This amount includes $500 million (pre-tax) related to the timing of recognizing Other (income)/deductions –– net primarily for upfront and milestone payments on our collaboration arrangements ( $394 million , pre-tax) and, to a lesser extent, product rights and out-licensing arrangements, and $84 million (pre-tax) related to the timing of recognizing Revenues and Cost of sales on certain product shipments. The impact of adoption did not have a material impact to our condensed consolidated statements of income for the three and six months ended July 1, 2018 or our condensed consolidated balance sheet as of July 1, 2018 . For additional information, see Note 1C . Financial Assets and Liabilities ––The new accounting standard related to the recognition and measurement of financial assets and liabilities makes the following changes to prior guidance and requires: • certain equity investments to be measured at fair value with changes in fair value now recognized in net income. However, equity investments that do not have readily determinable fair values may be measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer; • a qualitative assessment of equity investments without readily determinable fair values to identify impairment; and • separate presentation of financial assets and financial liabilities by measurement category and form of financial asset on the balance sheet or in the accompanying notes to the financial statements. We adopted the new accounting standard utilizing the modified retrospective method, and, therefore, no adjustments were made to amounts in our prior period financial statements. We recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained earnings by $462 million on a pre-tax basis ( $419 million after-tax) related to the net impact of unrealized gains and losses primarily on available-for-sale equity securities, restricted stock and private equity securities. In the second quarter and first six months of 2018, we recorded net unrealized gains on equity securities of $226 million and $337 million , respectively, in Other (income)/deductions––net . For additional information, see Note 4 and Note 7 . Presentation of Net Periodic Pension and Postretirement Benefit Cost ––We adopted a new accounting standard that requires the net periodic pension and postretirement benefit costs other than the service costs be presented in Other (income)/deductions––net, and that the presentation be applied retrospectively. We adopted the presentation of the net periodic benefit costs other than service costs by reclassifying these costs from Cost of sales , Selling, informational and administrative expenses , Research and development expenses and Restructuring charges and certain acquisition-related costs to Other (income)/deductions––net . We elected to apply the practical expedient as it is impracticable to determine the disaggregation of the cost components for amounts capitalized within Inventories and property, plant and equipment and amortized in each of those periods. We have therefore reclassified the prior period net periodic benefit costs/(credits) disclosed in Note 10 to apply the retrospective presentation for comparative periods. As of January 1, 2018, only service costs will be included in amounts capitalized in Inventories or property, plant and equipment, while the other components of net periodic benefit costs will be included in Other (income)/deductions –– net . For additional information, see Note 4 and Note 10 . Income Tax Accounting ––The new guidance removes the prohibition against recognizing current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to a third party, unless the asset transferred is inventory. We adopted the standard utilizing the modified retrospective method, and, therefore, no adjustments were made to amounts in our prior period financial statements. We recorded the cumulative effect of adopting the standard as an adjustment to decrease the opening balance of Retained earnings by $189 million . Accounting for Hedging Activities ––The standard makes the following changes: • Permits hedge accounting for risk components in hedging relationships involving nonfinancial risk and interest rate risk; • Changes the guidance for designating fair value hedges of interest rate risk and for measuring the change in fair value of the hedged item in fair value hedges of interest rate risk; • No longer requires the separate measurement and reporting of hedge ineffectiveness, but requires the income statement presentation of the earnings effect of the hedging instrument with the earnings effect of the hedged item; • Permits us to exclude the portion of the change in fair value of a currency swap that is attributable to a cross-currency basis spread from the assessment of hedge effectiveness; and • Simplifies hedge effectiveness testing. We early adopted the new accounting standard on January 1, 2018 on a prospective basis. In the second quarter and first six months of 2018, we recorded income of $16 million and $45 million , respectively, in Other (income)/deductions –– net , whereas this item would have been classified in interest income in prior periods. For additional information, see Note 7F . Reclassification of Certain Tax Effects from AOCI ––We early adopted a new accounting standard that provides guidance on the reclassification of certain tax effects from AOCI. Under the new guidance, we elected to reclassify the stranded tax amounts related to the TCJA from AOCI to Retained earnings . We adopted the new accounting standard utilizing the modified retrospective method, and recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained earnings by $495 million , primarily due to the effect of the change in the U.S. Federal corporate tax rate. The impact on other stranded tax amounts related to the application of the TCJA was not material to our condensed consolidated financial statements. Classification of Certain Transactions in the Statement of Cash Flows ––We retrospectively adopted an accounting standard that changed the presentation of certain information in the condensed consolidated statements of cash flows, including the classification of: • debt prepayment and extinguishment costs, resulting in an increase in Operating activities –– Other adjustments, net and a decrease in Financing activities –– Other financing activities, net of $7 million for the six months ended July 1, 2018 ; and • accreted interest on the settlement of commercial paper debt instruments, resulting in a decrease in Operating activities –– Other adjustments, net , and an increase in Financing activities –– Other financing activities, net of $38 million for the six months ended July 1, 2018 . The new standard also establishes guidance on the classification of certain cash flows related to contingent consideration in a business acquisition. Cash payments made soon after a business acquisition date will be classified as Investing activities , while payments made thereafter will be classified as Financing activities . Payments made in excess of the amount of the original contingent consideration liability will be classified as Operating activities . The adoption of this guidance did not have a material impact to our condensed consolidated financial statements. Presentation of Restricted Cash in the Statement of Cash Flows ––We adopted, on a retrospective basis, the new accounting standard, which requires that restricted cash and restricted cash equivalents be included with Cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the condensed consolidated statements of cash flows. As a result, for the six months ended July 1, 2018 , $19 million is presented as an increase in Cash, cash equivalents, restricted cash and restricted cash equivalents. Definition of a Business ––We prospectively adopted the standard for determining whether business development transactions should be accounted for as acquisitions (or disposals) of assets or businesses. If substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, the transaction will not qualify for treatment as a business. To be considered a business, a set of integrated activities and assets must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs, without regard as to whether a purchaser could replace missing elements. In addition, the definition of the term “output” has been narrowed to make it consistent with the updated revenue recognition guidance. In the second quarter and first six months of 2018, there was no impact to our condensed consolidated financial statements from the adoption of this new standard. Derecognition of Nonfinancial Assets ––We prospectively adopted the standard, which applies to the full or partial sale or transfer of nonfinancial assets, including intangible assets, real estate and inventory. The standard provides that the gain or loss is determined by the difference between the consideration received and the carrying value of the asset. In the second quarter and first six months of 2018, there was no impact to our condensed consolidated financial statements from the adoption of this new standard. Accounting for Modifications of Share-Based Payment Awards ––We prospectively adopted the standard, which clarifies that certain changes in the terms or conditions of a share-based payment award be accounted for as a modification. There was no impact to our condensed consolidated financial statements from the adoption of this new standard. Impacts to our Condensed Consolidated Financial Statements ––The impacts on our prior period condensed consolidated financial statements of adopting the new standards described above are summarized in the following tables: Adoption of the standard related to pension and postretirement benefit costs impacted our prior period condensed consolidated statements of income as follows: Three Months Ended July 2, 2017 (MILLIONS OF DOLLARS) As Previously Reported Effect of Change Higher/(Lower) As Restated Cost of sales $ 2,663 $ (3 ) $ 2,660 Selling, informational and administrative expenses 3,425 5 3,430 Research and development expenses 1,780 7 1,787 Restructuring charges and certain acquisition-related costs 70 (1 ) 70 Other (income)/deductions––net (66 ) (8 ) (75 ) Income from continuing operations before provision for taxes on income 3,815 — 3,815 Six Months Ended July 2, 2017 (MILLIONS OF DOLLARS) As Previously Reported Effect of Change Higher/(Lower) As Restated Cost of sales $ 5,134 $ (6 ) $ 5,128 Selling, informational and administrative expenses 6,733 12 6,745 Research and development expenses 3,487 15 3,502 Restructuring charges and certain acquisition-related costs 228 (74 ) 153 Other (income)/deductions––net (68 ) 53 (14 ) Income from continuing operations before provision for taxes on income 7,767 — 7,767 Adoption of the standards impacted our condensed consolidated balance sheet as follows: Effect of New Accounting Standards Higher/(Lower) (MILLIONS OF DOLLARS) As Previously Reported Balance at December 31, 2017 Revenues Financial Assets and Liabilities Income Tax Accounting Reclassification of Certain Tax Effects from AOCI Balance at January 1, 2018 Trade accounts receivable $ 8,221 $ 13 $ — $ — $ — $ 8,234 Inventories 7,578 (11 ) — — — 7,567 Current tax assets 3,050 (11 ) — (3 ) — 3,036 Noncurrent deferred tax assets and other noncurrent tax assets 1,855 (17 ) — — — 1,838 Other noncurrent assets 3,227 — — (204 ) — 3,023 Other current liabilities 11,115 (123 ) — — — 10,992 Noncurrent deferred tax liabilities 3,900 106 — (18 ) — 3,988 Other noncurrent liabilities 6,149 (459 ) — — — 5,690 Retained earnings 85,291 450 419 (189 ) 495 86,466 Accumulated other comprehensive loss (9,321 ) — (419 ) — (495 ) (10,235 ) Adoption of the standards related to the classification of certain transactions in the statement of cash flows and the presentation of restricted cash in the statement of cash flows impacted our condensed consolidated statement of cash flows as follows: Six Months Ended July 2, 2017 Effect of New Accounting Standards Inflow/(Outflow) (MILLIONS OF DOLLARS) As Previously Reported Cash Flow Classification Restricted Cash As Restated Operating Activities Other adjustments, net $ (433 ) $ (26 ) $ — $ (458 ) Other changes in assets and liabilities, net of acquisitions and divestitures (3,853 ) — 9 (3,844 ) Investing Activities Proceeds from redemptions/sales of short-term investments 3,520 — (3 ) 3,517 Proceeds from redemptions/sales of long-term investments 1,539 — (2 ) 1,538 Financing Activities Principal payments on short-term borrowings (5,110 ) 22 — (5,088 ) Net proceeds from short-term borrowings with original maturities of three months or less 261 4 — 265 Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents (10 ) — 5 (5 ) Cash and cash equivalents and restricted cash and cash equivalents, beginning 2,595 — 70 2,666 Cash and cash equivalents and restricted cash and cash equivalents, ending 2,585 — 75 2,661 The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheet that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows: (MILLIONS OF DOLLARS) July 1, 2018 December 31, Cash and cash equivalents $ 2,704 $ 1,342 Restricted cash and cash equivalents in Short-term investments 42 — Restricted cash and cash equivalents in Long-term investments 66 — Restricted cash and cash equivalents in Other current assets — 14 Restricted cash and cash equivalents in Other noncurrent assets — 75 Total cash and cash equivalents and restricted cash and cash equivalents shown in the condensed consolidated balance sheets $ 2,811 $ 1,431 Amounts included in restricted cash represent those required to be set aside by a contractual agreement in connection with ongoing litigation or to secure delivery of Pfizer medicines at the agreed upon terms. The restriction will lapse upon the resolution of the litigation or the proper delivery of the medicines. C. Revenues On January 1, 2018, we adopted a new accounting standard for revenue recognition. For further information, see Note 1B . We recorded direct product and/or alliance revenues of more than $1 billion for each of nine products in 2017. These direct products sales and/or alliance product revenues represented 46% of our revenues in 2017. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices due to added competition and we generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights. Our Consumer Healthcare business includes OTC brands with a focus on dietary supplements, pain management, gastrointestinal and respiratory and personal care. According to Euromonitor International’s retail sales data, in 2017, our Consumer Healthcare business was the fifth-largest branded multi-national, OTC consumer healthcare business in the world and produced two of the ten largest selling consumer healthcare brands ( Centrum and Advil ) in the world. We sell biopharmaceutical products after patent expiration, and under patent, and, to a much lesser extent, consumer healthcare products worldwide to developed and emerging market countries. Revenue Recognition ––We record revenues from product sales when there is a transfer of control of the product from us to the customer. We determine transfer of control based on when the product is shipped or delivered and title passes to the customer. • Customers ––Our biopharmaceutical products are sold principally to wholesalers but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies, and, in the case of our vaccine products in the U.S., we primarily sell directly to the CDC, wholesalers and individual provider offices. Our consumer healthcare customers include retailers and, to a lesser extent, wholesalers and distributors. Biopharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs, including those managed through pharmacy benefit managers, and are subject to sales allowances and/or rebates payable directly to those programs. Those sales allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented or unpatented). • Our Sales Contracts ––Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in the U.S. Sales are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns occur due to loss of exclusivity, product recalls or a changing competitive environment. • Deductions from Revenues –– Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period. Specifically: • In the U.S., we sell our products to distributors and hospitals under our sales contracts. However, we also have contracts with managed care or pharmacy benefit managers and legislatively mandated contracts with the federal and state governments under which we provide rebates to them based on medicines utilized by the lives they cover. We record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior quarters. We apply the experience ratio to the respective period’s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap,” also known as the “doughnut hole,” based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates. • Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government’s total unbudgeted pharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals. • Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices to third parties) closely approximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability. • Provisions for pharmaceutical sales returns are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as loss of exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit. • We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior. Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $5.4 billion and $4.9 billion as of July 1, 2018 and December 31, 2017 , respectively. The following table provides information about the balance sheet classification of these accruals: (MILLIONS OF DOLLARS) July 1, 2018 December 31, 2017 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 1,252 $ 1,352 Other current liabilities : Accrued rebates 3,039 2,674 Other accruals 698 512 Other noncurrent liabilities 406 385 Total accrued rebates and other accruals $ 5,396 $ 4,923 Amounts recorded for revenue deductions can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. On a quarterly basis, our adjustments of estimates to reflect actual results generally have been less than 1% of revenues, and have resulted in either a net increase or a net decrease in Revenues . Product-specific rebates, however, can have a significant impact on year-over-year individual product growth trends. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from Revenues . D. Collaborative Arrangements Payments to and from our collaboration partners are presented in our condensed consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received from our collaboration partners as alliance revenues, a component of Revenues, when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded as we perform co-promotion services for the collaboration and the collaboration partners sell the products to their customers within the applicable period. The related expenses for selling and marketing these products are included in Selling, informational and administrative expenses. In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. All royalty payments to collaboration partners are included in Cost of sales . Royalty payments received from collaboration partners are included in Other (income)/deductions—net. Reimbursements to or from our collaboration partners for development costs are recorded net in Research and development expenses . Upfront payments and pre-approval milestone payments due from us to our collaboration partners in development stage collaborations are recorded as Research and development expenses . Milestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in Identifiable intangible assets—Developed technology rights . Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in Other (income)/deductions—net over the development period for the collaboration products, when our performance obligations include providing R&D services to our collaboration partners. Upfront, pre-approval and post-approval milestone payments earned by us may be recognized in Other (income)/deductions—net immediately when earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be probable of a significant reversal. On January 1, 2018, we adopted a new accounting standard on revenue recognition (see Note 1B ). As a result of the adoption, we recognized the following cumulative effect adjustments related to collaboration arrangements to Retained earnings : • $394 million (pre-tax) for collaborative arrangements where the period over which upfront, pre-approval and regulatory approval milestone payments received from our collaboration partners are recognized in Other (income)/deductions—net over a reduced period. Under the new standard, the income from upfront and pre-approval milestone payments due to us is typically recognized over the development period for the collaboration when our performance obligation, in addition to granting a license, is to provide research and development services to our collaboration partners, and major regulatory approval milestones are typically recognized immediately when earned as the related development period has ended. The income from upfront and milestone payments is typically recognized immediately as earned if our performance obligation, in addition to granting a license, is only for commercialization activities. Under the old standard, this income was recognized over the combined development and estimated commercialization (including co-promotion) period for the collaboration products. • $82 million (pre-tax) for collaborative arrangements where we manufacture products for our collaboration partners and recognize Revenues and Cost of sales for product shipments at an earlier point in time. Under the new standard, revenue is recognized when we transfer control of the products to our collaboration partners. Under the old standard, revenue was recognized when our collaboration partners sell the products and transfer title to their third party customers.

Basis of Presentation and Sig22

Basis of Presentation and Significant Accounting Policies (Tables)	6 Months Ended
	Jul. 01, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Impact of Adoption of Accounting Standard Updates	Adoption of the standard related to pension and postretirement benefit costs impacted our prior period condensed consolidated statements of income as follows: Three Months Ended July 2, 2017 (MILLIONS OF DOLLARS) As Previously Reported Effect of Change Higher/(Lower) As Restated Cost of sales $ 2,663 $ (3 ) $ 2,660 Selling, informational and administrative expenses 3,425 5 3,430 Research and development expenses 1,780 7 1,787 Restructuring charges and certain acquisition-related costs 70 (1 ) 70 Other (income)/deductions––net (66 ) (8 ) (75 ) Income from continuing operations before provision for taxes on income 3,815 — 3,815 Six Months Ended July 2, 2017 (MILLIONS OF DOLLARS) As Previously Reported Effect of Change Higher/(Lower) As Restated Cost of sales $ 5,134 $ (6 ) $ 5,128 Selling, informational and administrative expenses 6,733 12 6,745 Research and development expenses 3,487 15 3,502 Restructuring charges and certain acquisition-related costs 228 (74 ) 153 Other (income)/deductions––net (68 ) 53 (14 ) Income from continuing operations before provision for taxes on income 7,767 — 7,767 Adoption of the standards impacted our condensed consolidated balance sheet as follows: Effect of New Accounting Standards Higher/(Lower) (MILLIONS OF DOLLARS) As Previously Reported Balance at December 31, 2017 Revenues Financial Assets and Liabilities Income Tax Accounting Reclassification of Certain Tax Effects from AOCI Balance at January 1, 2018 Trade accounts receivable $ 8,221 $ 13 $ — $ — $ — $ 8,234 Inventories 7,578 (11 ) — — — 7,567 Current tax assets 3,050 (11 ) — (3 ) — 3,036 Noncurrent deferred tax assets and other noncurrent tax assets 1,855 (17 ) — — — 1,838 Other noncurrent assets 3,227 — — (204 ) — 3,023 Other current liabilities 11,115 (123 ) — — — 10,992 Noncurrent deferred tax liabilities 3,900 106 — (18 ) — 3,988 Other noncurrent liabilities 6,149 (459 ) — — — 5,690 Retained earnings 85,291 450 419 (189 ) 495 86,466 Accumulated other comprehensive loss (9,321 ) — (419 ) — (495 ) (10,235 ) Adoption of the standards related to the classification of certain transactions in the statement of cash flows and the presentation of restricted cash in the statement of cash flows impacted our condensed consolidated statement of cash flows as follows: Six Months Ended July 2, 2017 Effect of New Accounting Standards Inflow/(Outflow) (MILLIONS OF DOLLARS) As Previously Reported Cash Flow Classification Restricted Cash As Restated Operating Activities Other adjustments, net $ (433 ) $ (26 ) $ — $ (458 ) Other changes in assets and liabilities, net of acquisitions and divestitures (3,853 ) — 9 (3,844 ) Investing Activities Proceeds from redemptions/sales of short-term investments 3,520 — (3 ) 3,517 Proceeds from redemptions/sales of long-term investments 1,539 — (2 ) 1,538 Financing Activities Principal payments on short-term borrowings (5,110 ) 22 — (5,088 ) Net proceeds from short-term borrowings with original maturities of three months or less 261 4 — 265 Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents (10 ) — 5 (5 ) Cash and cash equivalents and restricted cash and cash equivalents, beginning 2,595 — 70 2,666 Cash and cash equivalents and restricted cash and cash equivalents, ending 2,585 — 75 2,661
Reconciliation of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheet that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows: (MILLIONS OF DOLLARS) July 1, 2018 December 31, Cash and cash equivalents $ 2,704 $ 1,342 Restricted cash and cash equivalents in Short-term investments 42 — Restricted cash and cash equivalents in Long-term investments 66 — Restricted cash and cash equivalents in Other current assets — 14 Restricted cash and cash equivalents in Other noncurrent assets — 75 Total cash and cash equivalents and restricted cash and cash equivalents shown in the condensed consolidated balance sheets $ 2,811 $ 1,431
Reconciliation of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheet that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows: (MILLIONS OF DOLLARS) July 1, 2018 December 31, Cash and cash equivalents $ 2,704 $ 1,342 Restricted cash and cash equivalents in Short-term investments 42 — Restricted cash and cash equivalents in Long-term investments 66 — Restricted cash and cash equivalents in Other current assets — 14 Restricted cash and cash equivalents in Other noncurrent assets — 75 Total cash and cash equivalents and restricted cash and cash equivalents shown in the condensed consolidated balance sheets $ 2,811 $ 1,431
Schedule of Balance Sheet Classification of Accruals	The following table provides information about the balance sheet classification of these accruals: (MILLIONS OF DOLLARS) July 1, 2018 December 31, 2017 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 1,252 $ 1,352 Other current liabilities : Accrued rebates 3,039 2,674 Other accruals 698 512 Other noncurrent liabilities 406 385 Total accrued rebates and other accruals $ 5,396 $ 4,923

Restructuring Charges and Oth23

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)	6 Months Ended
	Jul. 01, 2018
Restructuring and Related Activities [Abstract]
Schedule of Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) July 1, July 2, July 1, July 2, Restructuring (credits)/charges: Employee terminations $ (21 ) $ (27 ) $ (29 ) $ (57 ) Asset impairments (6 ) — (4 ) 24 Exit costs 3 4 — 6 Restructuring credits (a) (24 ) (23 ) (33 ) (27 ) Transaction costs (b) — 6 — 18 Integration costs (c) 68 86 120 163 Restructuring charges and certain acquisition-related costs 44 70 87 153 Net periodic benefit costs recorded in Other (income)/deductions––net (d) 29 1 61 74 Additional depreciation––asset restructuring, virtually all of which is recorded in Cost of sales (e) 13 21 31 35 Implementation costs recorded in our condensed consolidated statements of income as follows (f) : Cost of sales 20 36 36 51 Selling, informational and administrative expenses 16 15 34 24 Research and development expenses 7 11 13 17 Total implementation costs 44 62 82 93 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 131 $ 153 $ 262 $ 356 (a) In the three and six months ended July 1, 2018 , restructuring credits are associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as acquisition-related costs, primarily associated with Hospira. In the three and six months ended July 2, 2017 , restructuring credits are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, partially offset by charges related to our acquisition of mainly Anacor in the second quarter of 2017, and mainly Anacor and Medivation in the first six months of 2017. In the three and six months ended July 1, 2018 , Employee terminations primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, many of which may be paid out during periods after termination. The restructuring activities for 2018 are associated with the following: • For the second quarter of 2018 , IH ( $12 million income); EH ( $2 million ); manufacturing operations ( $13 million ); and Corporate ( $26 million income). • For the first six months of 2018 , IH ( $12 million income); EH ( $12 million income); WRD/GPD ( $2 million income); manufacturing operations ( $15 million ); and Corporate ( $22 million income). The restructuring activities for 2017 are associated with the following: • For the second quarter of 2017 , IH ( $8 million income); EH ( $7 million ); WRD/GPD ( $14 million income); manufacturing operations ( $8 million income); and Corporate ( $1 million ). • For the first six months of 2017 , IH ( $1 million income); EH ( $11 million income); WRD/GPD ( $26 million income); manufacturing operations ( $9 million ); and Corporate ( $3 million ). (b) Transaction costs represent external costs for banking, legal, accounting and other similar services, virtually all of which for the second quarter and first six months of 2017 were directly related to our acquisition of Medivation. (c) Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the second quarter and first six months of 2018 , integration costs were primarily related to our acquisition of Hospira. In the second quarter and first six months of 2017 , integration costs were primarily related to our acquisitions of Hospira and Medivation, including a net gain of $12 million related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see Note 10 ). (d) In the three and six months ended July 1, 2018 , primarily represents the net pension curtailments and settlements included in Other (income)/deductions––net upon the adoption of a new accounting standard in the first quarter of 2018. In the three and six months ended July 2, 2017 , primarily represents the net pension curtailments and settlements, partially offset by net periodic benefit credits, excluding service costs, related to our acquisition of Hospira, both of which were reclassified to Other (income)/deductions––net as a result of the retrospective adoption of a new accounting standard in the first quarter of 2018. These credits included a net settlement gain, partially offset by accelerated amortization of actuarial losses and prior service costs upon the settlement of the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. For additional information, see Note 1B and Note 10 . (e) Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (f) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
Schedule of Components of and Changes in Restructuring Accruals	The following table provides the components of and changes in our restructuring accruals: (MILLIONS OF DOLLARS) Employee Termination Costs Asset Impairment Charges Exit Costs Accrual Balance, December 31, 2017 (a) $ 1,039 $ — $ 66 $ 1,105 Credits (29 ) (4 ) — (33 ) Utilization and other (b) (171 ) 4 (28 ) (195 ) Balance, July 1, 2018 (c) $ 839 $ — $ 38 $ 877 (a) Included in Other current liabilities ( $643 million ) and Other noncurrent liabilities ( $462 million ). (b) Includes adjustments for foreign currency translation. (c) Included in Other current liabilities ( $460 million ) and Other noncurrent liabilities ( $418 million ).

Other (Income)_Deductions - N24

Other (Income)/Deductions - Net (Tables)	6 Months Ended
	Jul. 01, 2018
Other Income and Expenses [Abstract]
Schedule of Other (Income)/Deductions - Net	The following table provides components of Other (income)/deductions––net : Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) July 1, July 2, July 1, July 2, Interest income (a) $ (80 ) $ (94 ) $ (157 ) $ (175 ) Interest expense (a) 326 312 635 621 Net interest expense 245 218 478 446 Royalty-related income (121 ) (105 ) (217 ) (191 ) Net gains on asset disposals (b) (17 ) (34 ) (36 ) (125 ) Income from collaborations, out-licensing arrangements and sales of compound/product rights (c) (174 ) (37 ) (316 ) (85 ) Net unrealized gains on equity securities (d) (226 ) — (337 ) — Net periodic benefit costs/(credits) other than service costs (e) (84 ) (8 ) (166 ) 53 Certain legal matters, net (f) (88 ) 3 (107 ) 11 Certain asset impairments (g) 31 — 31 13 Adjustments to loss on sale of HIS net assets (h) (2 ) 28 1 64 Business and legal entity alignment costs (i) 1 17 4 38 Other, net (j) (115 ) (155 ) (64 ) (239 ) Other (income)/deductions––net $ (551 ) $ (75 ) $ (728 ) $ (14 ) (a) Interest income decreased in the second quarter and first six months of 2018 , primarily driven by a lower investment balance. Interest expense increased in the second quarter and first six months of 2018 , primarily as a result of higher short-term interest rates, offset, in part, by refinancing activity that occurred in the fourth quarter of 2017. (b) In the second quarter of 2018 , primarily includes gains on fixed assets and other asset disposals of $15 million . In the first six months of 2018 , includes gains on fixed assets and other asset disposals of $22 million and net gains on sales of investments in equity and debt securities of approximately $14 million . In the second quarter of 2017 , primarily includes gains on sales and redemptions of investments in equity and debt securities (approximately $60 million ), partially offset by a net loss related to the sale of our 40% ownership investment in Teuto, including the extinguishment of a put option for the then remaining 60% ownership interest (approximately $30 million ). In the first six months of 2017 , primarily includes gains on sales and redemptions of investments in equity and debt securities (approximately $102 million ) and a gain on sale of property (approximately $50 million ), partially offset by the net loss related to the sale of our investment in Teuto discussed above. (c) Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the second quarter of 2018 , primarily includes, among other things, approximately $88 million in milestone income from multiple licensees and an upfront payment to us of $75 million for the sale of an AMPA receptor potentiator for CIAS to Biogen. In the first six months of 2018 , primarily includes, among other things, all of the factors discussed above for the second quarter of 2018 , as well as a $75 million milestone payment received from Shire related to their first dosing of a patient in a Phase 3 clinical trial of a compound out-licensed by Pfizer to Shire for the treatment of ulcerative colitis, and a $40 million milestone payment from Merck in conjunction with the approval of ertugliflozin in the EU. For additional information, see Note 2B, Note 2C and Note 2D . (d) Represents the unrealized net gains on equity securities reflecting the adoption of a new accounting standard in the first quarter of 2018. Approximately $142 million of these unrealized gains in the second quarter of 2018 and approximately $203 million of these unrealized gains in the first six months of 2018 relate to 3.2 million shares of ICU Medical stock that were received as part of the consideration for the sale of HIS net assets to ICU Medical. Prior to the adoption of the new standard, net unrealized gains and losses on virtually all equity securities with readily determinable fair values were reported in Accumulated other comprehensive income. For additional information, see Note 1B and Note 7B . (e) Represents the net periodic benefit costs/(credits), excluding service costs, as a result of the adoption of a new accounting standard in the first quarter of 2018. Effective January 1, 2018, the U.S. Pfizer Consolidated Pension Plan was frozen to future benefit accruals and for the second quarter and first six months of 2018 , resulted in the recognition of lower net periodic benefit costs due to the extension of the amortization period for the actuarial losses and the elimination of service costs. There was also a greater than expected gain on plan assets due to a higher plan asset base compared to the second quarter and first six months of 2017. For additional information, see Note 1B and Note 10 . (f) In the second quarter and first six months of 2018 , primarily represents the reversal of a legal accrual where a loss was no longer deemed probable. (g) In the second quarter and first six months of 2018 , includes an intangible asset impairment charge related to a finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the U.S. market only. The impairment charge for the second quarter and first six months of 2018 is associated with IH and reflects , among other things, updated commercial forecasts. (h) In the second quarter and first six months of 2018 and 2017 , represents adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical on February 3, 2017. For additional information, see Note 2B . (i) In the second quarter and first six months of 2018 and 2017 , represents expenses for changes to our infrastructure to align our commercial operations of our current segments, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. (j) In the second quarter and first six months of 2018 , includes, among other things, dividend income of $76 million and $135 million , respectively, from our investment in ViiV, and charges of $23 million and $135 million , respectively, reflecting the change in the fair value of contingent consideration. The second quarter and first six months of 2018 also include a non-cash $50 million pre-tax gain on the contribution of Pfizer’s allogeneic CAR T therapy development program assets obtained from Cellectis and Servier in connection with our contribution agreement entered into with Allogene in which Pfizer obtained a 25% ownership stake in Allogene (see Note 2B ), and a non-cash $17 million pre-tax gain on the cash settlement of a liability that we incurred in April 2018 upon the EU approval of Mylotarg (see Note 7E ). In the second quarter and first six months of 2017 , primarily includes, among other things, dividend income of $114 million and $157 million , respectively, from our investment in ViiV.
Schedule of Additional Information About Intangible Assets Impaired	The following table provides additional information about the intangible asset that was impaired during 2018 in Other (income)/deductions: Fair Value (a) Three and Six Months Ended July 1, 2018 (MILLIONS OF DOLLARS) Amount Level 1 Level 2 Level 3 Impairment Intangible assets––Developed technology right, finite-lived (b) $ 35 $ — $ — $ 35 $ 31 (a) The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. (b) Reflects intangible assets written down to fair value in the second quarter and first six months of 2018 . Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax Matters (Tables)

Tax Matters (Tables)	6 Months Ended
	Jul. 01, 2018
Income Tax Disclosure [Abstract]
Schedule of Tax Provision (Benefit) on Other Comprehensive Income/(Loss)	The following table provides the components of Tax provision/(benefit) on other comprehensive income/(loss): Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) July 1, July 2, July 1, July 2, Foreign currency translation adjustments, net (a) $ 101 $ (109 ) $ 67 $ (130 ) Unrealized holding gains/(losses) on derivative financial instruments, net 8 (1 ) 4 2 Reclassification adjustments for (gains)/losses included in net income 72 (88 ) 65 (140 ) Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b) — — 1 — 79 (89 ) 70 (138 ) Unrealized holding gains/(losses) on available-for-sale securities, net (48 ) 18 (28 ) 55 Reclassification adjustments for (gains)/losses included in net income 20 (7 ) (2 ) 4 Reclassification adjustments for tax on unrealized gains from AOCI to Retained earnings (c) — — (45 ) — (29 ) 11 (76 ) 59 Benefit plans: actuarial gains/(losses), net (13 ) 22 25 22 Reclassification adjustments related to amortization 14 43 28 92 Reclassification adjustments related to settlements, net 7 (4 ) 15 8 Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b) — — 637 — Other 27 (17 ) 6 (13 ) 34 43 712 110 Benefit plans: prior service costs and other, net — — — — Reclassification adjustments related to amortization (11 ) (17 ) (22 ) (33 ) Reclassification adjustments related to curtailments, net 4 (1 ) (3 ) (4 ) Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b) — — (144 ) — Other (6 ) — — — (13 ) (19 ) (168 ) (38 ) Tax provision/(benefit) on other comprehensive income/(loss) $ 173 $ (163 ) $ 605 $ (138 ) (a) Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely. (b) For additional information on the adoption of a new accounting standard related to reclassification of certain tax effects from AOCI, see Note 1B. (c) For additional information on the adoption of a new accounting standard related to financial assets and liabilities, see Note 1B .

Accumulated Other Comprehensi26

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)	6 Months Ended
	Jul. 01, 2018
Equity [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax	The following table provides the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gains/(Losses) Benefit Plans (MILLIONS OF DOLLARS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Actuarial Gains/(Losses) Prior Service (Costs)/Credits and Other Accumulated Other Comprehensive Income/(Loss) Balance, December 31, 2017 $ (5,180 ) $ (30 ) $ 401 $ (5,262 ) $ 750 $ (9,321 ) Other comprehensive income/(loss) due to the adoption of new accounting standards (a) (2 ) (1 ) (416 ) (637 ) 144 (913 ) Other comprehensive income/(loss) (b) (15 ) 298 (215 ) 241 (80 ) 231 Balance, July 1, 2018 $ (5,198 ) $ 267 $ (230 ) $ (5,657 ) $ 814 $ (10,003 ) (a) Amounts represent the cumulative effect adjustments as of January 1, 2018 from the adoption of new accounting standards related to (i) financial assets and liabilities and (ii) the reclassification of certain tax effects from AOCI. For additional information, see Note 1B. (b) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $11 million loss for the first six months of 2018 .

Financial Instruments (Tables)

Financial Instruments (Tables)	6 Months Ended
	Jul. 01, 2018
Financial Instruments [Abstract]
Schedule of Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis	The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in Notes to Consolidated Financial Statements–– Note 1E. Basis of Presentation and Significant Accounting Policies: Fair Value in Pfizer’s 2017 Financial Report: July 1, 2018 December 31, 2017 (MILLIONS OF DOLLARS) Total Level 1 Level 2 Total Level 1 Level 2 Financial assets measured at fair value on a recurring basis: Short-term investments Classified as equity securities: Money market funds $ 1,302 $ — $ 1,302 $ 2,115 $ — $ 2,115 Equity (a) 30 19 12 35 16 19 1,332 19 1,314 2,150 16 2,134 Classified as available-for-sale debt securities: Government and agency—non-U.S. 5,527 — 5,527 12,242 — 12,242 Corporate 2,659 — 2,659 2,766 — 2,766 Government—U.S. 8 — 8 252 — 252 Agency asset-backed—U.S. 19 — 19 23 — 23 Other asset-backed 7 — 7 79 — 79 8,220 — 8,220 15,362 — 15,362 Total short-term investments 9,553 19 9,534 17,512 16 17,496 Other current assets Derivative assets: Interest rate contracts 98 — 98 104 — 104 Foreign exchange contracts 353 — 353 234 — 234 Total other current assets 451 — 451 337 — 337 Long-term investments Classified as equity securities: Equity (a) 1,737 1,704 33 1,440 1,398 42 Classified as trading securities: Debt 50 50 — 73 73 — 1,787 1,754 33 1,514 1,472 42 Classified as available-for-sale debt securities: Government and agency—non-U.S. 141 — 141 387 — 387 Corporate 3,579 — 3,579 4,172 36 4,136 Government—U.S. 425 — 425 495 — 495 Other asset-backed 14 — 14 35 — 35 4,160 — 4,160 5,090 36 5,054 Total long-term investments 5,947 1,754 4,193 6,603 1,507 5,096 Other noncurrent assets Derivative assets: Interest rate contracts 290 — 290 477 — 477 Foreign exchange contracts 200 — 200 7 — 7 Total other noncurrent assets 489 — 489 484 — 484 Total assets $ 16,440 $ 1,773 $ 14,668 $ 24,937 $ 1,523 $ 23,414 Financial liabilities measured at fair value on a recurring basis: Other current liabilities Derivative liabilities: Interest rate contracts $ 11 $ — $ 11 $ 1 $ — $ 1 Foreign exchange contracts 115 — 115 201 — 201 Total other current liabilities 126 — 126 201 — 201 Other noncurrent liabilities Derivative liabilities: Interest rate contracts 499 — 499 177 — 177 Foreign exchange contracts 413 — 413 313 — 313 Total other noncurrent liabilities 912 — 912 490 — 490 Total liabilities $ 1,038 $ — $ 1,038 $ 691 $ — $ 691 (a) As of July 1, 2018 , short-term equity securities of $11 million and long-term equity securities of $32 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. As of December 31, 2017 , short-term equity securities of $19 million and long-term equity securities of $42 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.
Schedule of Financial Liabilities Not Measured At Fair Value On a Recurring Basis	The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values: July 1, 2018 December 31, 2017 Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value (MILLIONS OF DOLLARS) Total Level 2 Total Level 2 Financial Liabilities Long-term debt, excluding the current portion $ 28,935 $ 30,011 $ 30,011 $ 33,538 $ 37,253 $ 37,253
Investments by Classification Type	The following table represents our investments by classification type: (MILLIONS OF DOLLARS) July 1, 2018 December 31, 2017 Short-term investments Equity securities $ 1,332 $ 2,150 Available-for-sale debt securities 8,220 15,362 Held-to-maturity debt securities 1,174 1,138 Total Short-term investments $ 10,727 $ 18,650 Long-term investments Equity securities $ 1,787 $ 1,514 Available-for-sale debt securities 4,160 5,090 Held-to-maturity debt securities 70 4 Private equity investments carried at equity-method or cost 578 408 Total Long-term investments $ 6,595 $ 7,015 Held-to-maturity cash equivalents $ 808 $ 719
Schedule of Held-to-maturity Securities	At July 1, 2018, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt and equity securities at July 1, 2018 and December 31, 2017 is as follows, including, as of July 1, 2018, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to maturity debt securities: July 1, 2018 December 31, 2017 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 to 5 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 5,797 $ 5 $ (133 ) $ 5,669 $ 5,527 $ 141 $ — $ 5,669 $ 12,616 $ 61 $ (48 ) $ 12,629 Corporate (a) 6,358 2 (122 ) 6,238 2,659 2,557 1,022 6,238 6,955 15 (33 ) 6,938 Government––U.S. 458 — (25 ) 433 8 415 10 433 765 — (19 ) 747 Agency asset-backed––U.S. 19 — — 19 19 — — 19 24 — (1 ) 24 Other asset-backed (b) 22 — — 22 7 13 2 22 114 — — 114 Held-to-maturity debt securities Time deposits and other 1,482 — — 1,482 1,412 66 4 1,482 1,091 — — 1,091 Government and agency––non-U.S. 570 — — 570 570 — — 570 770 — — 770 Total debt securities $ 14,705 $ 7 $ (280 ) $ 14,432 $ 10,202 $ 3,192 $ 1,038 $ 14,432 $ 22,337 $ 77 $ (100 ) $ 22,313 Available-for-sale equity securities (c) Money market funds $ 2,115 $ — $ — $ 2,115 Equity 728 586 (124 ) 1,190 Total available-for-sale equity securities $ 2,843 $ 586 $ (124 ) $ 3,304 (a) Issued by a diverse group of corporations. (b) Includes loan-backed, mortgage-backed and receivable-backed securities, all of which are in senior positions in the capital structure of the security. Loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages. Receivable-backed securities are collateralized by credit cards receivables. (c) Upon the 2018 adoption of a new accounting standard related to financial assets and liabilities, available-for-sale equity securities were classified as equity securities. For additional information see Note 1B .
Schedule of Available-for-sale Securities	At July 1, 2018, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt and equity securities at July 1, 2018 and December 31, 2017 is as follows, including, as of July 1, 2018, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to maturity debt securities: July 1, 2018 December 31, 2017 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 to 5 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 5,797 $ 5 $ (133 ) $ 5,669 $ 5,527 $ 141 $ — $ 5,669 $ 12,616 $ 61 $ (48 ) $ 12,629 Corporate (a) 6,358 2 (122 ) 6,238 2,659 2,557 1,022 6,238 6,955 15 (33 ) 6,938 Government––U.S. 458 — (25 ) 433 8 415 10 433 765 — (19 ) 747 Agency asset-backed––U.S. 19 — — 19 19 — — 19 24 — (1 ) 24 Other asset-backed (b) 22 — — 22 7 13 2 22 114 — — 114 Held-to-maturity debt securities Time deposits and other 1,482 — — 1,482 1,412 66 4 1,482 1,091 — — 1,091 Government and agency––non-U.S. 570 — — 570 570 — — 570 770 — — 770 Total debt securities $ 14,705 $ 7 $ (280 ) $ 14,432 $ 10,202 $ 3,192 $ 1,038 $ 14,432 $ 22,337 $ 77 $ (100 ) $ 22,313 Available-for-sale equity securities (c) Money market funds $ 2,115 $ — $ — $ 2,115 Equity 728 586 (124 ) 1,190 Total available-for-sale equity securities $ 2,843 $ 586 $ (124 ) $ 3,304 (a) Issued by a diverse group of corporations. (b) Includes loan-backed, mortgage-backed and receivable-backed securities, all of which are in senior positions in the capital structure of the security. Loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages. Receivable-backed securities are collateralized by credit cards receivables. (c) Upon the 2018 adoption of a new accounting standard related to financial assets and liabilities, available-for-sale equity securities were classified as equity securities. For additional information see Note 1B .
Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities	At July 1, 2018, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt and equity securities at July 1, 2018 and December 31, 2017 is as follows, including, as of July 1, 2018, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to maturity debt securities: July 1, 2018 December 31, 2017 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 to 5 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 5,797 $ 5 $ (133 ) $ 5,669 $ 5,527 $ 141 $ — $ 5,669 $ 12,616 $ 61 $ (48 ) $ 12,629 Corporate (a) 6,358 2 (122 ) 6,238 2,659 2,557 1,022 6,238 6,955 15 (33 ) 6,938 Government––U.S. 458 — (25 ) 433 8 415 10 433 765 — (19 ) 747 Agency asset-backed––U.S. 19 — — 19 19 — — 19 24 — (1 ) 24 Other asset-backed (b) 22 — — 22 7 13 2 22 114 — — 114 Held-to-maturity debt securities Time deposits and other 1,482 — — 1,482 1,412 66 4 1,482 1,091 — — 1,091 Government and agency––non-U.S. 570 — — 570 570 — — 570 770 — — 770 Total debt securities $ 14,705 $ 7 $ (280 ) $ 14,432 $ 10,202 $ 3,192 $ 1,038 $ 14,432 $ 22,337 $ 77 $ (100 ) $ 22,313 Available-for-sale equity securities (c) Money market funds $ 2,115 $ — $ — $ 2,115 Equity 728 586 (124 ) 1,190 Total available-for-sale equity securities $ 2,843 $ 586 $ (124 ) $ 3,304 (a) Issued by a diverse group of corporations. (b) Includes loan-backed, mortgage-backed and receivable-backed securities, all of which are in senior positions in the capital structure of the security. Loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages. Receivable-backed securities are collateralized by credit cards receivables. (c) Upon the 2018 adoption of a new accounting standard related to financial assets and liabilities, available-for-sale equity securities were classified as equity securities. For additional information see Note 1B .
Schedule of Gains and Losses on Investment Securities	The following table presents the net unrealized gains and losses for the period that relates to equity securities still held at the reporting date, calculated as follows: (MILLIONS OF DOLLARS) Three Months Ended July 1, 2018 Six Months Ended July 1, 2018 Net gains recognized during the period on equity securities (a) $ 232 $ 330 Less: Net gains recognized during the period on equity securities sold during the period (19 ) (31 ) Net unrealized gains during the reporting period on equity securities still held at the reporting date $ 213 $ 299 (a) The second quarter of 2018 includes $226 million of unrealized net gains reflecting the adoption of a new accounting standard in the first quarter of 2018 and $7 million of unrealized gains on other equity securities. The first six months of 2018 includes $337 million of unrealized net gains reflecting the adoption of a new accounting standard in the first quarter of 2018 and $7 million of unrealized losses on other equity securities. For additional information, see Note 1B and Note 4 .
Schedule of Short-term Borrowings	Short-term borrowings include: (MILLIONS OF DOLLARS) July 1, December 31, Commercial paper $ 6,800 $ 6,100 Current portion of long-term debt, principal amount 4,267 3,532 Other short-term borrowings, principal amount (a) 538 320 Total short-term borrowings, principal amount 11,605 9,951 Net fair value adjustments related to hedging and purchase accounting (4 ) 14 Net unamortized discounts, premiums and debt issuance costs (18 ) (12 ) Total Short-term borrowings, including current portion of long-term debt , carried at historical proceeds, as adjusted $ 11,583 $ 9,953 (a) Other short-term borrowings primarily include cash collateral. For additional information, see Note 7F .
Schedule of Principal Amounts of Senior Unsecured Long-Term Debt and Adjustments	The following table provides the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt: (MILLIONS OF DOLLARS) July 1, December 31, Total long-term debt, principal amount $ 28,701 $ 32,783 Net fair value adjustments related to hedging and purchase accounting 338 872 Net unamortized discounts, premiums and debt issuance costs (112 ) (125 ) Other long-term debt 8 8 Total long-term debt, carried at historical proceeds, as adjusted $ 28,935 $ 33,538 Current portion of long-term debt, carried at historical proceeds $ 4,262 $ 3,546
Schedule of Derivative Instruments	The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) July 1, 2018 December 31, 2017 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 19,254 $ 472 $ 458 $ 18,723 $ 179 $ 459 Interest rate contracts 11,300 387 510 12,430 581 178 859 968 760 637 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 12,134 81 70 $ 14,300 62 54 Total $ 940 $ 1,038 $ 822 $ 691 (a) As of July 1, 2018 , the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion .
Schedule of Derivative Assets	The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) July 1, 2018 December 31, 2017 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 19,254 $ 472 $ 458 $ 18,723 $ 179 $ 459 Interest rate contracts 11,300 387 510 12,430 581 178 859 968 760 637 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 12,134 81 70 $ 14,300 62 54 Total $ 940 $ 1,038 $ 822 $ 691 (a) As of July 1, 2018 , the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion .
Schedule of Derivative Liabilities	The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) July 1, 2018 December 31, 2017 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 19,254 $ 472 $ 458 $ 18,723 $ 179 $ 459 Interest rate contracts 11,300 387 510 12,430 581 178 859 968 760 637 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 12,134 81 70 $ 14,300 62 54 Total $ 940 $ 1,038 $ 822 $ 691 (a) As of July 1, 2018 , the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion .
Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk	The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Amount of (a), (b) Amount of Gains/(Losses) (a), (c) Amount of Gains/(Losses) (a), (c) (MILLIONS OF DOLLARS) July 1, July 2, July 1, July 2, July 1, July 2, Three Months Ended Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (d) $ — $ (4 ) $ 107 $ (90 ) $ (330 ) $ 208 Amount excluded from effectiveness testing recognized in earnings based on an amortization approach — — 20 — 20 — Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts (121 ) 100 — — — — Hedged item gain/(loss) 121 (100 ) — — — — Foreign exchange contracts 12 (11 ) — — — — Hedged item gain/(loss) (12 ) 11 — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — — 153 — — — The portion of gains/(losses) on foreign exchange contracts excluded from the assessment of hedge effectiveness — — 25 — 21 — Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings (e) — — 85 — — — Foreign currency long-term debt (e) — — 186 (295 ) — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts 61 (5 ) — — — — All other net — — 1 — 1 — $ 62 $ (9 ) $ 577 $ (384 ) $ (289 ) $ 208 Amount of (a), (b) Amount of Gains/(Losses) (a), (c) Amount of Gains/(Losses) (a), (c) (MILLIONS OF DOLLARS) July 1, July 2, July 1, July 2, July 1, July 2, Six Months Ended Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (d) $ — $ (6 ) $ (36 ) $ (99 ) $ (402 ) $ 449 Amount excluded from effectiveness testing recognized in earnings based on an amortization approach — — 48 — 48 — Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts (520 ) 8 — — — — Hedged item gain/(loss) 520 (8 ) — — — — Foreign exchange contracts 4 (8 ) — — — — Hedged item gain/(loss) (4 ) 8 — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — — 148 — — — The portion of gains/(losses) on foreign exchange contracts excluded from the assessment of hedge effectiveness — — 27 — 26 — Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings (e) — — 43 — — — Foreign currency long-term debt (e) — — 94 (352 ) — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts 6 (145 ) — — — — All other net — — 1 — 1 — $ 6 $ (151 ) $ 325 $ (450 ) $ (328 ) $ 450 (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income . COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income . (b) For the second quarter and first six months ended July 2, 2017 , there was no significant ineffectiveness. (c) For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in Other comprehensive income/(loss)––Unrealized holding gains/(losses) on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income/(loss)––Foreign currency translation adjustments, net. (d) Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $55 million within the next 12 months into Cost of sales. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.8 billion U.K. pound debt maturing in 2043. (e) Short-term borrowings include foreign currency short-term borrowings with carrying values of $1.5 billion as of July 1, 2018 , which are used as hedging instruments in net investment hedges. Long-term debt includes foreign currency long-term borrowings with carrying values of $3.2 billion as of July 1, 2018 , which are used as hedging instruments in net investment hedges.
Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Fair Value Hedges	The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges: Carrying Amount of Hedged Assets/Liabilities Cumulative Amount of Fair Value Hedging Adjustment Gains/(Losses) Included in the Carrying Amount of the Hedged Assets/Liabilities (MILLIONS OF DOLLARS) July 1, 2018 July 1, 2018 Short-term investments $ 155 $ (1 ) Long-term investments 45 (1 ) Short-term borrowings, including current portion of long-term debt 1,487 11 Long-term debt 9,753 210 The following table provides the total amount of each income and expense line in which the results of fair value or cash flow hedges are recorded: Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) July 1, 2018 July 1, 2018 Cost of sales $ 2,916 $ 5,479 Other (income)/deductions—net (551 ) (728 )
Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Fair Value Hedges	The following table provides the total amount of each income and expense line in which the results of fair value or cash flow hedges are recorded: Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) July 1, 2018 July 1, 2018 Cost of sales $ 2,916 $ 5,479 Other (income)/deductions—net (551 ) (728 )

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jul. 01, 2018
Inventory Disclosure [Abstract]
Schedule of Components of Inventories, Current	The following table provides the components of Inventories : (MILLIONS OF DOLLARS) July 1, December 31, Finished goods $ 2,756 $ 2,883 Work-in-process 4,542 3,908 Raw materials and supplies 776 788 Inventories (a) $ 8,074 $ 7,578 Noncurrent inventories not included above (b) $ 615 $ 683 (a) The change from December 31, 2017 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery, network strategy and new product launches, partially offset by a decrease due to foreign exchange. (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.
Schedule of Components of Inventories, Noncurrent	The following table provides the components of Inventories : (MILLIONS OF DOLLARS) July 1, December 31, Finished goods $ 2,756 $ 2,883 Work-in-process 4,542 3,908 Raw materials and supplies 776 788 Inventories (a) $ 8,074 $ 7,578 Noncurrent inventories not included above (b) $ 615 $ 683 (a) The change from December 31, 2017 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery, network strategy and new product launches, partially offset by a decrease due to foreign exchange. (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Identifiable Intangible Asset29

Identifiable Intangible Assets and Goodwill (Tables)	6 Months Ended
	Jul. 01, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	The following table provides the components of Identifiable intangible assets : July 1, 2018 December 31, 2017 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights $ 89,582 $ (56,829 ) $ 32,753 $ 89,550 $ (54,785 ) $ 34,765 Brands 2,126 (1,203 ) 923 2,134 (1,152 ) 982 Licensing agreements and other 1,957 (1,139 ) 818 1,911 (1,096 ) 815 93,665 (59,171 ) 34,494 93,595 (57,033 ) 36,562 Indefinite-lived intangible assets Brands and other 6,927 6,927 6,929 6,929 IPR&D 5,163 5,163 5,249 5,249 12,090 12,090 12,179 12,179 Identifiable intangible assets (a) $ 105,755 $ (59,171 ) $ 46,584 $ 105,774 $ (57,033 ) $ 48,741 (a) The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization, minimally offset by additions, mainly consisting of $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E ).
Schedule of Indefinite Lived Intangible Assets	The following table provides the components of Identifiable intangible assets : July 1, 2018 December 31, 2017 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights $ 89,582 $ (56,829 ) $ 32,753 $ 89,550 $ (54,785 ) $ 34,765 Brands 2,126 (1,203 ) 923 2,134 (1,152 ) 982 Licensing agreements and other 1,957 (1,139 ) 818 1,911 (1,096 ) 815 93,665 (59,171 ) 34,494 93,595 (57,033 ) 36,562 Indefinite-lived intangible assets Brands and other 6,927 6,927 6,929 6,929 IPR&D 5,163 5,163 5,249 5,249 12,090 12,090 12,179 12,179 Identifiable intangible assets (a) $ 105,755 $ (59,171 ) $ 46,584 $ 105,774 $ (57,033 ) $ 48,741 (a) The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization, minimally offset by additions, mainly consisting of $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E ).
Identifiable Intangible Assets as a Percentage of Total Identifiable Intangible Assets Less Accumulated Amortization, By Segment	Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: July 1, 2018 IH EH WRD Developed technology rights 68 % 32 % — % Brands, finite-lived 75 % 25 % — % Brands, indefinite-lived 71 % 29 % — % IPR&D 82 % 11 % 7 %
Schedule of Goodwill	The following table provides the components of and changes in the carrying amount of Goodwill : (MILLIONS OF DOLLARS) IH EH Total Balance, December 31, 2017 $ 31,141 $ 24,811 $ 55,952 Other (a) (65 ) (51 ) (117 ) Balance, July 1, 2018 $ 31,076 $ 24,760 $ 55,836 (a) Primarily reflects the impact of foreign exchange, as well as the contribution of the allogeneic CAR T developmental program assets and operations to Allogene that constituted a business for accounting purposes (see Note 2B ).

Pension and Postretirement Be30

Pension and Postretirement Benefit Plans (Tables)	6 Months Ended
	Jul. 01, 2018
Retirement Benefits [Abstract]
Schedule of Net Periodic Benefit Costs	The following table provides the components of net periodic benefit cost/(credit): Three Months Ended Pension Plans U.S. Qualified (a) U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 Net periodic benefit cost/(credit) (b) : Service cost (c) $ — $ 67 $ — $ 6 $ 34 $ 42 $ 10 $ 11 Interest cost 150 159 14 13 55 50 18 23 Expected return on plan assets (261 ) (252 ) — — (93 ) (85 ) (9 ) (9 ) Amortization of: Actuarial losses (c) 30 97 3 12 26 28 2 8 Prior service costs/(credits) — 1 — — (1 ) (1 ) (45 ) (46 ) Curtailments 7 4 — — — — (7 ) (5 ) Settlements 25 (7 ) 5 4 — 2 — — $ (49 ) $ 69 $ 21 $ 35 $ 21 $ 37 $ (32 ) $ (19 ) Six Months Ended Pension Plans U.S. Qualified (a) U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 Net periodic benefit cost/(credit) (b) : Service cost (c) $ — $ 135 $ — $ 12 $ 71 $ 83 $ 20 $ 21 Interest cost 301 321 26 28 109 100 36 45 Expected return on plan assets (524 ) (511 ) — — (185 ) (169 ) (18 ) (18 ) Amortization of: Actuarial losses (c) 60 212 7 25 52 56 4 15 Prior service costs/(credits) 1 3 — — (2 ) (2 ) (90 ) (92 ) Curtailments 9 9 — — — — (14 ) (12 ) Settlements 45 24 21 24 — 3 — — $ (107 ) $ 193 $ 55 $ 88 $ 44 $ 71 $ (63 ) $ (40 ) (a) In the second quarter of 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the $156 million net pension benefit obligation and recorded a pre-tax settlement gain of $41 million , partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately $30 million in Other (income)/deductions––net (see Note 3 ). (b) We adopted a new accounting standard on January 1, 2018 that requires the net periodic pension and postretirement benefit costs other than service costs be presented in Other (income)/deductions––net on the condensed consolidated statements of income. For additional information, see Note 1B and Note 4 . (c) Effective January 1, 2018, we froze two significant defined benefit pension plans to future benefit accruals in the U.S. and U.K. and as a result, service costs for those plans are eliminated. In addition, due to the plan freeze, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans was extended to the expected life expectancy of the plan participants, whereas the average amortization period in prior years utilized the expected future service period of plan participants.
Schedule of Employer Contributions to Pension and Postretirement Plans	The following table provides the amounts we contributed, and the amounts we expect to contribute during 2018, to our pension and postretirement plans from our general assets for the periods indicated: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Contributions from our general assets for the six months ended July 1, 2018 $ 500 $ 99 $ 84 $ 71 Expected contributions from our general assets during 2018 (a) 500 140 235 155 (a) Contributions expected to be made for 2018 are inclusive of amounts contributed during the six months ended July 1, 2018 , including the $500 million voluntary contribution that was made in February 2018 for the U.S. qualified plans, which was considered pre-funding for future anticipated mandatory contributions and is also expected to reduce Pension Benefit Guaranty Corporation variable rate premiums. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.

Earnings Per Common Share Att31

Earnings Per Common Share Attributable to Common Shareholders (Tables)	6 Months Ended
	Jul. 01, 2018
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earning Per Share	The following table provides the detailed calculation of EPS : Three Months Ended Six Months Ended (IN MILLIONS) July 1, July 2, July 1, July 2, EPS Numerator––Basic Income from continuing operations $ 3,879 $ 3,077 $ 7,450 $ 6,207 Less: Net income attributable to noncontrolling interests 7 5 16 14 Income from continuing operations attributable to Pfizer Inc. 3,872 3,071 7,434 6,193 Less: Preferred stock dividends––net of tax — — 1 — Income from continuing operations attributable to Pfizer Inc. common shareholders 3,871 3,071 7,433 6,192 Discontinued operations––net of tax — 2 (1 ) 1 Net income attributable to Pfizer Inc. common shareholders $ 3,871 $ 3,073 $ 7,432 $ 6,194 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions $ 3,872 $ 3,071 $ 7,434 $ 6,193 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions — 2 (1 ) 1 Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 3,872 $ 3,073 $ 7,432 $ 6,194 EPS Denominator Weighted-average number of common shares outstanding––Basic 5,866 5,958 5,911 5,982 Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements 86 80 93 83 Weighted-average number of common shares outstanding––Diluted 5,952 6,037 6,004 6,065 Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (a) 3 47 2 47 (a) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Segment, Geographic and Other32

Segment, Geographic and Other Revenue Information (Tables)	6 Months Ended
	Jul. 01, 2018
Segment Reporting [Abstract]
Reconciliation of Revenue from Segments to Consolidated	The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) July 1, July 2, July 1, July 2, Reportable Segments: IH (b) $ 8,273 $ 7,671 $ 5,100 $ 4,786 EH (b) 5,193 5,226 2,818 2,832 Total reportable segments 13,466 12,896 7,918 7,619 Other business activities (c), (d) — — (669 ) (758 ) Reconciling Items: Corporate (b), (d) — — (1,144 ) (1,209 ) Purchase accounting adjustments (d) — — (1,134 ) (1,201 ) Acquisition-related costs (d) — — (62 ) (68 ) Certain significant items (e) — — (20 ) (191 ) Other unallocated (b), (d) — — (362 ) (377 ) $ 13,466 $ 12,896 $ 4,527 $ 3,815 Six Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) July 1, July 2, July 1, July 2, Reportable Segments: IH (b) $ 16,102 $ 15,086 $ 10,031 $ 9,534 EH (b) 10,271 10,590 5,606 5,871 Total reportable segments 26,373 25,675 15,636 15,405 Other business activities (c), (d) — — (1,394 ) (1,445 ) Reconciling Items: Corporate (b), (d) — — (2,296 ) (2,545 ) Purchase accounting adjustments (d) — — (2,355 ) (2,373 ) Acquisition-related costs (d) — — (110 ) (192 ) Certain significant items (e) — — (221 ) (348 ) Other unallocated (b), (d) — — (607 ) (736 ) $ 26,373 $ 25,675 $ 8,654 $ 7,767 (a) Income from continuing operations before provision for taxes on income. IH’s earnings include d ividend income of $76 million and $114 million in the second quarter of 2018 and 2017 , respectively, and $135 million and $157 million in the first six months of 2018 and 2017 , respectively, from our investment in ViiV. For additional information, see Note 4. (b) In connection with the StratCO reporting change, in the second quarter of 2017 we reclassified approximately $120 million of costs from IH, approximately $45 million of costs from EH and approximately $12 million of costs from Corporate to Other unallocated costs to conform to the current period presentation. In the first six months of 2017, we reclassified approximately $218 million of costs from IH, approximately $78 million of costs from EH and approximately $21 million of costs from Corporate to Other unallocated costs to conform to the current period presentation. (c) Other business activities includes the costs managed by our WRD and GPD organizations. (d) For a description, see the “Other Costs and Business Activities” section above. (e) Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the second quarter of 2018 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $42 million , (ii) a net credit for certain legal matters of $88 million , (iii) adjustments of $2 million income to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairments of $31 million , (v) charges for business and legal entity alignment of $1 million and (vi) other charges of $37 million . For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the second quarter of 2017 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $49 million , (ii) an incremental charge to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $28 million , (iii) charges for business and legal entity alignment of $17 million and (iv) other charges of $97 million . For additional information, see Note 2B , Note 3 and Note 4 . For Earnings in the first six months of 2018 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $93 million , (ii) net credits for certain legal matters of $107 million , (iii) adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $1 million , (iv) certain asset impairments of $31 million , (v) charges for business and legal entity alignment of $4 million and (vi) other charges of $199 million , which primarily includes $119 million , in the aggregate, for a special one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA on us. For additional information, see Note 2B , Note 3 and Note 4 . For Earnings in the first six months of 2017 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $79 million , (ii) charges for certain legal matters of $8 million , (iii) adjustments to amounts previously recorded to the write-down the HIS net assets to fair value less costs to sell of $64 million , (iv) charges for business and legal entity alignment of $38 million and (v) other charges of $158 million . For additional information, see Note 2B , Note 3 and Note 4 .
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) July 1, July 2, July 1, July 2, Reportable Segments: IH (b) $ 8,273 $ 7,671 $ 5,100 $ 4,786 EH (b) 5,193 5,226 2,818 2,832 Total reportable segments 13,466 12,896 7,918 7,619 Other business activities (c), (d) — — (669 ) (758 ) Reconciling Items: Corporate (b), (d) — — (1,144 ) (1,209 ) Purchase accounting adjustments (d) — — (1,134 ) (1,201 ) Acquisition-related costs (d) — — (62 ) (68 ) Certain significant items (e) — — (20 ) (191 ) Other unallocated (b), (d) — — (362 ) (377 ) $ 13,466 $ 12,896 $ 4,527 $ 3,815 Six Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) July 1, July 2, July 1, July 2, Reportable Segments: IH (b) $ 16,102 $ 15,086 $ 10,031 $ 9,534 EH (b) 10,271 10,590 5,606 5,871 Total reportable segments 26,373 25,675 15,636 15,405 Other business activities (c), (d) — — (1,394 ) (1,445 ) Reconciling Items: Corporate (b), (d) — — (2,296 ) (2,545 ) Purchase accounting adjustments (d) — — (2,355 ) (2,373 ) Acquisition-related costs (d) — — (110 ) (192 ) Certain significant items (e) — — (221 ) (348 ) Other unallocated (b), (d) — — (607 ) (736 ) $ 26,373 $ 25,675 $ 8,654 $ 7,767 (a) Income from continuing operations before provision for taxes on income. IH’s earnings include d ividend income of $76 million and $114 million in the second quarter of 2018 and 2017 , respectively, and $135 million and $157 million in the first six months of 2018 and 2017 , respectively, from our investment in ViiV. For additional information, see Note 4. (b) In connection with the StratCO reporting change, in the second quarter of 2017 we reclassified approximately $120 million of costs from IH, approximately $45 million of costs from EH and approximately $12 million of costs from Corporate to Other unallocated costs to conform to the current period presentation. In the first six months of 2017, we reclassified approximately $218 million of costs from IH, approximately $78 million of costs from EH and approximately $21 million of costs from Corporate to Other unallocated costs to conform to the current period presentation. (c) Other business activities includes the costs managed by our WRD and GPD organizations. (d) For a description, see the “Other Costs and Business Activities” section above. (e) Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the second quarter of 2018 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $42 million , (ii) a net credit for certain legal matters of $88 million , (iii) adjustments of $2 million income to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairments of $31 million , (v) charges for business and legal entity alignment of $1 million and (vi) other charges of $37 million . For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the second quarter of 2017 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $49 million , (ii) an incremental charge to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $28 million , (iii) charges for business and legal entity alignment of $17 million and (iv) other charges of $97 million . For additional information, see Note 2B , Note 3 and Note 4 . For Earnings in the first six months of 2018 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $93 million , (ii) net credits for certain legal matters of $107 million , (iii) adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $1 million , (iv) certain asset impairments of $31 million , (v) charges for business and legal entity alignment of $4 million and (vi) other charges of $199 million , which primarily includes $119 million , in the aggregate, for a special one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA on us. For additional information, see Note 2B , Note 3 and Note 4 . For Earnings in the first six months of 2017 , certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $79 million , (ii) charges for certain legal matters of $8 million , (iii) adjustments to amounts previously recorded to the write-down the HIS net assets to fair value less costs to sell of $64 million , (iv) charges for business and legal entity alignment of $38 million and (v) other charges of $158 million . For additional information, see Note 2B , Note 3 and Note 4 .
Schedule of Revenues by Geographic Region	The following table provides revenues by geographic area: Three Months Ended Six Months Ended (MILLIONS OF DOLLARS) July 1, July 2, % Change July 1, July 2, % Change U.S. $ 6,225 $ 6,345 (2 ) $ 12,500 $ 12,982 (4 ) Developed Europe (a) 2,334 2,124 10 4,426 4,145 7 Developed Rest of World (b) 1,694 1,611 5 3,155 3,165 — Emerging Markets (c) 3,214 2,815 14 6,292 5,382 17 Revenues $ 13,466 $ 12,896 4 $ 26,373 $ 25,675 3 (a) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.9 billion and $1.7 billion in the second quarter of 2018 and 2017 , respectively, and $3.6 billion and $3.3 billion in the first six months of 2018 and 2017 , respectively. (b) Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand. (c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.
Schedule of Significant Product Revenues	The following table provides detailed revenue information: (MILLIONS OF DOLLARS) Three Months Ended Six Months Ended PRODUCT PRIMARY INDICATIONS OR CLASS July 1, July 2, July 1, July 2, TOTAL REVENUES $ 13,466 $ 12,896 $ 26,373 $ 25,675 PFIZER INNOVATIVE HEALTH (IH) (a) $ 8,273 $ 7,671 $ 16,102 $ 15,086 Internal Medicine $ 2,530 $ 2,412 $ 4,876 $ 4,789 Lyrica IH (b) Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury 1,134 1,101 2,266 2,231 Eliquis alliance revenues and direct sales Atrial fibrillation, deep vein thrombosis, pulmonary embolism 889 605 1,654 1,169 Chantix/Champix An aid to smoking cessation treatment in adults 18 years of age or older 277 248 528 487 BMP2 Development of bone and cartilage 80 57 153 119 Toviaz Overactive bladder 70 62 130 125 Viagra IH (c) Erectile dysfunction — 255 — 505 All other Internal Medicine Various 79 84 145 153 Vaccines $ 1,400 $ 1,270 $ 2,863 $ 2,735 Prevnar 13/Prevenar 13 Vaccines for prevention of pneumococcal disease 1,250 1,154 2,631 2,547 FSME/IMMUN-TicoVac Tick-borne encephalitis vaccine 73 50 105 76 All other Vaccines Various 77 66 127 112 Oncology $ 1,822 $ 1,589 $ 3,519 $ 2,935 Ibrance Advanced breast cancer 1,027 853 1,960 1,532 Sutent Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor 275 279 537 529 Xtandi alliance revenues Castration-resistant prostate cancer 171 141 330 272 Xalkori ALK-positive and ROS1-positive advanced NSCLC 137 155 290 296 Inlyta Advanced RCC 81 88 155 172 Bosulif Philadelphia chromosome–positive chronic myelogenous leukemia 77 59 138 106 All other Oncology Various 53 14 109 28 Inflammation & Immunology (I&I) $ 1,064 $ 992 $ 1,933 $ 1,863 Enbrel (Outside the U.S. and Canada) Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis 551 617 1,057 1,205 Xeljanz Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis 463 336 788 587 Eucrisa Mild-to-moderate atopic dermatitis (eczema) 39 9 65 17 All other I&I Various 11 31 22 54 Rare Disease $ 571 $ 562 $ 1,120 $ 1,069 BeneFIX Hemophilia 141 153 288 302 Genotropin Replacement of human growth hormone 140 135 272 238 Refacto AF/Xyntha Hemophilia 141 139 271 269 Somavert Acromegaly 68 61 131 117 All other Rare Disease Various 81 74 157 141 Consumer Healthcare $ 886 $ 846 $ 1,791 $ 1,694 PFIZER ESSENTIAL HEALTH (EH) (d) $ 5,193 $ 5,226 $ 10,271 $ 10,590 Legacy Established Products (LEP) (e) $ 2,695 $ 2,707 $ 5,331 $ 5,313 Lipitor Reduction of LDL cholesterol 521 445 1,032 849 Norvasc Hypertension 271 231 526 458 Premarin family Symptoms of menopause 210 245 401 473 Zithromax Bacterial infections 72 62 162 140 Xalatan/Xalacom Glaucoma and ocular hypertension 85 81 157 158 Zoloft Depression and certain anxiety disorders 77 69 151 137 Effexor Depression and certain anxiety disorders 79 73 150 139 EpiPen Epinephrine injection used in treatment of life-threatening allergic reactions 95 90 148 171 Xanax Anxiety disorders 56 52 111 107 Sildenafil Citrate Erectile dysfunction 8 — 71 — All other LEP Various 1,220 1,360 2,424 2,681 (MILLIONS OF DOLLARS) Three Months Ended Six Months Ended PRODUCT PRIMARY INDICATIONS OR CLASS July 1, July 2, July 1, July 2, Sterile Injectable Pharmaceuticals (SIP) (f) $ 1,329 $ 1,444 $ 2,688 $ 2,996 Sulperazon Treatment of infections 150 110 319 232 Medrol Steroid anti-inflammatory 104 123 223 243 Fragmin Slows blood clotting 74 71 145 142 Tygacil Tetracycline class antibiotic 63 57 126 131 Zosyn/Tazocin Antibiotic 58 40 119 78 Precedex Sedation agent in surgery or intensive care 64 67 119 132 All other SIP Various 815 975 1,638 2,038 Peri-LOE Products (g) $ 773 $ 782 $ 1,509 $ 1,604 Viagra EH (c) Erectile dysfunction 185 93 372 183 Celebrex Arthritis pain and inflammation, acute pain 161 178 306 353 Vfend Fungal infections 110 101 207 208 Lyrica EH (b) Epilepsy, neuropathic pain and generalized anxiety disorder 88 154 170 294 Zyvox Bacterial infections 66 75 134 152 Revatio Pulmonary arterial hypertension 54 67 109 131 Pristiq Depression 51 46 104 161 All other Peri-LOE Products Various 59 68 107 121 Biosimilars (h) Various $ 188 $ 121 $ 361 $ 226 Inflectra/Remsima Inflammatory diseases 158 94 303 172 All other Biosimilars Various 29 27 58 54 Pfizer CentreOne (i) $ 209 $ 171 $ 381 $ 353 Hospira Infusion Systems (HIS) (j) Various $ — $ — $ — $ 97 Total Lyrica (b) Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury $ 1,223 $ 1,254 $ 2,436 $ 2,526 Total Viagra (c) Erectile dysfunction $ 185 $ 349 $ 372 $ 687 Total Alliance revenues Various $ 987 $ 715 $ 1,842 $ 1,370 (a) The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare. (b) Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH. (c) Viagra lost exclusivity in the U.S. in December 2017. Beginning in 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, are reported in EH (which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, beginning in 2018, total Viagra revenues are reported in EH. Total Viagra revenues in 2017 represent the aggregate of worldwide revenues from Viagra IH and Viagra EH. (d) The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017). (e) Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne. (f) Sterile Injectable Pharmaceuticals includes branded and generic injectables (excluding Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne. (g) Peri-LOE Products includes products that have recently lost or are anticipated to soon lose patent protection. These products primarily include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra; and beginning in 2018, Viagra revenues for all countries (and Viagra revenues for all countries other than the U.S. and Canada in 2017, see note (c) above). (h) Biosimilars includes Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets. (i) Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne. (j) HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.

Basis of Presentation and Sig33

Basis of Presentation and Significant Accounting Policies (Details) $ in Millions		Jan. 01, 2018USD ($)Accounting_standard	Jul. 01, 2018USD ($)	Apr. 01, 2018USD ($)	Jul. 02, 2017USD ($)	Jul. 01, 2018USD ($)Operating_Segment	Jul. 02, 2017USD ($)	Dec. 31, 2017USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of business segments | Operating_Segment						2
Number of accounting standards adopted | Accounting_standard		11
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net unrealized gains on equity securities			$ 213			$ 299
Other (income)/deductions––net	[1]		(551)		$ (75)	(728)	$ (14)
Net increase in cash and cash equivalents and restricted cash and cash equivalents	[2]					1,381	(5)
Accrued rebates and other accruals			5,396			5,396		$ 4,923
Financial Assets and Liabilities [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment to retained earnings, pre-tax		$ 462
Cumulative effect adjustment to retained earnings, after-tax		419
Net unrealized gains on equity securities	[3]		226		$ 0	337	$ 0
Accounting for Hedging Activities [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Other (income)/deductions––net			$ (16)			(45)
Restricted Cash in the Statement of Cash Flows [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net increase in cash and cash equivalents and restricted cash and cash equivalents						19
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Revenues [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment to retained earnings, pre-tax		584		$ 584
Cumulative effect adjustment to retained earnings, after-tax		450
Reclassification From Financing Activities To Operating Activities [Member] | Classification of Certain Transactions in the Statement of Cash Flows [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt prepayment and extinguishment costs						7
Reclassification From Operating Activities To Financing Activities [Member] | Classification of Certain Transactions in the Statement of Cash Flows [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accreted interest						$ 38
Collaboration Arrangements [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Revenues [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment to retained earnings, pre-tax		500
Collaboration Arrangements, Income From Upfront And Pre-Approval Milestone Payments [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Revenues [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment to retained earnings, pre-tax		394
Collaboration Arrangements, Product Manufacturing [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Revenues [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment to retained earnings, pre-tax		82
Product Rights And Out-Licensing Arrangements [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Revenues [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment to retained earnings, pre-tax		394
Product Shipments [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Revenues [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment to retained earnings, pre-tax		84
Sales Revenue, Product Line [Member] | Product Concentration Risk [Member] | Top Nine Products [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk, amount								$ 1,000
Concentration risk, percentage								46.00%
Retained Earnings [Member] | Income Tax Accounting [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment to retained earnings, after-tax		(189)
Retained Earnings [Member] | Reclassification of Certain Tax Effects from AOCI [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment to retained earnings, after-tax		$ 495
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Represents the unrealized net gains on equity securities reflecting the adoption of a new accounting standard in the first quarter of 2018. Approximately $142 million of these unrealized gains in the second quarter of 2018 and approximately $203 million of these unrealized gains in the first six months of 2018 relate to 3.2 million shares of ICU Medical stock that were received as part of the consideration for the sale of HIS net assets to ICU Medical. Prior to the adoption of the new standard, net unrealized gains and losses on virtually all equity securities with readily determinable fair values were reported in Accumulated other comprehensive income. For additional information, see Note 1B and Note 7B.

Basis of Presentation and Sig34

Basis of Presentation and Significant Accounting Policies - Impact of Adoption of Pension and Postretirement Benefit Costs Accounting Standard (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cost of sales	[1],[2]	$ 2,916	$ 2,660	$ 5,479	$ 5,128
Selling, informational and administrative expenses	[1],[2]	3,542	3,430	6,954	6,745
Research and development expenses	[1],[2]	1,797	1,787	3,540	3,502
Restructuring charges and certain acquisition-related costs	[1]	44	70	87	153
Other (income)/deductions––net	[1]	(551)	(75)	(728)	(14)
Income from continuing operations before provision for taxes on income	[1],[3]	$ 4,527	3,815	$ 8,654	7,767
As Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cost of sales			2,663		5,134
Selling, informational and administrative expenses			3,425		6,733
Research and development expenses			1,780		3,487
Restructuring charges and certain acquisition-related costs			70		228
Other (income)/deductions––net			(66)		(68)
Income from continuing operations before provision for taxes on income			3,815		7,767
Effect of Change Higher/(Lower) [Member] | Accounting Standards Update 2017-07 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cost of sales			(3)		(6)
Selling, informational and administrative expenses			5		12
Research and development expenses			7		15
Restructuring charges and certain acquisition-related costs			(1)		(74)
Other (income)/deductions––net			(8)		53
Income from continuing operations before provision for taxes on income			$ 0		$ 0
[1]	Amounts may not add due to rounding.
[2]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
[3]	Income from continuing operations before provision for taxes on income. IH’s earnings include dividend income of $76 million and $114 million in the second quarter of 2018 and 2017, respectively, and $135 million and $157 million in the first six months of 2018 and 2017, respectively, from our investment in ViiV. For additional information, see Note 4.

Basis of Presentation and Sig35

Basis of Presentation and Significant Accounting Policies - Impact of Adoption of Accounting Standards on Consolidated Balance Sheet (Details) - USD ($) $ in Millions	Jul. 01, 2018	[1]	Jan. 01, 2018	Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Trade accounts receivable	$ 9,873		$ 8,234	$ 8,221	[1]
Inventories	8,074	[2]	7,567	7,578	[1],[2]
Current tax assets	3,582		3,036	3,050	[1]
Noncurrent deferred tax assets and other noncurrent tax assets	1,848		1,838	1,855	[1]
Other noncurrent assets	2,896		3,023	3,227	[1]
Other current liabilities	10,125		10,992	11,115	[1]
Noncurrent deferred tax liabilities	5,743		3,988	3,900	[1]
Other noncurrent liabilities	5,947		5,690	6,149	[1]
Retained earnings	89,860		86,466	85,291	[1]
Accumulated other comprehensive loss	$ (10,003)		$ (10,235)	(9,321)	[1]
As Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Trade accounts receivable				8,221
Inventories				7,578
Current tax assets				3,050
Noncurrent deferred tax assets and other noncurrent tax assets				1,855
Other noncurrent assets				3,227
Other current liabilities				11,115
Noncurrent deferred tax liabilities				3,900
Other noncurrent liabilities				6,149
Retained earnings				85,291
Accumulated other comprehensive loss				(9,321)
Revenues [Member] | Effect of Change Higher/(Lower) [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Trade accounts receivable				13
Inventories				(11)
Current tax assets				(11)
Noncurrent deferred tax assets and other noncurrent tax assets				(17)
Other noncurrent assets				0
Other current liabilities				(123)
Noncurrent deferred tax liabilities				106
Other noncurrent liabilities				(459)
Retained earnings				450
Accumulated other comprehensive loss				0
Financial Assets and Liabilities [Member] | Effect of Change Higher/(Lower) [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Trade accounts receivable				0
Inventories				0
Current tax assets				0
Noncurrent deferred tax assets and other noncurrent tax assets				0
Other noncurrent assets				0
Other current liabilities				0
Noncurrent deferred tax liabilities				0
Other noncurrent liabilities				0
Retained earnings				419
Accumulated other comprehensive loss				(419)
Income Tax Accounting [Member] | Effect of Change Higher/(Lower) [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Trade accounts receivable				0
Inventories				0
Current tax assets				(3)
Noncurrent deferred tax assets and other noncurrent tax assets				0
Other noncurrent assets				(204)
Other current liabilities				0
Noncurrent deferred tax liabilities				(18)
Other noncurrent liabilities				0
Retained earnings				(189)
Accumulated other comprehensive loss				0
Reclassification of Certain Tax Effects from AOCI [Member] | Effect of Change Higher/(Lower) [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Trade accounts receivable				0
Inventories				0
Current tax assets				0
Noncurrent deferred tax assets and other noncurrent tax assets				0
Other noncurrent assets				0
Other current liabilities				0
Noncurrent deferred tax liabilities				0
Other noncurrent liabilities				0
Retained earnings				495
Accumulated other comprehensive loss				$ (495)
[1]	Amounts may not add due to rounding.
[2]	The change from December 31, 2017 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery, network strategy and new product launches, partially offset by a decrease due to foreign exchange.

Basis of Presentation and Sig36

Basis of Presentation and Significant Accounting Policies - Impact of Adoption of Accounting Standards Related to Classification of Certain Transactions in the Statement of Cash Flows (Details) - USD ($) $ in Millions		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017
Operating Activities
Other adjustments, net	[1]	$ (523)	$ (458)
Other changes in assets and liabilities, net of acquisitions and divestitures	[1]	(3,250)	(3,844)
Investing Activities
Proceeds from redemptions/sales of short-term investments	[1]	10,497	3,517
Proceeds from redemptions/sales of long-term investments	[1]	1,361	1,538
Financing Activities
Principal payments on short-term borrowings	[1]	(2,921)	(5,088)
Net proceeds from short-term borrowings with original maturities of three months or less	[1]	2,092	265
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents	[1]	1,381	(5)
Cash and cash equivalents and restricted cash and cash equivalents, beginning	[1]	1,431	2,666
Cash and cash equivalents and restricted cash and cash equivalents, end	[1]	2,811	2,661
As Previously Reported [Member]
Operating Activities
Other adjustments, net			(433)
Other changes in assets and liabilities, net of acquisitions and divestitures			(3,853)
Investing Activities
Proceeds from redemptions/sales of short-term investments			3,520
Proceeds from redemptions/sales of long-term investments			1,539
Financing Activities
Principal payments on short-term borrowings			(5,110)
Net proceeds from short-term borrowings with original maturities of three months or less			261
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents			(10)
Cash and cash equivalents and restricted cash and cash equivalents, beginning			2,595
Cash and cash equivalents and restricted cash and cash equivalents, end			2,585
Cash Flow Classification [Member] | Effect of Change Higher/(Lower) [Member]
Operating Activities
Other adjustments, net			(26)
Financing Activities
Principal payments on short-term borrowings			22
Net proceeds from short-term borrowings with original maturities of three months or less			4
Restricted Cash [Member]
Financing Activities
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents		$ 19
Restricted Cash [Member] | Effect of Change Higher/(Lower) [Member]
Operating Activities
Other changes in assets and liabilities, net of acquisitions and divestitures			9
Investing Activities
Proceeds from redemptions/sales of short-term investments			(3)
Proceeds from redemptions/sales of long-term investments			(2)
Financing Activities
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents			5
Cash and cash equivalents and restricted cash and cash equivalents, beginning			70
Cash and cash equivalents and restricted cash and cash equivalents, end			$ 75
[1]	Amounts may not add due to rounding.

Basis of Presentation and Sig37

Basis of Presentation and Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions		Jul. 01, 2018	Dec. 31, 2017		Jul. 02, 2017	Dec. 31, 2016
Restricted Cash and Cash Equivalents Items [Line Items]
Cash and cash equivalents	[1]	$ 2,704	$ 1,342	[2]
Total cash and cash equivalents and restricted cash and cash equivalents shown in the condensed consolidated balance sheets	[2]	2,811	1,431		$ 2,661	$ 2,666
Short-term investments [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and cash equivalents		42	0
Long-term investments [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and cash equivalents		66	0
Other current assets [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and cash equivalents		0	14
Other noncurrent assets [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and cash equivalents		$ 0	$ 75
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.

Basis of Presentation and Sig38

Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details) - USD ($) $ in Millions	Jul. 01, 2018	Dec. 31, 2017
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates and other accruals	$ 5,396	$ 4,923
Trade accounts receivable, less allowance for doubtful accounts [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates and other accruals	1,252	1,352
Other current liabilities [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates	3,039	2,674
Other accruals	698	512
Other noncurrent liabilities [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates and other accruals	$ 406	$ 385

Acquisition, Divestitures, Li39

Acquisition, Divestitures, Licensing Arrangements, Collaborative Arrangements and Privately Held Investment - AstraZeneca (Details) - USD ($)		Dec. 22, 2016	Apr. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill	[1]				$ 55,836,000,000	$ 55,952,000,000
AstraZeneca [Member]
Business Acquisition [Line Items]
Initial payment		$ 552,000,000
Additional payment made for a purchase price adjustment				$ 3,000,000
Milestone payment			$ 125,000,000	$ 50,000,000
Deferred payment		175,000,000
Maximum amount of potential milestone payments		75,000,000
Maximum amount of potential sales-related payments		$ 600,000,000
Term of royalty payments		10 years
Consideration transferred in business acquisition		$ 1,040,000,000
Payments for acquisitions, cash portion		555,000,000
Contingent consideration assumed		485,000,000
Identifiable intangible assets		894,000,000
Other current assets		92,000,000
Goodwill		73,000,000
Deferred tax liabilities		19,000,000
In Process Research and Development [Member] | AstraZeneca [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		166,000,000
Developed Technology Rights [Member] | AstraZeneca [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		728,000,000
Minimum [Member] | AstraZeneca [Member]
Business Acquisition [Line Items]
Undiscounted royalty payments		250,000,000
Maximum [Member] | AstraZeneca [Member]
Business Acquisition [Line Items]
Undiscounted royalty payments		$ 430,000,000
[1]	Amounts may not add due to rounding.

Acquisition, Divestitures, Li40

Acquisition, Divestitures, Licensing Arrangements, Collaborative Arrangements and Privately Held Investment - Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH) (Details) - USD ($) shares in Millions, $ in Millions		Feb. 03, 2017	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018		Jul. 02, 2017		Jan. 05, 2017	Oct. 06, 2016
Business Acquisition [Line Items]
Gain (loss) on sale of HIS net assets	[1]		$ 2	$ (28)	$ (1)	[2]	$ (64)	[2]
HIS [Member] | Disposed of by Sale [Member] | ICU Medical [Member]
Business Acquisition [Line Items]
Consideration transferred									$ 900	$ 1,000
Number of shares received in disposition		3.2
Value of shares received from disposition		$ 428
Promissory note		75
Cash received from disposition							200
Contingent consideration		$ 225
Ownership percentage			16.00%		16.00%
Minimum share transfer restriction term		18 months
Gain (loss) on sale of HIS net assets			$ 2	$ (28)	$ (1)		$ (64)
Administrative service period		24 months
Maximum manufacturing service period		5 years
[1]	In the second quarter and first six months of 2018 and 2017, represents adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical on February 3, 2017. For additional information, see Note 2B.
[2]	Amounts may not add due to rounding.

Acquisition, Divestitures, Li41

Acquisition, Divestitures, Licensing Arrangements, Collaborative Arrangements and Privately Held Investment - Allogene (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	Apr. 30, 2018	Jul. 01, 2018	Jul. 01, 2018	Dec. 31, 2014
Allogene [Member]
Schedule of Equity Method Investments [Line Items]
Investment ownership percentage	25.00%
Non-cash pre-tax gain from the difference between the fair value of equity investment received and book value of assets transferred		$ 50	$ 50
Cellectis [Member]
Schedule of Equity Method Investments [Line Items]
Investment ownership percentage	7.00%
Upfront payment to Cellectis				$ 80

Acquisition, Divestitures, Li42

Acquisition, Divestitures, Licensing Arrangements, Collaborative Arrangements and Privately Held Investment - Biogen (Details) - Disposed of by Sale [Member] - Phase 2b Ready AMPA Receptor Potentiator For CIAS [Member] $ in Millions	1 Months Ended
	Apr. 30, 2018USD ($)
Indefinite-lived Intangible Assets [Line Items]
Proceeds from sale of Phase 2b Ready AMPA Receptor Potentiator for CIAS to Biogen	$ 75
Potential development and commercialization milestones	515
Other (Income)/Deductions, Net [Member]
Indefinite-lived Intangible Assets [Line Items]
Proceeds from sale of Phase 2b Ready AMPA Receptor Potentiator for CIAS to Biogen	$ 75

Acquisition, Divestitures, Li43

Acquisition, Divestitures, Licensing Arrangements, Collaborative Arrangements and Privately Held Investment - Licensing Arrangement (Details) - Shire [Member] - Licensing Arrangement [Member] - USD ($) $ in Millions	3 Months Ended	6 Months Ended	12 Months Ended
	Apr. 01, 2018	Jul. 01, 2018	Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum amount of possible development and sales-based milestone payments and potential future royalty payments			$ 460
Other (Income)/Deductions, Net [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from licensing arrangement	$ 75	$ (75)	$ 90

Acquisition, Divestitures, Li44

Acquisition, Divestitures, Licensing Arrangements, Collaborative Arrangements and Privately Held Investment - Collaboration Arrangement (Details) - USD ($) $ in Millions	Jan. 01, 2018	Apr. 01, 2018	Apr. 02, 2017	Jul. 01, 2018	Dec. 31, 2013	Dec. 31, 2017
Merck [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborator's revenue and expense ownership percentage				60.00%
Company's revenue and expense ownership percentage				40.00%
Eli Lilly & Company [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred milestone revenue recognized				$ 43
Other (Income)/Deductions, Net [Member] | Merck [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payments received			$ 90	40
Milestone payment receivable		$ 40				$ 60
Deferred milestone revenue recognized		90
Other Noncurrent Liabilities [Member] | Merck [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred milestone payment						$ 60
Other Noncurrent Liabilities [Member] | Eli Lilly & Company [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred milestone revenue recognized				14
Deferred Revenue [Member] | Eli Lilly & Company [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payments received					$ 200
Other Current Liabilities [Member] | Eli Lilly & Company [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred milestone revenue recognized				$ 29
Revenues [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cumulative effect adjustment to retained earnings, pre-tax	$ 584	584
Revenues [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Other (Income)/Deductions, Net [Member] | Merck [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred milestone revenue recognized		85
Revenues [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Other Noncurrent Liabilities [Member] | Merck [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred milestone payment		60
Revenues [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Deferred Revenue [Member] | Eli Lilly & Company [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred milestone revenue recognized		$ 107

Restructuring Charges and Oth45

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended		36 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017	Sep. 03, 2018
Restructuring Cost and Reserve [Line Items]
Integration costs	[1]	$ 68	$ 86	$ 120	$ 163
Enterprise-wide Cost Reduction/Productivity Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred				152
Expected restructuring cost		1,200		$ 1,200
Percentage of expected costs to be non-cash				20.00%
Manufacturing Plant Network Optimization [Member] | Enterprise-wide Cost Reduction/Productivity Plan [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost		800		$ 800
Restructuring costs incurred		283		283
Centralization of Corporate and Platform Functions [Member] | Enterprise-wide Cost Reduction/Productivity Plan [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost		400		400
Restructuring costs incurred		$ 217		217
Business Integration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred				$ 29
Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Expected integration related costs, period				3 years
Hospira [Member] | Return of Acquired Rights [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred				$ 215
Hospira [Member] | Business Integration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred				$ 81
Forecast [Member] | Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Integration costs						$ 1,000
[1]	Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the second quarter and first six months of 2018, integration costs were primarily related to our acquisition of Hospira. In the second quarter and first six months of 2017, integration costs were primarily related to our acquisitions of Hospira and Medivation, including a net gain of $12 million related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see Note 10).

Restructuring Charges and Oth46

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Restructuring charges:
Employee terminations		$ (21)	$ (27)	$ (29)	$ (57)
Asset impairments		(6)	0	(4)	24
Exit costs		3	4	0	6
Restructuring credits	[1]	(24)	(23)	(33)	(27)
Transaction costs	[2]	0	6	0	18
Integration costs	[3]	68	86	120	163
Restructuring charges and certain acquisition-related costs	[4]	44	70	87	153
Additional depreciation––asset restructuring recorded in Cost of sales:	[5]	13	21	31	35
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[6]	44	62	82	93
Total costs associated with acquisitions and cost-reduction/productivity initiatives		131	153	262	356
Other (Income)/Deductions, Net [Member]
Restructuring charges:
Net periodic pension and postretirement benefit costs recorded in Other (income)/deductions––net	[7]	29	1	61	74
Cost of Sales [Member]
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[6]	20	36	36	51
Selling, Informational and Administrative Expenses [Member]
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[6]	16	15	34	24
Research and Development Expense [Member]
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[6]	$ 7	$ 11	$ 13	$ 17
[1]	In the three and six months ended July 1, 2018, restructuring credits are associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as acquisition-related costs, primarily associated with Hospira. In the three and six months ended July 2, 2017, restructuring credits are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, partially offset by charges related to our acquisition of mainly Anacor in the second quarter of 2017, and mainly Anacor and Medivation in the first six months of 2017. In the three and six months ended July 1, 2018, Employee terminations primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, many of which may be paid out during periods after termination.The restructuring activities for 2018 are associated with the following:•For the second quarter of 2018, IH ($12 million income); EH ($2 million); manufacturing operations ($13 million); and Corporate ($26 million income).•For the first six months of 2018, IH ($12 million income); EH ($12 million income); WRD/GPD ($2 million income); manufacturing operations ($15 million); and Corporate ($22 million income).The restructuring activities for 2017 are associated with the following:•For the second quarter of 2017, IH ($8 million income); EH ($7 million); WRD/GPD ($14 million income); manufacturing operations ($8 million income); and Corporate ($1 million).•For the first six months of 2017, IH ($1 million income); EH ($11 million income); WRD/GPD ($26 million income); manufacturing operations ($9 million); and Corporate ($3 million).
[2]	Transaction costs represent external costs for banking, legal, accounting and other similar services, virtually all of which for the second quarter and first six months of 2017 were directly related to our acquisition of Medivation.
[3]	Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the second quarter and first six months of 2018, integration costs were primarily related to our acquisition of Hospira. In the second quarter and first six months of 2017, integration costs were primarily related to our acquisitions of Hospira and Medivation, including a net gain of $12 million related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see Note 10).
[4]	Amounts may not add due to rounding.
[5]	Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[6]	Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
[7]	In the three and six months ended July 1, 2018, primarily represents the net pension curtailments and settlements included in Other (income)/deductions––net upon the adoption of a new accounting standard in the first quarter of 2018. In the three and six months ended July 2, 2017, primarily represents the net pension curtailments and settlements, partially offset by net periodic benefit credits, excluding service costs, related to our acquisition of Hospira, both of which were reclassified to Other (income)/deductions––net as a result of the retrospective adoption of a new accounting standard in the first quarter of 2018. These credits included a net settlement gain, partially offset by accelerated amortization of actuarial losses and prior service costs upon the settlement of the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. For additional information, see Note 1B and Note 10.

Restructuring Charges and Oth47

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring charges (income)	[1]	$ (24)	$ (23)	$ (33)	$ (27)
Corporate [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (income)		(26)	1	(22)	3
IH [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (income)		(12)	(8)	(12)	(1)
EH [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (income)		2	7	(12)	(11)
WRD & GPD [Member] | Segment Reconciling Items [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (income)			(14)	(2)	(26)
Manufacturing operations [Member] | Segment Reconciling Items [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (income)		13	(8)	15	9
Pension Plan [Member] | U.S. [Member] | Qualified Plan [Member]
Restructuring Cost and Reserve [Line Items]
Gain related to settlement of Hospira U.S. qualified defined benefit pension plan	[2],[3]	$ (25)	7	$ (45)	(24)
Pension Plan [Member] | U.S. [Member] | Hospira [Member] | Qualified Plan [Member]
Restructuring Cost and Reserve [Line Items]
Gain related to settlement of Hospira U.S. qualified defined benefit pension plan			$ 12		$ 12
[1]	In the three and six months ended July 1, 2018, restructuring credits are associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as acquisition-related costs, primarily associated with Hospira. In the three and six months ended July 2, 2017, restructuring credits are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, partially offset by charges related to our acquisition of mainly Anacor in the second quarter of 2017, and mainly Anacor and Medivation in the first six months of 2017. In the three and six months ended July 1, 2018, Employee terminations primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, many of which may be paid out during periods after termination.The restructuring activities for 2018 are associated with the following:•For the second quarter of 2018, IH ($12 million income); EH ($2 million); manufacturing operations ($13 million); and Corporate ($26 million income).•For the first six months of 2018, IH ($12 million income); EH ($12 million income); WRD/GPD ($2 million income); manufacturing operations ($15 million); and Corporate ($22 million income).The restructuring activities for 2017 are associated with the following:•For the second quarter of 2017, IH ($8 million income); EH ($7 million); WRD/GPD ($14 million income); manufacturing operations ($8 million income); and Corporate ($1 million).•For the first six months of 2017, IH ($1 million income); EH ($11 million income); WRD/GPD ($26 million income); manufacturing operations ($9 million); and Corporate ($3 million).
[2]	(a) In the second quarter of 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the $156 million net pension benefit obligation and recorded a pre-tax settlement gain of $41 million, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately $30 million in Other (income)/deductions––net (see Note 3).
[3]	We adopted a new accounting standard on January 1, 2018 that requires the net periodic pension and postretirement benefit costs other than service costs be presented in Other (income)/deductions––net on the condensed consolidated statements of income. For additional information, see Note 1B and Note 4.

Restructuring Charges and Oth48

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Restructuring Reserve [Roll Forward]
Balance, December 31, 2017	[1]			$ 1,105
Credits	[2]	$ (24)	$ (23)	(33)	$ (27)
Utilization and other	[3]			(195)
Balance, July 1, 2018	[4]	877		877
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2017	[1]			1,039
Credits				(29)
Utilization and other	[3]			(171)
Balance, July 1, 2018	[4]	839		839
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2017	[1]			0
Credits				(4)
Utilization and other	[3]			4
Balance, July 1, 2018	[4]	0		0
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2017	[1]			66
Credits				0
Utilization and other	[3]			(28)
Balance, July 1, 2018	[4]	$ 38		$ 38
[1]	Included in Other current liabilities ($643 million) and Other noncurrent liabilities ($462 million).
[2]	In the three and six months ended July 1, 2018, restructuring credits are associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as acquisition-related costs, primarily associated with Hospira. In the three and six months ended July 2, 2017, restructuring credits are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, partially offset by charges related to our acquisition of mainly Anacor in the second quarter of 2017, and mainly Anacor and Medivation in the first six months of 2017. In the three and six months ended July 1, 2018, Employee terminations primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, many of which may be paid out during periods after termination.The restructuring activities for 2018 are associated with the following:•For the second quarter of 2018, IH ($12 million income); EH ($2 million); manufacturing operations ($13 million); and Corporate ($26 million income).•For the first six months of 2018, IH ($12 million income); EH ($12 million income); WRD/GPD ($2 million income); manufacturing operations ($15 million); and Corporate ($22 million income).The restructuring activities for 2017 are associated with the following:•For the second quarter of 2017, IH ($8 million income); EH ($7 million); WRD/GPD ($14 million income); manufacturing operations ($8 million income); and Corporate ($1 million).•For the first six months of 2017, IH ($1 million income); EH ($11 million income); WRD/GPD ($26 million income); manufacturing operations ($9 million); and Corporate ($3 million).
[3]	Includes adjustments for foreign currency translation.
[4]	Included in Other current liabilities ($460 million) and Other noncurrent liabilities ($418 million).

Restructuring Charges and Oth49

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail) - USD ($) $ in Millions	Jul. 01, 2018		Dec. 31, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 877	[1]	$ 1,105	[2]
Other Current Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	460		643
Other Noncurrent Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 418		$ 462
[1]	Included in Other current liabilities ($460 million) and Other noncurrent liabilities ($418 million).
[2]	Included in Other current liabilities ($643 million) and Other noncurrent liabilities ($462 million).

Other (Income)_Deductions - N50

Other (Income)/Deductions - Net (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018		Jul. 02, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest income	[1]	$ (80)	$ (94)	$ (157)		$ (175)
Interest expense	[1]	326	312	635		621
Net interest expense		245	218	478		446
Royalty-related income		(121)	(105)	(217)		(191)
Net gains on asset disposals	[2]	(17)	(34)	(36)		(125)
Income from collaborations, out-licensing arrangements and sales of compound/product rights	[3]	(174)	(37)	(316)		(85)
Net unrealized gains on equity securities		(213)		(299)
Net periodic benefit costs/(credits) other than service costs	[4]	(84)	(8)	(166)		53
Certain legal matters, net	[5]	(88)	3	(107)		11
Certain asset impairments	[6]	31	0	31		13
Adjustments to loss on sale of HIS net assets	[7]	(2)	28	1	[8]	64	[8]
Business and legal entity alignment costs	[9]	1	17	4		38
Other, net	[10]	(115)	(155)	(64)		(239)
Other (income)/deductions––net	[11]	(551)	(75)	(728)		(14)
Financial Assets and Liabilities [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net unrealized gains on equity securities	[12]	$ (226)	$ 0	$ (337)		$ 0
[1]	Interest income decreased in the second quarter and first six months of 2018, primarily driven by a lower investment balance. Interest expense increased in the second quarter and first six months of 2018, primarily as a result of higher short-term interest rates, offset, in part, by refinancing activity that occurred in the fourth quarter of 2017.
[2]	In the second quarter of 2018, primarily includes gains on fixed assets and other asset disposals of $15 million. In the first six months of 2018, includes gains on fixed assets and other asset disposals of $22 million and net gains on sales of investments in equity and debt securities of approximately $14 million. In the second quarter of 2017, primarily includes gains on sales and redemptions of investments in equity and debt securities (approximately $60 million), partially offset by a net loss related to the sale of our 40% ownership investment in Teuto, including the extinguishment of a put option for the then remaining 60% ownership interest (approximately $30 million). In the first six months of 2017, primarily includes gains on sales and redemptions of investments in equity and debt securities (approximately $102 million) and a gain on sale of property (approximately $50 million), partially offset by the net loss related to the sale of our investment in Teuto discussed above.
[3]	Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the second quarter of 2018, primarily includes, among other things, approximately $88 million in milestone income from multiple licensees and an upfront payment to us of $75 million for the sale of an AMPA receptor potentiator for CIAS to Biogen. In the first six months of 2018, primarily includes, among other things, all of the factors discussed above for the second quarter of 2018, as well as a $75 million milestone payment received from Shire related to their first dosing of a patient in a Phase 3 clinical trial of a compound out-licensed by Pfizer to Shire for the treatment of ulcerative colitis, and a $40 million milestone payment from Merck in conjunction with the approval of ertugliflozin in the EU. For additional information, see Note 2B, Note 2C and Note 2D.
[4]	Represents the net periodic benefit costs/(credits), excluding service costs, as a result of the adoption of a new accounting standard in the first quarter of 2018. Effective January 1, 2018, the U.S. Pfizer Consolidated Pension Plan was frozen to future benefit accruals and for the second quarter and first six months of 2018, resulted in the recognition of lower net periodic benefit costs due to the extension of the amortization period for the actuarial losses and the elimination of service costs. There was also a greater than expected gain on plan assets due to a higher plan asset base compared to the second quarter and first six months of 2017. For additional information, see Note 1B and Note 10.
[5]	In the second quarter and first six months of 2018, primarily represents the reversal of a legal accrual where a loss was no longer deemed probable.
[6]	In the second quarter and first six months of 2018, includes an intangible asset impairment charge related to a finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the U.S. market only. The impairment charge for the second quarter and first six months of 2018 is associated with IH and reflects, among other things, updated commercial forecasts.
[7]	In the second quarter and first six months of 2018 and 2017, represents adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical on February 3, 2017. For additional information, see Note 2B.
[8]	Amounts may not add due to rounding.
[9]	In the second quarter and first six months of 2018 and 2017, represents expenses for changes to our infrastructure to align our commercial operations of our current segments, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.
[10]	In the second quarter and first six months of 2018, includes, among other things, dividend income of $76 million and $135 million, respectively, from our investment in ViiV, and charges of $23 million and $135 million, respectively, reflecting the change in the fair value of contingent consideration. The second quarter and first six months of 2018 also include a non-cash $50 million pre-tax gain on the contribution of Pfizer’s allogeneic CAR T therapy development program assets obtained from Cellectis and Servier in connection with our contribution agreement entered into with Allogene in which Pfizer obtained a 25% ownership stake in Allogene (see Note 2B), and a non-cash $17 million pre-tax gain on the cash settlement of a liability that we incurred in April 2018 upon the EU approval of Mylotarg (see Note 7E). In the second quarter and first six months of 2017, primarily includes, among other things, dividend income of $114 million and $157 million, respectively, from our investment in ViiV.
[11]	Amounts may not add due to rounding.
[12]	Represents the unrealized net gains on equity securities reflecting the adoption of a new accounting standard in the first quarter of 2018. Approximately $142 million of these unrealized gains in the second quarter of 2018 and approximately $203 million of these unrealized gains in the first six months of 2018 relate to 3.2 million shares of ICU Medical stock that were received as part of the consideration for the sale of HIS net assets to ICU Medical. Prior to the adoption of the new standard, net unrealized gains and losses on virtually all equity securities with readily determinable fair values were reported in Accumulated other comprehensive income. For additional information, see Note 1B and Note 7B.

Other (Income)_Deductions - N51

Other (Income)/Deductions - Net - Footnotes (Detail) - USD ($) shares in Millions, $ in Millions	1 Months Ended	3 Months Ended				6 Months Ended		12 Months Ended
	Apr. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Jul. 02, 2017	Apr. 02, 2017	Jul. 01, 2018	Jul. 02, 2017	Dec. 31, 2016	Feb. 03, 2017	Jan. 05, 2017	Oct. 06, 2016
Loss Contingencies [Line Items]
Gain on fixed assets and other asset disposals		$ 15				$ 22
Gain on sale of investments in debt and equity securities				$ 60		14	$ 102
Gain on sale of property							$ 50
Net unrealized gains on equity securities		213				299
Laboratorio Teuto Brasilero [Member]
Loss Contingencies [Line Items]
Equity method investment, ownership percentage				40.00%			40.00%
Loss on disposal of equity method investment				$ 30
Allogene [Member]
Loss Contingencies [Line Items]
Non-cash pre-tax gain from the difference between the fair value of equity investment received and book value of assets transferred		50				50
Investment ownership percentage	25.00%
ViiV Healthcare Limited [Member]
Loss Contingencies [Line Items]
Change in fair value of contingent consideration		23				135
Operating Segments [Member] | IH [Member] | ViiV Healthcare Limited [Member]
Loss Contingencies [Line Items]
Dividend income		76		$ 114		135	$ 157
Other (Income)/Deductions, Net [Member] | Licensing Arrangement [Member]
Loss Contingencies [Line Items]
Milestone payment received		$ 88
Other (Income)/Deductions, Net [Member] | Shire [Member] | Licensing Arrangement [Member]
Loss Contingencies [Line Items]
Proceeds from licensing arrangement			$ 75			(75)		$ 90
Other (Income)/Deductions, Net [Member] | Merck [Member] | Collaborative Arrangement [Member]
Loss Contingencies [Line Items]
Milestone payment received					$ 90	$ 40
Disposed of by Sale [Member] | Phase 2b Ready AMPA Receptor Potentiator For CIAS [Member]
Loss Contingencies [Line Items]
Proceeds from sale of Phase 2b Ready AMPA Receptor Potentiator for CIAS to Biogen	$ 75
Disposed of by Sale [Member] | Phase 2b Ready AMPA Receptor Potentiator For CIAS [Member] | Other (Income)/Deductions, Net [Member]
Loss Contingencies [Line Items]
Proceeds from sale of Phase 2b Ready AMPA Receptor Potentiator for CIAS to Biogen	$ 75
Disposed of by Sale [Member] | HIS [Member] | ICU Medical [Member]
Loss Contingencies [Line Items]
Ownership percentage		16.00%				16.00%
Proceeds from sale of Phase 2b Ready AMPA Receptor Potentiator for CIAS to Biogen										$ 900	$ 1,000
Net unrealized gains on equity securities		$ 142				$ 203
Number of shares received in disposition									3.2
Laboratorio Teuto Brasilero [Member] | Laboratorio Teuto Brasilero [Member]
Loss Contingencies [Line Items]
Ownership percentage				60.00%			60.00%
Developed Technology Rights [Member] | EU [Member] | Mylotarg [Member]
Loss Contingencies [Line Items]
Non-cash gain from buyout transaction		$ 17				$ 17

Other (Income)_Deductions - N52

Other (Income)/Deductions - Net - Intangible Assets (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Finite-Lived Intangible Assets [Line Items]
Impairment	[1]	$ 31	$ 0	$ 31	$ 13
Developed Technology Right [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets at fair value	[2],[3]	35		35
Impairment	[2]	31		31
Level 1 [Member] | Developed Technology Right [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets at fair value	[2],[3]	0		0
Level 2 [Member] | Developed Technology Right [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets at fair value	[2],[3]	0		0
Level 3 [Member] | Developed Technology Right [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets at fair value	[2],[3]	$ 35		$ 35
[1]	In the second quarter and first six months of 2018, includes an intangible asset impairment charge related to a finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the U.S. market only. The impairment charge for the second quarter and first six months of 2018 is associated with IH and reflects, among other things, updated commercial forecasts.
[2]	Reflects intangible assets written down to fair value in the second quarter and first six months of 2018. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
[3]	The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis.

Tax Matters - Narrative (Detail

Tax Matters - Narrative (Detail) - USD ($) $ in Billions	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Repatriation tax liability					$ 15.2
Provisional deferred tax liability					$ 1
Effective tax rate for income from continuing operations	14.30%	19.40%	13.90%	20.10%

Tax Matters (Detail)

Tax Matters (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Foreign currency translation adjustments, net	[1]	$ 101	$ (109)	$ 67	$ (130)
Unrealized holding gains/(losses) on derivative financial instruments, net		8	(1)	4	2
Reclassification adjustments for (gains)/losses included in net income		72	(88)	65	(140)
Derivatives qualifying as hedges, tax, total		79	(89)	70	(138)
Unrealized holding gains/(losses) on available-for-sale securities, net		(48)	18	(28)	55
Reclassification adjustments for (gains)/losses included in net income		20	(7)	(2)	4
Reclassification adjustments for tax on unrealized gains from AOCI to Retained earnings	[2]			(45)	0
Available-for-sale securities, tax, total		(29)	11	(76)	59
Benefit plans: actuarial gains/(losses), net		(13)	22	25	22
Reclassification adjustments related to amortization		14	43	28	92
Reclassification adjustments related to settlements, net		7	(4)	15	8
Other		27	(17)	6	(13)
Defined benefit plans, actuarial gain (loss), tax, total		34	43	712	110
Benefit plans: prior service costs and other, net		0	0	0	0
Reclassification adjustments related to amortization		(11)	(17)	(22)	(33)
Reclassification adjustments related to curtailments, net		4	(1)	(3)	(4)
Other		(6)	0	0	0
Pension and other postretirement benefit plans, net prior service cost (credit), tax		(13)	(19)	(168)	(38)
Tax provision/(benefit) on other comprehensive income/(loss)	[3]	173	(163)	605	(138)
ASU 2018-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reclassification adjustments of certain tax effects from AOCI to Retained earnings	[4]	0	0	1	0
Reclassification adjustments of certain tax effects from AOCI to Retained earnings	[4]	0	0	637	0
Reclassification adjustments of certain tax effects from AOCI to Retained earnings	[4]	0	0	$ (144)	$ 0
ASU 2016-01 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reclassification adjustments for tax on unrealized gains from AOCI to Retained earnings	[2]	$ 0	$ 0
[1]	Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.
[2]	For additional information on the adoption of a new accounting standard related to financial assets and liabilities, see Note 1B.
[3]	Amounts may not add due to rounding.
[4]	For additional information on the adoption of a new accounting standard related to reclassification of certain tax effects from AOCI, see Note 1B.

Accumulated Other Comprehensi55

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail) - USD ($) $ in Millions		6 Months Ended
		Jul. 01, 2018	Dec. 31, 2017
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2017	[1]	$ 71,308
Balance, July 1, 2018	[1]	69,778
Foreign currency translation adjustments attributable to noncontrolling interests		11
Accumulated Other Comprehensive Income (Loss) [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2017		(9,321)
Other comprehensive income/(loss) due to the adoption of new accounting standards	[2]		$ (913)
Other comprehensive income/(loss)	[3]	231
Balance, July 1, 2018		(10,003)
Foreign Currency Translation Adjustment [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2017		(5,180)
Other comprehensive income/(loss)	[3]	(15)
Balance, July 1, 2018		(5,198)
Derivative Financial Instruments [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2017		(30)
Other comprehensive income/(loss)	[3]	298
Balance, July 1, 2018		267
Cash flow hedge gain to be reclassified within twelve months		213
Available-For-Sale Securities [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2017		401
Other comprehensive income/(loss)	[3]	(215)
Balance, July 1, 2018		(230)
Actuarial Gains/(Losses) [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2017		(5,262)
Other comprehensive income/(loss)	[3]	241
Balance, July 1, 2018		(5,657)
Prior Service (Costs)/Credits and Other [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2017		750
Other comprehensive income/(loss)	[3]	(80)
Balance, July 1, 2018		$ 814
ASU 2018-02 [Member] | Derivative Financial Instruments [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Other comprehensive income/(loss) due to the adoption of new accounting standards	[2]		(1)
ASU 2018-02 [Member] | Actuarial Gains/(Losses) [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Other comprehensive income/(loss) due to the adoption of new accounting standards	[2]		(637)
ASU 2018-02 [Member] | Prior Service (Costs)/Credits and Other [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Other comprehensive income/(loss) due to the adoption of new accounting standards	[2]		144
ASU 2016-01 [Member] | Foreign Currency Translation Adjustment [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Other comprehensive income/(loss) due to the adoption of new accounting standards	[2]		(2)
ASU 2016-01 [Member] | Available-For-Sale Securities [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Other comprehensive income/(loss) due to the adoption of new accounting standards	[2]		$ (416)
[1]	Amounts may not add due to rounding.
[2]	Amounts represent the cumulative effect adjustments as of January 1, 2018 from the adoption of new accounting standards related to (i) financial assets and liabilities and (ii) the reclassification of certain tax effects from AOCI. For additional information, see Note 1B.
[3]	Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $11 million loss for the first six months of 2018.

Financial Instruments - Financi

Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Millions		Jul. 01, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		$ 1,332	$ 2,150
Total assets	[1]	164,980	171,797
Total liabilities		1,038	691
Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		16,440	24,937
Total liabilities		1,038	691
Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		1,332	2,150
Available-for-sale debt securities		8,220	15,362
Total short-term investments		9,553	17,512
Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		451	337
Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		98	104
Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		353	234
Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	[2]	1,737	1,440
Available-for-sale debt securities		4,160	5,090
Trading securities, debt		50	73
Trading funds and securities		1,787	1,514
Total long-term investments		5,947	6,603
Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		489	484
Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		290	477
Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		200	7
Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		126	201
Other Current Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		11	1
Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		115	201
Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		912	490
Other Noncurrent Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		499	177
Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		413	313
Level 1 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		1,773	1,523
Total liabilities		0	0
Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		19	16
Available-for-sale debt securities		0	0
Total short-term investments		19	16
Level 1 [Member] | Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Level 1 [Member] | Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Level 1 [Member] | Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	[2]	1,704	1,398
Available-for-sale debt securities		0	36
Trading securities, debt		50	73
Trading funds and securities		1,754	1,472
Total long-term investments		1,754	1,507
Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	0
Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	0
Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	0
Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Level 2 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		14,668	23,414
Total liabilities		1,038	691
Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		1,314	2,134
Available-for-sale debt securities		8,220	15,362
Total short-term investments		9,534	17,496
Level 2 [Member] | Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		451	337
Level 2 [Member] | Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		98	104
Level 2 [Member] | Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		353	234
Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	[2]	33	42
Available-for-sale debt securities		4,160	5,054
Trading securities, debt		0	0
Trading funds and securities		33	42
Total long-term investments		4,193	5,096
Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		489	484
Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		290	477
Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		200	7
Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		126	201
Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		11	1
Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		115	201
Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		912	490
Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		499	177
Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		413	313
Money market funds [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		1,302	2,115
Money market funds [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		0	0
Money market funds [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		1,302	2,115
Equity [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	[2]	30	35
Equity [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	[2]	19	16
Equity [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	[2]	12	19
Government and agency - non U.S. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		5,669	12,629
Government and agency - non U.S. [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		5,527	12,242
Government and agency - non U.S. [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		141	387
Government and agency - non U.S. [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Government and agency - non U.S. [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Government and agency - non U.S. [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		5,527	12,242
Government and agency - non U.S. [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		141	387
Corporate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	[3]	6,238	6,938
Corporate [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		2,659	2,766
Corporate [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		3,579	4,172
Corporate [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Corporate [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	36
Corporate [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		2,659	2,766
Corporate [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		3,579	4,136
Government - U.S. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		433	747
Government - U.S. [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		8	252
Government - U.S. [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		425	495
Government - U.S. [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Government - U.S. [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Government - U.S. [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		8	252
Government - U.S. [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		425	495
Agency asset-backed - U.S. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		19	24
Agency asset-backed - U.S. [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		19	23
Agency asset-backed - U.S. [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Agency asset-backed - U.S. [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		19	23
Other asset-backed [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	[4]	22	114
Other asset-backed [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		7	79
Other asset-backed [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		14	35
Other asset-backed [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Other asset-backed [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Other asset-backed [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		7	79
Other asset-backed [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		$ 14	$ 35
[1]	Amounts may not add due to rounding.
[2]	As of July 1, 2018, short-term equity securities of $11 million and long-term equity securities of $32 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. As of December 31, 2017, short-term equity securities of $19 million and long-term equity securities of $42 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.
[3]	Issued by a diverse group of corporations.
[4]	Includes loan-backed, mortgage-backed and receivable-backed securities, all of which are in senior positions in the capital structure of the security. Loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages. Receivable-backed securities are collateralized by credit cards receivables.

Financial Instruments - Finan57

Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Detail) - Recurring [Member] - USD ($) $ in Millions	Jul. 01, 2018	Dec. 31, 2017
Footnotes to selected financial assets and liabilities:
Short-term equity securities held in trust	$ 11	$ 19
Long-term equity securities held in trust	$ 32	$ 42

Financial Instruments - Finan58

Financial Instruments - Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Millions	Jul. 01, 2018	Dec. 31, 2017
Carrying Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, excluding the current portion	$ 28,935	$ 33,538
Estimated Fair Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, excluding the current portion	30,011	37,253
Estimated Fair Value [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, excluding the current portion	$ 30,011	$ 37,253

Financial Instruments - Total S

Financial Instruments - Total Short-Term and Long-Term Investments (Details) - USD ($) $ in Millions		Jul. 01, 2018	Dec. 31, 2017
Financial Instruments [Abstract]
Equity securities		$ 1,332	$ 2,150
Available-for-sale debt securities		8,220	15,362
Held-to-maturity debt securities		1,174	1,138
Total Short-term investments	[1]	10,727	18,650
Equity securities		1,787	1,514
Available-for-sale debt securities		4,160	5,090
Held-to-maturity debt securities		70	4
Private equity investments carried at equity-method or cost		578	408
Total Long-term investments	[1]	6,595	7,015
Held-to-maturity cash equivalents		$ 808	$ 719
[1]	Amounts may not add due to rounding.

Financial Instruments - Investm

Financial Instruments - Investments (Details) - USD ($) $ in Millions		Jul. 01, 2018	Dec. 31, 2017
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Debt securities, amortized cost		$ 14,705	$ 22,337
Debt securities, gross unrealized gains		7	77
Debt securities, gross unrealized losses		(280)	(100)
Available-for-sale securities and held-to-maturity securities		14,432	22,313
Debt securities maturities, within 1 year, fair value		10,202
Debt securities maturities, over 1 to 5 years, fair value		3,192
Debt securities maturities, over 5 years, fair value		1,038
Available-for-sale Equity Securities [Abstract]
Available-for-sale equity securities, amortized cost	[1]		2,843
Available-for-sale equity securities, gross unrealized gain	[1]		586
Available-for-sale equity securities, gross unrealized losses	[1]		(124)
Available-for-sale securities, equity securities	[1]		3,304
Government and agency - non U.S. [Member]
Available-for-sale Debt Securities, Amortized Cost Basis [Abstract] (Deprecated 2018-01-31)
Available-for-sale debt securities, amortized cost		5,797	12,616
Available-for-sale debt securities, gross unrealized gains		5	61
Available-for-sale debt securities, gross unrealized losses		(133)	(48)
Available-for-sale debt securities, fair value		5,669	12,629
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value		5,527
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value		141
Available-for-sale securities, debt maturities, over 5 years, fair value		0
Available-for-sale debt securities, fair value		5,669	12,629
Debt Securities, Held-to-maturity, Maturity [Abstract]
Held-to-maturity securities, debt maturities, total		570	770
Held-to-maturity securities, gross unrealized gains		0	0
Held-to-maturity securities, gross unrealized losses		0	0
Held-to-maturity securities, fair value		570	770
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Held-to-maturity securities, debt maturities, within 1 year, fair value		570
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value		0
Held-to-maturity securities, debt maturities, over 5 years, fair value		0
Held-to-maturity securities, debt maturities, total		570	770
Corporate [Member]
Available-for-sale Debt Securities, Amortized Cost Basis [Abstract] (Deprecated 2018-01-31)
Available-for-sale debt securities, amortized cost	[2]	6,358	6,955
Available-for-sale debt securities, gross unrealized gains	[2]	2	15
Available-for-sale debt securities, gross unrealized losses	[2]	(122)	(33)
Available-for-sale debt securities, fair value	[2]	6,238	6,938
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value	[2]	2,659
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	[2]	2,557
Available-for-sale securities, debt maturities, over 5 years, fair value	[2]	1,022
Available-for-sale debt securities, fair value	[2]	6,238	6,938
Government - U.S. [Member]
Available-for-sale Debt Securities, Amortized Cost Basis [Abstract] (Deprecated 2018-01-31)
Available-for-sale debt securities, amortized cost		458	765
Available-for-sale debt securities, gross unrealized gains		0	0
Available-for-sale debt securities, gross unrealized losses		(25)	(19)
Available-for-sale debt securities, fair value		433	747
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value		8
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value		415
Available-for-sale securities, debt maturities, over 5 years, fair value		10
Available-for-sale debt securities, fair value		433	747
Agency asset-backed - U.S. [Member]
Available-for-sale Debt Securities, Amortized Cost Basis [Abstract] (Deprecated 2018-01-31)
Available-for-sale debt securities, amortized cost		19	24
Available-for-sale debt securities, gross unrealized gains		0	0
Available-for-sale debt securities, gross unrealized losses		0	(1)
Available-for-sale debt securities, fair value		19	24
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value		19
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value		0
Available-for-sale securities, debt maturities, over 5 years, fair value		0
Available-for-sale debt securities, fair value		19	24
Other asset-backed [Member]
Available-for-sale Debt Securities, Amortized Cost Basis [Abstract] (Deprecated 2018-01-31)
Available-for-sale debt securities, amortized cost	[3]	22	114
Available-for-sale debt securities, gross unrealized gains	[3]	0	0
Available-for-sale debt securities, gross unrealized losses	[3]	0	0
Available-for-sale debt securities, fair value	[3]	22	114
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value	[3]	7
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	[3]	13
Available-for-sale securities, debt maturities, over 5 years, fair value	[3]	2
Available-for-sale debt securities, fair value	[3]	22	114
Time deposits and other [Member]
Debt Securities, Held-to-maturity, Maturity [Abstract]
Held-to-maturity securities, debt maturities, total		1,482	1,091
Held-to-maturity securities, gross unrealized gains		0	0
Held-to-maturity securities, gross unrealized losses		0	0
Held-to-maturity securities, fair value		1,482	1,091
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Held-to-maturity securities, debt maturities, within 1 year, fair value		1,412
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value		66
Held-to-maturity securities, debt maturities, over 5 years, fair value		4
Held-to-maturity securities, debt maturities, total		$ 1,482	1,091
Money market funds [Member]
Available-for-sale Equity Securities [Abstract]
Available-for-sale equity securities, amortized cost	[1]		2,115
Available-for-sale equity securities, gross unrealized gain	[1]		0
Available-for-sale equity securities, gross unrealized losses	[1]		0
Available-for-sale securities, equity securities	[1]		2,115
Equity [Member]
Available-for-sale Equity Securities [Abstract]
Available-for-sale equity securities, amortized cost	[1]		728
Available-for-sale equity securities, gross unrealized gain	[1]		586
Available-for-sale equity securities, gross unrealized losses	[1]		(124)
Available-for-sale securities, equity securities	[1]		$ 1,190
[1]	Upon the 2018 adoption of a new accounting standard related to financial assets and liabilities, available-for-sale equity securities were classified as equity securities. For additional information see Note 1B.The following table presents the net unrealized gains and losses for the period that relates to equity securities still held at the reporting date, calculated as follows:(MILLIONS OF DOLLARS) Three Months Ended July 1, 2018Six Months Ended July 1, 2018Net gains recognized during the period on equity securities(a) $232$330Less: Net gains recognized during the period on equity securities sold during the period (19)(31)Net unrealized gains during the reporting period on equity securities still held at the reporting date $213$299
[2]	Issued by a diverse group of corporations.
[3]	Includes loan-backed, mortgage-backed and receivable-backed securities, all of which are in senior positions in the capital structure of the security. Loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages. Receivable-backed securities are collateralized by credit cards receivables.

Financial Instruments - Inves61

Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) - USD ($) $ in Millions		3 Months Ended	6 Months Ended
		Jul. 01, 2018	Jul. 01, 2018
Financial Instruments [Abstract]
Net gains recognized during the period on equity securities	[1]	$ 232	$ 330
Less: Net gains recognized during the period on equity securities sold during the period		(19)	(31)
Unrealized gains (losses) on equity securities		$ 213	$ 299
[1]	The second quarter of 2018 includes $226 million of unrealized net gains reflecting the adoption of a new accounting standard in the first quarter of 2018 and $7 million of unrealized gains on other equity securities. The first six months of 2018 includes $337 million of unrealized net gains reflecting the adoption of a new accounting standard in the first quarter of 2018 and $7 million of unrealized losses on other equity securities. For additional information, see Note 1B and Note 4.

Financial Instruments - Inves62

Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Unrealized gains (losses) on equity securities		$ 213		$ 299
Financial Assets and Liabilities [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Unrealized gains (losses) on equity securities	[1]	226	$ 0	337	$ 0
Other equity securities [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Unrealized gains (losses) on equity securities		$ 7		$ 7
[1]	Represents the unrealized net gains on equity securities reflecting the adoption of a new accounting standard in the first quarter of 2018. Approximately $142 million of these unrealized gains in the second quarter of 2018 and approximately $203 million of these unrealized gains in the first six months of 2018 relate to 3.2 million shares of ICU Medical stock that were received as part of the consideration for the sale of HIS net assets to ICU Medical. Prior to the adoption of the new standard, net unrealized gains and losses on virtually all equity securities with readily determinable fair values were reported in Accumulated other comprehensive income. For additional information, see Note 1B and Note 7B.

Financial Instruments - Short-t

Financial Instruments - Short-term Borrowings (Details) - USD ($) $ in Millions		Jul. 01, 2018	Dec. 31, 2017
Financial Instruments [Abstract]
Commercial paper		$ 6,800	$ 6,100
Current portion of long-term debt, principal amount		4,267	3,532
Other short-term borrowings, principal amount	[1]	538	320
Total short-term borrowings, principal amount		11,605	9,951
Net fair value adjustments related to hedging and purchase accounting		(4)	14
Net unamortized discounts, premiums and debt issuance costs		(18)	(12)
Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted	[2]	$ 11,583	$ 9,953
[1]	Other short-term borrowings primarily include cash collateral. For additional information, see Note 7F.
[2]	Amounts may not add due to rounding.

Financial Instruments - Long-Te

Financial Instruments - Long-Term Debt (Details) - USD ($) $ in Millions		Jul. 01, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Net fair value adjustments related to hedging and purchase accounting		$ (4)	$ 14
Net unamortized discounts, premiums and debt issuance costs		(18)	(12)
Total long-term debt, carried at historical proceeds, as adjusted	[1]	28,935	33,538
Current portion of long-term debt, carried at historical proceeds	[1]	4,262	3,546
Unsecured Debt [Member]
Debt Instrument [Line Items]
Total long-term debt, principal amount		28,701	32,783
Net fair value adjustments related to hedging and purchase accounting		338	872
Net unamortized discounts, premiums and debt issuance costs		(112)	(125)
Other long-term debt		8	8
Total long-term debt, carried at historical proceeds, as adjusted		28,935	33,538
Current portion of long-term debt, carried at historical proceeds		$ 4,262	$ 3,546
[1]	Amounts may not add due to rounding.

Financial Instruments - Other N

Financial Instruments - Other Noncurrent Liabilities (Detail) - USD ($) $ in Millions	1 Months Ended				3 Months Ended	6 Months Ended
	Apr. 30, 2018	Dec. 31, 2017	Aug. 31, 2017	Jun. 30, 2017	Jul. 01, 2018	Jul. 01, 2018	Jun. 30, 2018
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net		$ 36,562			$ 34,494	$ 34,494
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net		34,765			32,753	32,753
Bosulif [Member]
Finite-Lived Intangible Assets [Line Items]
Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement		$ 416
EU [Member] | Mylotarg [Member]
Finite-Lived Intangible Assets [Line Items]
Term over which fixed annual payments are to be made	10 years
Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement	$ 301
EU [Member] | Mylotarg [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net	$ 240
Lump sum payment for liability buyout							$ 224
Non-cash gain from buyout transaction					17	17
EU [Member] | Besponsa [Member]
Finite-Lived Intangible Assets [Line Items]
Term over which fixed annual payments are to be made				9 years
Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement				$ 148
EU [Member] | Besponsa [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net				$ 123	120	120
EU [Member] | Besponsa [Member] | Developed Technology Rights [Member] | Other Current Liabilities [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net					3	3
EU [Member] | Besponsa [Member] | Developed Technology Rights [Member] | Other Noncurrent Liabilities [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net					117	117
U.S. [Member] | Bosulif [Member]
Finite-Lived Intangible Assets [Line Items]
Term over which fixed annual payments are to be made		10 years
U.S. [Member] | Bosulif [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net		$ 364			285	285
U.S. [Member] | Bosulif [Member] | Developed Technology Rights [Member] | Other Current Liabilities [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net					30	30
U.S. [Member] | Bosulif [Member] | Developed Technology Rights [Member] | Other Noncurrent Liabilities [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net					255	255
U.S. [Member] | Besponsa [Member]
Finite-Lived Intangible Assets [Line Items]
Term over which fixed annual payments are to be made			9 years
Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement			$ 296
U.S. [Member] | Besponsa [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net			$ 248		239	239
U.S. [Member] | Besponsa [Member] | Developed Technology Rights [Member] | Other Current Liabilities [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net					7	7
U.S. [Member] | Besponsa [Member] | Developed Technology Rights [Member] | Other Noncurrent Liabilities [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net					$ 232	$ 232

Financial Instruments - Fair Va

Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details) - USD ($) $ in Millions		Jul. 01, 2018	Dec. 31, 2017
Derivative [Line Items]
Asset		$ 940	$ 822
Liability		1,038	691
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Asset		859	760
Liability		968	637
Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Notional	[1]	19,254	18,723
Asset	[1]	472	179
Liability	[1]	458	459
Designated as Hedging Instrument [Member] | Interest rate contracts [Member]
Derivative [Line Items]
Notional		11,300	12,430
Asset		387	581
Liability		510	178
Not Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Notional		12,134	14,300
Asset		81	62
Liability		70	$ 54
Inventory sales [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Notional	[1]	$ 5,100
[1]	As of July 1, 2018, the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.1 billion.

Financial Instruments - Derivat

Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
OID [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2]	$ 62	$ (9)	$ 6	$ (151)
Not Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2]	61	(5)	6	(145)
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2],[3]	0	(4)	0	(6)
Amount excluded from effectiveness testing recognized in earnings based on an amortization approach	[1],[2]	0	0	0	0
Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2]	12	(11)	4	(8)
Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Interest rate contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2]	(121)	100	(520)	8
Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Interest rate contracts, hedged item gain/(loss) [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2]	121	(100)	520	(8)
Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts, hedged item gain (loss) [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2]	(12)	11	(4)	8
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2]	0	0	0	0
The portion of gains/(losses) on foreign exchange contracts excluded from the assessment of hedge effectiveness	[1],[2]	0	0	0	0
Net Investment Hedging, Nonderivative Instruments [Member] | OID [Member] | Foreign currency short-term borrowings [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2],[4]	0	0	0	0
Net Investment Hedging, Nonderivative Instruments [Member] | OID [Member] | Foreign currency Long-term debt [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2],[4]	0	0	0	0
Other Derivative Instruments [Member] | OID [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[1],[2]	0	0	0	0
Amount of Gains/(Losses) Recognized in OCI [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[2],[5]	577	(384)	325	(450)
Amount of Gains/(Losses) Recognized in OCI [Member] | Not Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[2],[5]	0	0	0	0
Amount of Gains/(Losses) Recognized in OCI [Member] | Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing recognized in earnings based on an amortization approach	[2],[5]	20	0	48	0
Amount of Gains/(Losses) Recognized in OCI	[2],[3],[5]	107	(90)	(36)	(99)
Amount of Gains/(Losses) Recognized in OCI [Member] | Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[2],[5]	0	0	0	0
Amount of Gains/(Losses) Recognized in OCI [Member] | Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | Interest rate contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[2],[5]	0	0	0	0
Amount of Gains/(Losses) Recognized in OCI [Member] | Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | Interest rate contracts, hedged item gain/(loss) [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[2],[5]	0	0	0	0
Amount of Gains/(Losses) Recognized in OCI [Member] | Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts, hedged item gain (loss) [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[2],[5]	0	0	0	0
Amount of Gains/(Losses) Recognized in OCI [Member] | Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
The portion of gains/(losses) on foreign exchange contracts excluded from the assessment of hedge effectiveness	[2],[5]	25	0	27	0
Amount of Gains/(Losses) Recognized in OCI	[2],[5]	153	0	148	0
Amount of Gains/(Losses) Recognized in OCI [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Foreign currency short-term borrowings [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[2],[4],[5]	85	0	43	0
Amount of Gains/(Losses) Recognized in OCI [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Foreign currency Long-term debt [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[2],[4],[5]	186	(295)	94	(352)
Amount of Gains/(Losses) Recognized in OCI [Member] | Other Derivative Instruments [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[2],[5]	1	0	1	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | OID [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[5]	(289)	208	(328)	450
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Not Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[5]	0	0	0	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing recognized in earnings based on an amortization approach	[2],[5]	20	0	48	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3],[5]	(330)	208	(402)	449
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[5]	0	0	0	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Interest rate contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[5]	0	0	0	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Interest rate contracts, hedged item gain/(loss) [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[5]	0	0	0	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts, hedged item gain (loss) [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[5]	0	0	0	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
The portion of gains/(losses) on foreign exchange contracts excluded from the assessment of hedge effectiveness	[2],[5]	21	0	26	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[5]	0	0	0	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | OID [Member] | Foreign currency short-term borrowings [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[4],[5]	0	0	0	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | OID [Member] | Foreign currency Long-term debt [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[4],[5]	0	0	0	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS [Member] | Other Derivative Instruments [Member] | OID [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[5]	$ 1	$ 0	$ 1	$ 0
[1]	For the second quarter and first six months ended July 2, 2017, there was no significant ineffectiveness.
[2]	OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income. COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income.
[3]	Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $55 million within the next 12 months into Cost of sales. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.8 billion U.K. pound debt maturing in 2043.
[4]	Short-term borrowings include foreign currency short-term borrowings with carrying values of $1.5 billion as of July 1, 2018, which are used as hedging instruments in net investment hedges. Long-term debt includes foreign currency long-term borrowings with carrying values of $3.2 billion as of July 1, 2018, which are used as hedging instruments in net investment hedges.
[5]	For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in Other comprehensive income/(loss)––Unrealized holding gains/(losses) on derivative financial instruments, net. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income/(loss)––Foreign currency translation adjustments, net.

Financial Instruments - Deriv68

Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details) - USD ($) $ in Millions		Jul. 01, 2018	Dec. 31, 2017
Derivative [Line Items]
Pre-tax gain expected to be reclassified within the next 12 months		$ 55
Short-term debt	[1]	11,583	$ 9,953
Unsecured Debt [Member]
Derivative [Line Items]
Long-term debt		1,800
Foreign currency short-term borrowings [Member]
Derivative [Line Items]
Short-term debt		1,500
Foreign currency Long-term debt [Member]
Derivative [Line Items]
Long-term debt		$ 3,200
[1]	Amounts may not add due to rounding.

Financial Instruments - Fair 69

Financial Instruments - Fair Value And Cash Flow Hedges (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Financial Instruments [Abstract]
Cost of sales	[1],[2]	$ 2,916	$ 2,660	$ 5,479	$ 5,128
Other (income)/deductions––net	[1]	$ (551)	$ (75)	$ (728)	$ (14)
[1]	Amounts may not add due to rounding.
[2]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

Financial Instruments - Cumulat

Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details) $ in Millions	Jul. 01, 2018USD ($)
Short-term investments [Member]
Derivative [Line Items]
Carrying Amount of Hedged Assets	$ 155
Cumulative Amount of Fair Value Hedging Adjustment Gains/(Losses) Included in the Carrying Amount of the Hedged Assets	(1)
Long-term investments [Member]
Derivative [Line Items]
Carrying Amount of Hedged Assets	45
Cumulative Amount of Fair Value Hedging Adjustment Gains/(Losses) Included in the Carrying Amount of the Hedged Assets	(1)
Short-term borrowings, including current portion of long-term debt [Member]
Derivative [Line Items]
Carrying Amount of Hedged Liabilities	1,487
Cumulative Amount of Fair Value Hedging Adjustment Gains/(Losses) Included in the Carrying Amount of the Hedged Liabilities	11
Long-term debt [Member]
Derivative [Line Items]
Carrying Amount of Hedged Liabilities	9,753
Cumulative Amount of Fair Value Hedging Adjustment Gains/(Losses) Included in the Carrying Amount of the Hedged Liabilities	$ 210

Financial Instruments - Narrati

Financial Instruments - Narrative (Details) $ in Millions	Jul. 01, 2018USD ($)
Financial Instruments [Abstract]
Derivatives in a net liability position	$ 413
Collateral posted	483
Cash collateral received	$ 473

Financial Instruments - Credit

Financial Instruments - Credit Risk (Details) $ in Millions	6 Months Ended
	Jul. 01, 2018USD ($)
Bank sector [Member]
Concentration Risk [Line Items]
Maximum exposure, amount	$ 2,100
Technology sector [Member]
Concentration Risk [Line Items]
Maximum exposure, amount	$ 751

Inventories (Detail)

Inventories (Detail) - USD ($) $ in Millions		Jul. 01, 2018		Jan. 01, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Finished goods		$ 2,756			$ 2,883
Work-in-process		4,542			3,908
Raw materials and supplies		776			788
Inventories		8,074	[1],[2]	$ 7,567	7,578	[1],[2]
Noncurrent inventories not included above	[3]	$ 615			$ 683
[1]	Amounts may not add due to rounding.
[2]	The change from December 31, 2017 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery, network strategy and new product launches, partially offset by a decrease due to foreign exchange.
[3]	Included in Other noncurrent assets. There are no recoverability issues associated with these amounts.

Identifiable Intangible Asset74

Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Detail) - USD ($) $ in Millions		Jul. 01, 2018	Dec. 31, 2017
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		$ 12,090	$ 12,179
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		93,665	93,595
Finite-lived intangible assets, accumulated amortization	[1]	(59,171)	(57,033)
Finite-lived intangible assets, net		34,494	36,562
Intangible assets, gross carrying amount	[1]	105,755	105,774
Finite-lived intangible assets, accumulated amortization	[1]	(59,171)	(57,033)
Identifiable Intangible Assets, less Accumulated Amortization	[1],[2]	46,584	48,741
Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		6,927	6,929
In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		5,163	5,249
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		89,582	89,550
Finite-lived intangible assets, accumulated amortization		(56,829)	(54,785)
Finite-lived intangible assets, net		32,753	34,765
Finite-lived intangible assets, accumulated amortization		(56,829)	(54,785)
Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		2,126	2,134
Finite-lived intangible assets, accumulated amortization		(1,203)	(1,152)
Finite-lived intangible assets, net		923	982
Finite-lived intangible assets, accumulated amortization		(1,203)	(1,152)
License Agreements and Other [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		1,957	1,911
Finite-lived intangible assets, accumulated amortization		(1,139)	(1,096)
Finite-lived intangible assets, net		818	815
Finite-lived intangible assets, accumulated amortization		$ (1,139)	$ (1,096)
[1]	The decrease in Identifiable intangible assets, less accumulated amortization, is primarily due to amortization, minimally offset by additions, mainly consisting of $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E).
[2]	Amounts may not add due to rounding.

Identifiable Intangible Asset75

Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details) - USD ($) $ in Millions	Jul. 01, 2018	Apr. 30, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net	$ 34,494		$ 36,562
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net	$ 32,753		$ 34,765
EU [Member] | Mylotarg [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net		$ 240

Identifiable Intangible Asset76

Identifiable Intangible Assets and Goodwill - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)	Jul. 01, 2018
Operating Segments [Member] | Developed Technology Rights [Member] | IH [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	68.00%
Operating Segments [Member] | Developed Technology Rights [Member] | EH [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	32.00%
Operating Segments [Member] | Brands [Member] | IH [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	75.00%
Operating Segments [Member] | Brands [Member] | EH [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	25.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%

Identifiable Intangible Asset77

Identifiable Intangible Assets and Goodwill - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)	Jul. 01, 2018
IH [Member] | Operating Segments [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	71.00%
IH [Member] | Operating Segments [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	82.00%
EH [Member] | Operating Segments [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	29.00%
EH [Member] | Operating Segments [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	11.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	7.00%

Identifiable Intangible Asset78

Identifiable Intangible Assets and Goodwill - Narrative (Detail) - USD ($) $ in Billions	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Finite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense for finite-lived intangible assets	$ 1.2	$ 1.2	$ 2.4	$ 2.4

Identifiable Intangible Asset79

Identifiable Intangible Assets and Goodwill - Goodwill (Detail) $ in Millions	6 Months Ended
	Jul. 01, 2018USD ($)
Goodwill [Roll Forward]
Balance, December 31, 2017	$ 55,952	[1]
Other	(117)	[2]
Balance, April 1, 2018	55,836	[1]
IH [Member]
Goodwill [Roll Forward]
Balance, December 31, 2017	31,141
Other	(65)	[2]
Balance, April 1, 2018	31,076
EH [Member]
Goodwill [Roll Forward]
Balance, December 31, 2017	24,811
Other	(51)	[2]
Balance, April 1, 2018	$ 24,760
[1]	Amounts may not add due to rounding.
[2]	Primarily reflects the impact of foreign exchange, as well as the contribution of the allogeneic CAR T developmental program assets and operations to Allogene that constituted a business for accounting purposes (see Note 2B).

Pension and Postretirement Be80

Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Pension Plan [Member] | U.S. [Member] | Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	[1],[2],[3]	$ 0	$ 67	$ 0	$ 135
Interest cost	[1],[3]	150	159	301	321
Expected return on plan assets	[1],[3]	(261)	(252)	(524)	(511)
Amortization of:
Actuarial losses	[1],[2],[3]	30	97	60	212
Prior service costs (credits)	[1],[3]	0	1	1	3
Curtailments	[1],[3]	7	4	9	9
Settlements	[1],[3]	25	(7)	45	24
Defined benefit plan, net periodic benefit cost	[1],[3]	(49)	69	(107)	193
Pension Plan [Member] | International [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	[2],[3]	34	42	71	83
Interest cost	[3]	55	50	109	100
Expected return on plan assets	[3]	(93)	(85)	(185)	(169)
Amortization of:
Actuarial losses	[2],[3]	26	28	52	56
Prior service costs (credits)	[3]	(1)	(1)	(2)	(2)
Curtailments	[3]	0	0	0	0
Settlements	[3]	0	2	0	3
Defined benefit plan, net periodic benefit cost	[3]	21	37	44	71
Supplemental Employee Retirement Plan [Member] | U.S. [Member] | Non-Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	[2],[3]	0	6	0	12
Interest cost	[3]	14	13	26	28
Expected return on plan assets	[3]	0	0	0	0
Amortization of:
Actuarial losses	[2],[3]	3	12	7	25
Prior service costs (credits)	[3]	0	0	0	0
Curtailments	[3]	0	0	0	0
Settlements	[3]	5	4	21	24
Defined benefit plan, net periodic benefit cost	[3]	21	35	55	88
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	[2],[3]	10	11	20	21
Interest cost	[3]	18	23	36	45
Expected return on plan assets	[3]	(9)	(9)	(18)	(18)
Amortization of:
Actuarial losses	[2],[3]	2	8	4	15
Prior service costs (credits)	[3]	(45)	(46)	(90)	(92)
Curtailments	[3]	(7)	(5)	(14)	(12)
Settlements	[3]	0	0	0	0
Defined benefit plan, net periodic benefit cost	[3]	$ (32)	$ (19)	$ (63)	$ (40)
[1]	(a) In the second quarter of 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the $156 million net pension benefit obligation and recorded a pre-tax settlement gain of $41 million, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately $30 million in Other (income)/deductions––net (see Note 3).
[2]	Effective January 1, 2018, we froze two significant defined benefit pension plans to future benefit accruals in the U.S. and U.K. and as a result, service costs for those plans are eliminated. In addition, due to the plan freeze, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans was extended to the expected life expectancy of the plan participants, whereas the average amortization period in prior years utilized the expected future service period of plan participants.
[3]	We adopted a new accounting standard on January 1, 2018 that requires the net periodic pension and postretirement benefit costs other than service costs be presented in Other (income)/deductions––net on the condensed consolidated statements of income. For additional information, see Note 1B and Note 4.

Pension and Postretirement Be81

Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost - Footnotes (Details) $ in Millions	3 Months Ended
	Jul. 02, 2017USD ($)	Jan. 01, 2018pension_plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Number of pension plans frozen | pension_plan		2
Hospira [Member] | Pension Plan [Member] | U.S. [Member] | Qualified Plan [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Decrease in pension benefit obligation in connection with Hospira pension plan	$ 156
Pretax settlement gain	41
Net pension benefit obligation	$ 30

Pension and Postretirement Be82

Pension and Postretirement Benefit Plans (Detail) - USD ($) $ in Millions		1 Months Ended	6 Months Ended
		Feb. 28, 2018	Jul. 01, 2018
Pension Plan [Member] | U.S. [Member] | Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the six months ended July 1, 2018		$ 500	$ 500
Expected contributions from our general assets during 2018	[1]		500
Pension Plan [Member] | International [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the six months ended July 1, 2018			84
Expected contributions from our general assets during 2018	[1]		235
Supplemental Employee Retirement Plan [Member] | U.S. [Member] | Non-Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the six months ended July 1, 2018			99
Expected contributions from our general assets during 2018	[1]		140
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the six months ended July 1, 2018			71
Expected contributions from our general assets during 2018	[1]		$ 155
[1]	Contributions expected to be made for 2018 are inclusive of amounts contributed during the six months ended July 1, 2018, including the $500 million voluntary contribution that was made in February 2018 for the U.S. qualified plans, which was considered pre-funding for future anticipated mandatory contributions and is also expected to reduce Pension Benefit Guaranty Corporation variable rate premiums. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.

Earnings Per Common Share Att83

Earnings Per Common Share Attributable to Common Shareholders (Details) - USD ($) shares in Millions, $ in Millions		3 Months Ended		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018		Jul. 02, 2017
EPS Numerator––Basic
Income from continuing operations	[1]	$ 3,879	$ 3,077	$ 7,450	[2]	$ 6,207	[2]
Less: Net income attributable to noncontrolling interests		7	5	16		14
Income from continuing operations attributable to Pfizer Inc.		3,872	3,071	7,434	[2]	6,193	[2]
Less: Preferred stock dividends––net of tax		0	0	1		0
Income from continuing operations attributable to Pfizer Inc. common shareholders		3,871	3,071	7,433	[2]	6,192	[2]
Discontinued operations––net of tax	[1]	0	2	(1)		1
Net income attributable to Pfizer Inc. common shareholders		3,871	3,073	7,432	[2]	6,194	[2]
EPS Numerator––Diluted
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions		3,872	3,071	7,434	[2]	6,193	[2]
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions		0	2	(1)		1
Net income attributable to Pfizer Inc. common shareholders and assumed conversions		$ 3,872	$ 3,073	$ 7,432	[2]	$ 6,194	[2]
EPS Denominator
Weighted-average number of common shares outstanding––Basic	[1]	5,866	5,958	5,911		5,982
Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements (shares)		86	80	93	[2]	83	[2]
Weighted-average number of common shares outstanding––Diluted	[1]	5,952	6,037	6,004	[2]	6,065	[2]
Equity Option [Member]
EPS Denominator
Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (shares)	[2]	3	47	2		47
[1]	Amounts may not add due to rounding.
[2]	These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Contingencies and Certain Com84

Contingencies and Certain Commitments (Actions In Which We Are The Plaintiff) (Details)

1 Months Ended

3 Months Ended

Jun. 30, 2018Patents

Feb. 28, 2018Patents

Jan. 31, 2018Patents

Dec. 31, 2017Patents

Oct. 31, 2017Patents

Sep. 30, 2017Patents

Jul. 31, 2017Patents

Mar. 31, 2017Patents

Feb. 28, 2017Patents

Aug. 31, 2016Patents

Jul. 31, 2016Patents

Jan. 31, 2016Patents

Dec. 31, 2015Patents

Jun. 30, 2015Patents

Apr. 30, 2017PatentsDefendant

Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents not infringed upon

4

Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Settled Litigation [Member]

Gain Contingencies [Line Items]

Number of patents infringed upon

1

Number of patents not infringed upon

3

Precedex Premix [Member] | Hospira Versus Fresenius [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents not infringed upon

4

Precedex Premix [Member] | Hospira Versus Par [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents not infringed upon

4

Precedex Premix [Member] | Hospira Versus Gland [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents not infringed upon

6

Number of patents allegedly infringed upon

4

Precedex Premix [Member] | Hospira Versus Hengrui [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents not infringed upon

6

Number of patents allegedly infringed upon

4

Precedex Premix [Member] | Hospira Versus Baxter [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents not infringed upon

4

Number of patents due to expire in 2019

1

Number of patents due to expire in 2032

3

Patent Infringement [Member] | Judicial Ruling [Member]

Gain Contingencies [Line Items]

Number of patents infringed upon

1

Patent Infringement [Member] | Bosulif [Member] | Wyeth Versus Sun [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

2

Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus MicroLabs [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Zydus [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Prinston and Breckenridge [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

2

Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Breckenridge [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

4

Number of patents due to expire in December 2020

3

Number or patents due to expire in December 2025

1

Patent Infringement [Member] | Toviaz [Member] | Pfizer Versus Mylan Laboratories Limited [Member] | Judicial Ruling [Member]

Gain Contingencies [Line Items]

Number of patents not infringed upon

5

Patent Infringement [Member] | Toviaz [Member] | Pfizer Versus Mylan Laboratories Limited [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

5

5

Patent Infringement [Member] | Toviaz Composition-of-matter Patents [Member] | Pfizer Versus Mylan Laboratories Limited [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents infringed upon

3

Patent Infringement [Member] | Eliquis [Member] | Pfizer and BMS Versus Several Generic Manufacturers [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Number of defendants | Defendant

25

Contingencies and Certain Com85

Contingencies and Certain Commitments (Actions In Which We Are The Defendant) (Detail) $ in Thousands, £ in Millions	1 Months Ended
	May 31, 2018USD ($)	Nov. 30, 2017USD ($)	Jul. 31, 2017Patents	Mar. 31, 2015Patents	Mar. 31, 2013lagoon	Jul. 01, 2018Claim	Dec. 31, 2016GBP (£)
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon				6
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Claims dismissed				4
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon				2
Celebrex [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Amount awarded to other party | $		$ 94,000
Patent Infringement [Member] | Bavencio [Member] | Pfizer Versus BMS, E.R. Squibb & Sons, Ono Pharmaceutical and Tasuku Honjo [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon			1
Damages from Product Defects [Member] | Class Action Versus American Optical Corporation And Various Other Defendants [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of pending claims | Claim						56,760
Average Wholesale Price [Member] | State of Illinois Versus Pfizer [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of pending claims | Claim						1
Environmental Remediation Litigation [Member]
Loss Contingencies [Line Items]
Number of lagoons | lagoon					2
Violation of Antitrust Laws [Member] | Phenytoin Sodium Capsules [Member]
Loss Contingencies [Line Items]
Imposed fine | £							£ 84.2
Copayment Assistance Organizations [Member] | Pfizer Versus United States District Of Massachusetts [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Amount awarded to other party | $	$ 23,850
Term of Corporate Integrity Agreement	5 years

Contingencies and Certain Com86

Contingencies and Certain Commitments (Details) - USD ($) $ / shares in Units, shares in Millions	Mar. 14, 2018	Mar. 12, 2018	Jul. 01, 2018	Apr. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Share repurchase agreement, amount		$ 4,000,000,000
Accelerated share repurchases, cash paid	$ 4,000,000,000
Shares repurchased	87
Shares repurchased, price per share (in dollars per share)	$ 36.61
Shares received in initial delivery, percentage of agreement amount		80.00%
Remaining authorized repurchase amount			$ 10,300,000,000
Office Building In Hudson Yards Neighborhood Of New York City [Member]
Property Subject to or Available for Operating Lease [Line Items]
Term of corporate headquarters lease agreement				20 years
Future minimum commitment for corporate headquarters lease				$ 1,700,000,000

Segment, Geographic and Other87

Segment, Geographic and Other Revenue Information - Narrative (Detail) $ in Millions		3 Months Ended	6 Months Ended
		Jul. 02, 2017USD ($)	Jul. 01, 2018USD ($)Operating_Segment	Jul. 02, 2017USD ($)	Dec. 31, 2017USD ($)
Segment Reporting Information [Line Items]
Number of business segments | Operating_Segment			2
Assets	[1]		$ 164,980		$ 171,797
Adjustment [Member] | Corporate [Member]
Segment Reporting Information [Line Items]
Costs		$ (12)		$ (21)
Adjustment [Member] | IH [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Costs		(120)		(218)
Adjustment [Member] | EH [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Costs		$ (45)		$ (78)
[1]	Amounts may not add due to rounding.

Segment, Geographic and Other88

Segment, Geographic and Other Revenue Information (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Segment Reporting Information [Line Items]
Revenues	[1]	$ 13,466	$ 12,896	$ 26,373	$ 25,675
Earnings	[1],[2]	4,527	3,815	8,654	7,767
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		13,466	12,896	26,373	25,675
Earnings	[2]	7,918	7,619	15,636	15,405
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Earnings	[2],[3],[4]	(669)	(758)	(1,394)	(1,445)
Segment Reconciling Items [Member] | Purchase Accounting Adjustments [Member]
Segment Reporting Information [Line Items]
Earnings	[2],[3]	(1,134)	(1,201)	(2,355)	(2,373)
Segment Reconciling Items [Member] | Acquisition-Related Costs [Member]
Segment Reporting Information [Line Items]
Earnings	[2],[3]	(62)	(68)	(110)	(192)
Segment Reconciling Items [Member] | Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Earnings	[2],[5]	(20)	(191)	(221)	(348)
Segment Reconciling Items [Member] | Other Unallocated [Member]
Segment Reporting Information [Line Items]
Earnings	[2],[3],[6]	(362)	(377)	(607)	(736)
Corporate [Member]
Segment Reporting Information [Line Items]
Earnings	[2],[3],[6]	(1,144)	(1,209)	(2,296)	(2,545)
IH [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	[6]	8,273	7,671	16,102	15,086
Earnings	[2],[6]	5,100	4,786	10,031	9,534
EH [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	[6]	5,193	5,226	10,271	10,590
Earnings	[2],[6]	$ 2,818	$ 2,832	$ 5,606	$ 5,871
[1]	Amounts may not add due to rounding.
[2]	Income from continuing operations before provision for taxes on income. IH’s earnings include dividend income of $76 million and $114 million in the second quarter of 2018 and 2017, respectively, and $135 million and $157 million in the first six months of 2018 and 2017, respectively, from our investment in ViiV. For additional information, see Note 4.
[3]	For a description, see the “Other Costs and Business Activities” section above.
[4]	Other business activities includes the costs managed by our WRD and GPD organizations.
[5]	Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.For Earnings in the second quarter of 2018, certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $42 million, (ii) a net credit for certain legal matters of $88 million, (iii) adjustments of $2 million income to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairments of $31 million, (v) charges for business and legal entity alignment of $1 million and (vi) other charges of $37 million. For additional information, see Note 2B, Note 3 and Note 4.For Earnings in the second quarter of 2017, certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $49 million, (ii) an incremental charge to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $28 million, (iii) charges for business and legal entity alignment of $17 million and (iv) other charges of $97 million. For additional information, see Note 2B, Note 3 and Note 4.For Earnings in the first six months of 2018, certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $93 million, (ii) net credits for certain legal matters of $107 million, (iii) adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $1 million, (iv) certain asset impairments of $31 million, (v) charges for business and legal entity alignment of $4 million and (vi) other charges of $199 million, which primarily includes $119 million, in the aggregate, for a special one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA on us. For additional information, see Note 2B, Note 3 and Note 4.For Earnings in the first six months of 2017, certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $79 million, (ii) charges for certain legal matters of $8 million, (iii) adjustments to amounts previously recorded to the write-down the HIS net assets to fair value less costs to sell of $64 million, (iv) charges for business and legal entity alignment of $38 million and (v) other charges of $158 million. For additional information, see Note 2B, Note 3 and Note 4.
[6]	In connection with the StratCO reporting change, in the second quarter of 2017 we reclassified approximately $120 million of costs from IH, approximately $45 million of costs from EH and approximately $12 million of costs from Corporate to Other unallocated costs to conform to the current period presentation. In the first six months of 2017, we reclassified approximately $218 million of costs from IH, approximately $78 million of costs from EH and approximately $21 million of costs from Corporate to Other unallocated costs to conform to the current period presentation.

Segment, Geographic and Other89

Segment, Geographic and Other Revenue Information - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018		Jul. 02, 2017
Segment Reporting Information [Line Items]
Income (charges) for certain legal matters	[1]	$ 88	$ (3)	$ 107		$ (11)
Gain (loss) on sale of HIS net assets	[2]	2	(28)	(1)	[3]	(64)	[3]
Business and legal entity alignment costs	[4]	1	17	4		38
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Cost reduction and productivity initiatives excluding acquisition related costs		42	49	93		79
Income (charges) for certain legal matters				107		(8)
Asset impairment charges		31		31
Business and legal entity alignment costs		1	17	4		38
Other charges		37	97	199		158
Special one-time bonus paid to all non-executive Pfizer colleagues				119
HIS [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Gain (loss) on sale of HIS net assets		2	(28)	(1)		(64)
ViiV Healthcare Limited [Member] | IH [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Dividend income		$ 76	114	$ 135		157
Adjustment [Member] | Corporate [Member]
Segment Reporting Information [Line Items]
Costs and expenses			(12)			(21)
Adjustment [Member] | IH [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Costs and expenses			(120)			(218)
Adjustment [Member] | EH [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Costs and expenses			$ (45)			$ (78)
[1]	In the second quarter and first six months of 2018, primarily represents the reversal of a legal accrual where a loss was no longer deemed probable.
[2]	In the second quarter and first six months of 2018 and 2017, represents adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical on February 3, 2017. For additional information, see Note 2B.
[3]	Amounts may not add due to rounding.
[4]	In the second quarter and first six months of 2018 and 2017, represents expenses for changes to our infrastructure to align our commercial operations of our current segments, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.

Segment, Geographic and Other90

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 13,466	$ 12,896	$ 26,373	$ 25,675
Percentage Change In Revenue		4.00%		3.00%
U.S. [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 6,225	6,345	$ 12,500	12,982
Percentage Change In Revenue		(2.00%)		(4.00%)
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2]	$ 2,334	2,124	$ 4,426	4,145
Percentage Change In Revenue	[2]	10.00%		7.00%
Developed Rest Of World [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[3]	$ 1,694	1,611	$ 3,155	3,165
Percentage Change In Revenue	[3]	5.00%
Emerging Markets [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[4]	$ 3,214	$ 2,815	$ 6,292	$ 5,382
Percentage Change In Revenue	[4]	14.00%		17.00%
[1]	Amounts may not add due to rounding.
[2]	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.9 billion and $1.7 billion in the second quarter of 2018 and 2017, respectively, and $3.6 billion and $3.3 billion in the first six months of 2018 and 2017, respectively.
[3]	Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand.
[4]	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.

Segment, Geographic and Other91

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 13,466	$ 12,896	$ 26,373	$ 25,675
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2]	2,334	2,124	4,426	4,145
Euro Member Countries, Euro [Member] | Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 1,900	$ 1,700	$ 3,600	$ 3,300
[1]	Amounts may not add due to rounding.
[2]	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.9 billion and $1.7 billion in the second quarter of 2018 and 2017, respectively, and $3.6 billion and $3.3 billion in the first six months of 2018 and 2017, respectively.

Segment, Geographic and Other92

Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Revenue from External Customer [Line Items]
Revenues	[1]	$ 13,466	$ 12,896	$ 26,373	$ 25,675
Innovative Health and Essential Health [Member]
Revenue from External Customer [Line Items]
Revenues		13,466	12,896	26,373	25,675
Innovative Health and Essential Health [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	1,223	1,254	2,436	2,526
Innovative Health and Essential Health [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	185	349	372	687
Innovative Health and Essential Health [Member] | Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		987	715	1,842	1,370
Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	8,273	7,671	16,102	15,086
Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	5,193	5,226	10,271	10,590
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[6]	2,695	2,707	5,331	5,313
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Lipitor [Member]
Revenue from External Customer [Line Items]
Revenues		521	445	1,032	849
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Norvasc [Member]
Revenue from External Customer [Line Items]
Revenues		271	231	526	458
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Premarin family [Member]
Revenue from External Customer [Line Items]
Revenues		210	245	401	473
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Zithromax [Member]
Revenue from External Customer [Line Items]
Revenues		72	62	162	140
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Xalatan/Xalacom [Member]
Revenue from External Customer [Line Items]
Revenues		85	81	157	158
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Zoloft [Member]
Revenue from External Customer [Line Items]
Revenues		77	69	151	137
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Effexor [Member]
Revenue from External Customer [Line Items]
Revenues		79	73	150	139
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | EpiPen [Member]
Revenue from External Customer [Line Items]
Revenues		95	90	148	171
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Xanax [Member]
Revenue from External Customer [Line Items]
Revenues		56	52	111	107
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Sildenafil Citrate [Member]
Revenue from External Customer [Line Items]
Revenues		8	0	71	0
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Other Legacy Established Products [Member]
Revenue from External Customer [Line Items]
Revenues		1,220	1,360	2,424	2,681
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[7]	1,329	1,444	2,688	2,996
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Sulperazon [Member]
Revenue from External Customer [Line Items]
Revenues		150	110	319	232
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Medrol [Member]
Revenue from External Customer [Line Items]
Revenues		104	123	223	243
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Fragmin [Member]
Revenue from External Customer [Line Items]
Revenues		74	71	145	142
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Tygacil [Member]
Revenue from External Customer [Line Items]
Revenues		63	57	126	131
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Tazosyn / Zosyn [Member]
Revenue from External Customer [Line Items]
Revenues		58	40	119	78
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Precedex [Member]
Revenue from External Customer [Line Items]
Revenues		64	67	119	132
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | All Other Sterile Injectable Pharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues		815	975	1,638	2,038
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[8]	773	782	1,509	1,604
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	88	154	170	294
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	185	93	372	183
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Celebrex [Member]
Revenue from External Customer [Line Items]
Revenues		161	178	306	353
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Vfend [Member]
Revenue from External Customer [Line Items]
Revenues		110	101	207	208
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Zyvox [Member]
Revenue from External Customer [Line Items]
Revenues		66	75	134	152
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Revatio [Member]
Revenue from External Customer [Line Items]
Revenues		54	67	109	131
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Pristiq [Member]
Revenue from External Customer [Line Items]
Revenues		51	46	104	161
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | All Other Peri-LOE Products [Member]
Revenue from External Customer [Line Items]
Revenues		59	68	107	121
Biosimilars [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[9]	188	121	361	226
Biosimilars [Member] | Essential Health Business [Member] | EH [Member] | Inflectra/Remsima [Member]
Revenue from External Customer [Line Items]
Revenues		158	94	303	172
Biosimilars [Member] | Essential Health Business [Member] | EH [Member] | All Other Biosimilars [Member]
Revenue from External Customer [Line Items]
Revenues		29	27	58	54
CentreOne [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[10]	209	171	381	353
Hospira Infusion Systems (HIS) [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[11]	0	0	0	97
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		2,530	2,412	4,876	4,789
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	1,134	1,101	2,266	2,231
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Eliquis [Member]
Revenue from External Customer [Line Items]
Revenues		889	605	1,654	1,169
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Chantix / Champix [Member]
Revenue from External Customer [Line Items]
Revenues		277	248	528	487
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | B M P 2 [Member]
Revenue from External Customer [Line Items]
Revenues		80	57	153	119
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Toviaz [Member]
Revenue from External Customer [Line Items]
Revenues		70	62	130	125
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	0	255	0	505
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | All Other Internal Medicine [Member]
Revenue from External Customer [Line Items]
Revenues		79	84	145	153
Vaccines [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		1,400	1,270	2,863	2,735
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | Prevnar 13/Prevenar 13 [Member]
Revenue from External Customer [Line Items]
Revenues		1,250	1,154	2,631	2,547
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | FSME-IMMUN/TicoVac [Member]
Revenue from External Customer [Line Items]
Revenues		73	50	105	76
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | All other Vaccines [Member]
Revenue from External Customer [Line Items]
Revenues		77	66	127	112
Oncology [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		1,822	1,589	3,519	2,935
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Ibrance [Member]
Revenue from External Customer [Line Items]
Revenues		1,027	853	1,960	1,532
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Sutent [Member]
Revenue from External Customer [Line Items]
Revenues		275	279	537	529
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Xtandi Alliance [Member]
Revenue from External Customer [Line Items]
Revenues		171	141	330	272
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Xalkori [Member]
Revenue from External Customer [Line Items]
Revenues		137	155	290	296
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Inlyta [Member]
Revenue from External Customer [Line Items]
Revenues		81	88	155	172
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Bosulif [Member]
Revenue from External Customer [Line Items]
Revenues		77	59	138	106
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | All other Oncology [Member]
Revenue from External Customer [Line Items]
Revenues		53	14	109	28
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		1,064	992	1,933	1,863
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | Enbrel (Outside the U.S. and Canada) [Member]
Revenue from External Customer [Line Items]
Revenues		551	617	1,057	1,205
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | Xeljanz [Member]
Revenue from External Customer [Line Items]
Revenues		463	336	788	587
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | Eucrisa [Member]
Revenue from External Customer [Line Items]
Revenues		39	9	65	17
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | All Other Inflammation and Immunology Products [Member]
Revenue from External Customer [Line Items]
Revenues		11	31	22	54
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		571	562	1,120	1,069
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | BeneFIX [Member]
Revenue from External Customer [Line Items]
Revenues		141	153	288	302
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Genotropin [Member]
Revenue from External Customer [Line Items]
Revenues		140	135	272	238
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | ReFacto AF/ Xyntha [Member]
Revenue from External Customer [Line Items]
Revenues		141	139	271	269
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Somavert [Member]
Revenue from External Customer [Line Items]
Revenues		68	61	131	117
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | All Other Rare Disease [Member]
Revenue from External Customer [Line Items]
Revenues		81	74	157	141
Consumer Healthcare [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		$ 886	$ 846	$ 1,791	$ 1,694
[1]	Amounts may not add due to rounding.
[2]	Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH.
[3]	Viagra lost exclusivity in the U.S. in December 2017. Beginning in 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, are reported in EH (which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, beginning in 2018, total Viagra revenues are reported in EH. Total Viagra revenues in 2017 represent the aggregate of worldwide revenues from Viagra IH and Viagra EH.
[4]	The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare.
[5]	The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017).
[6]	Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.
[7]	Sterile Injectable Pharmaceuticals includes branded and generic injectables (excluding Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.
[8]	Peri-LOE Products includes products that have recently lost or are anticipated to soon lose patent protection. These products primarily include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra; and beginning in 2018, Viagra revenues for all countries (and Viagra revenues for all countries other than the U.S. and Canada in 2017, see note (c) above).
[9]	Biosimilars includes Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets.
[10]	Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.
[11]	HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.